

chain nodes :

7 8 9

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

chain bonds :

3-7 7-8

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 16-17 16-20 17-18 18-19 19-20 21-22  
21-25 22-23 23-24 24-25 26-27 26-30 26-31 27-28 27-31 28-29 29-30

exact/norm bonds :

3-7 7-8 11-15 14-15 16-20 19-20 21-25 24-25 26-27 26-30 26-31 27-28 27-31 28-29 29-30

exact bonds :

11-12 12-13 13-14 16-17 17-18 18-19 21-22 22-23 23-24

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 11 : 16 : 21 : 26 :

G1:[\*1],[\*2],[\*3],[\*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom  
24:Atom

25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom

Generic attributes :


8:

Saturation : Unsaturated



=&gt;

Uploading C:\Program Files\Stnexp\Queries\10809944.str



chain nodes :

7 8 9

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26  
27 28 29 30 31

chain bonds :

3-7 7-8

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 16-17 16-20  
17-18 18-19 19-20 21-22 21-25 22-23 23-24 24-25 26-27 26-30 26-31 27-28  
27-31 28-29 29-30

exact/norm bonds :

3-7 7-8 11-15 14-15 16-20 19-20 21-25 24-25 26-27 26-30 26-31 27-28  
27-31 28-29 29-30

exact bonds :

11-12 12-13 13-14 16-17 17-18 18-19 21-22 22-23 23-24

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 11 : 16 : 21 : 26 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom  
29:Atom 30:Atom 31:Atom

L1

STRUCTURE UPLOADED

10/809,946

```
=> d l1
L1 HAS NO ANSWERS
L1          STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 12:21:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -          1 TO ITERATE
```

```
100.0% PROCESSED          1 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   1 TO      80
PROJECTED ANSWERS:      0 TO      0
```

```
L2          0 SEA SSS SAM L1
```

```
=>
Uploading C:\Program Files\Stnexp\Queries\10809944 (a).str
```



chain nodes :

7 8 9

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26  
27 28 29 30 31

```

chain bonds :
3-7 7-8
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 16-17 16-20
17-18 18-19 19-20 21-22 21-25 22-23 23-24 24-25 26-27 26-30 26-31 27-28
27-31 28-29 29-30
exact/norm bonds :
3-7 7-8 11-15 14-15 16-20 19-20 21-25 24-25 26-27 26-30 26-31 27-28
27-31 28-29 29-30
exact bonds :
11-12 12-13 13-14 16-17 17-18 18-19 21-22 22-23 23-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 11 : 16 : 21 : 26 :

```

```
G1:[*1],[*2],[*3],[*4]
```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom

```

```
L3      STRUCTURE UPLOADED
```

```
=> d l3
```

```
L3 HAS NO ANSWERS
```

```
L3      STR
```

```
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

Structure attributes must be viewed using STN Express query preparation.

```
=> s l3 sss sam
```

```
SAMPLE SEARCH INITIATED 12:22:34 FILE 'REGISTRY'
```

```
SAMPLE SCREEN SEARCH COMPLETED -      574 TO ITERATE
```

```
100.0% PROCESSED      574 ITERATIONS
```

```
50 ANSWERS
```

```
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
```

```
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
```

```
                        BATCH  **COMPLETE**
```

```
PROJECTED ITERATIONS:      10043 TO      12917
```

```
PROJECTED ANSWERS:         948 TO      1972
```

```
L4      50 SEA SSS SAM L3
```

```
=> =>
```

```
Uploading C:\Program Files\Stnexp\Queries\10809944 (b).str
```



```

chain nodes :
7 8 9
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
27 28 29 30 31
chain bonds :
3-7 7-8
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 16-17 16-20
17-18 18-19 19-20 21-22 21-25 22-23 23-24 24-25 26-27 26-30 26-31 27-28
27-31 28-29 29-30
exact/norm bonds :
3-7 7-8 11-15 14-15 16-20 19-20 21-25 24-25 26-27 26-30 26-31 27-28
27-31 28-29 29-30
exact bonds :
11-12 12-13 13-14 16-17 17-18 18-19 21-22 22-23 23-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 11 : 16 : 21 : 26 :

```

```
G1:[*1],[*2],[*3],[*4]
```

```
Match level :
```

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom

```

Generic attributes :

8:

Saturation : Unsaturated

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

=> s 15 sss sam

SAMPLE SEARCH INITIATED 12:23:51 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 574 TO ITERATE

100.0% PROCESSED 574 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 10043 TO 12917

PROJECTED ANSWERS: 833 TO 1807

L6 50 SEA SSS SAM L5

=> => s 15 sss ful

FULL SEARCH INITIATED 12:27:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 10768 TO ITERATE

100.0% PROCESSED 10768 ITERATIONS

1187 ANSWERS

SEARCH TIME: 00.00.01

L7 1187 SEA SSS FUL L5

=> => s 17


L8 35 L7

=> d 18 1-35 bib,ab,hitstr

L8 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:318550 CAPLUS  
 DN 144:370117  
 TI Preparation of HIV inhibiting 5-heterocyclyl pyrimidines  
 IN Guillemont, Jerome Emile Georges; Heeres, Jan; Lewi, Paulus Joannes  
 PA Tibotec Pharmaceuticals Ltd., Ire.  
 SO PCT Int. Appl., 67 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006035067	A2	20060406	WO 2005-EP54930	20050929
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2004-104812	A	20040930		
OS	MARPAT 144:370117				
AB	HIV replication inhibitors I [-a1=a2-a3=a4- = -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N-, -N=N-CH=CH-; -b1=b2-b3=b4- = -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N-, -N=N-CH=CH-; R1 = H, aryl, formyl, alkylcarbonyl, etc.; R2 = OH, halo, (un)substituted alkyl, alkenyl, etc.; R2a = CN, (un)substituted amino, (un)substituted alkyl, etc.; X1 = NR1, O, C(O), CH2, CHOH, S, S(O)p; R3 = CN, amino, alkyl, etc.; R4 = halo, OH, (un)substituted alkyl, alkenyl, etc.; R5 = 5-6 membered completely unsatd. ring system wherein 1-4 ring members are N, O or S, which ring may optionally be substituted and may optionally be annelated with a benzene ring; Q = H, alkyl, halo, etc.; n, m = 0-4; p = 1-2; and N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof]. E.g., a multi-step synthesis of II, starting from 2,4-dichloro-5-nitropyrimidine and 4-(2-cyanoethenyl)-2,6-dimethylphenylamine, was given. The antiviral activity of the compds. I was evaluated in the presence of the wild type HIV and HIV mutants bearing mutations at the reverse transcriptase gene (data given). The invention also relates to the use of compds. I for the prevention or the treatment of HIV infection.				
IT	882054-44-6P 882054-45-7P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of HIV inhibiting 5-heterocyclyl pyrimidines)				
RN	882054-44-6 CAPLUS				
CN	Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)				


Double bond geometry as shown.



RN 882054-45-7 CAPLUS

CN Benzonitrile, 4-[[5-(2-amino-5-thiazolyl)-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



L8 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:193566 CAPLUS  
 DN 144:267267  
 TI Method of treatment and compositions for a disease associated with  
 antinuclear antibodies  
 IN Benigni, Ariela; Zoja, Carla; Remuzzi, Giuseppe; Giannella-Borradori,  
 Athos  
 PA Cyclacel Limited, UK  
 SO PCT Int. Appl., 87 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021803	A2	20060302	WO 2005-GB3350	20050825
	WO 2006021803	A3	20060420		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	GB 2004-19175	A	20040827		
	GB 2004-19176	A	20040827		
AB	The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof is administered in an amount sufficient to down-regulate the levels of antinuclear antibodies. A further aspect of the invention relates to a combination comprising an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, such as systemic lupus erythematosus. Mice treated with CYC202 at the doses of 200 and 100 mg/kg survived significantly longer than vehicle-treated mice.				
IT	364334-88-3 693228-63-6 693229-59-3 870780-24-8 870780-29-3 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (method of treatment and compns. for disease associated with antinuclear antibodies)				
RN	364334-88-3 CAPLUS				
CN	1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)				






RN 693228-63-6 CAPLUS

CN 2-Pyrimidinamine, 4-[(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 693229-59-3 CAPLUS

CN 2-Pyrimidinamine, 4-[(4-methyl-2-(methylanino)-5-thiazolyl)-N-[4-(1-piperazinyl)phenyl]]- (9CI) (CA INDEX NAME)



RN 870780-24-8 CAPLUS

CN Acetamide, N-[[4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-29-3 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(acetamidomethyl)phenyl]- (9CI) (CA INDEX NAME)

10/809,946


(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:183501 CAPLUS  
 DN 144:343077  
 TI Differential Binding of Inhibitors to Active and Inactive CDK2 Provides Insights for Drug Design  
 AU Kontopidis, George; McInnes, Campbell; Pandalaneni, Sravan R.; McNae, Iain; Gibson, Darren; Mezna, Mokdad; Thomas, Mark; Wood, Gavin; Wang, Shudong; Walkinshaw, Malcolm D.; Fischer, Peter M.  
 CS James Lindsay Place, Cyclacel Ltd., Dundee, DD1 5JJ, UK  
 SO Chemistry & Biology (Cambridge, MA, United States) (2006), 13(2), 201-211  
 CODEN: CBOLE2; ISSN: 1074-5521  
 PB Cell Press  
 DT Journal  
 LA English  
 AB The cyclin-dependent kinases (CDKs) have been characterized in complex with a variety of inhibitors, but the majority of structures solved are in the inactive form. We have solved the structures of six inhibitors in both the monomeric CDK2 and binary CDK2/cyclinA complexes and demonstrate that significant differences in ligand binding occur depending on the activation state. The binding mode of two ligands in particular varies substantially in active and inactive CDK2. Furthermore, energetic anal. of CDK2/cyclin/inhibitors demonstrates that a good correlation exists between the in vitro potency and the calculated energies of interaction, but no such relationship exists for CDK2/inhibitor structures. These results confirm that monomeric CDK2 ligand complexes do not fully reflect active conformations, revealing significant implications for inhibitor design while also suggesting that the monomeric CDK2 conformation can be selectively inhibited.  
 IT 364333-96-0 364334-88-3 507487-89-0  
 693228-63-6  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (differential binding of inhibitors to active and inactive CDK2 provides insights for drug design)  
 RN 364333-96-0 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-88-3 CAPLUS  
 CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-  
(9CI) (CA INDEX NAME)



RN 693228-63-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:1289100 CAPLUS  
 DN 144:36367  
 TI Preparation of 2-substituted 4-thiazolylpyrimidines as protein kinase inhibitors with improved solubility properties  
 IN Wang, Shudong; Wood, Gavin; Duncan, Kenneth; Meades, Christopher; Gibson, Darron; McLachlan, Janice; Fischer, Peter  
 PA Cyclacel Limited, UK  
 SO PCT Int. Appl., 216 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005116025	A2	20051208	WO 2005-GB2134	20050526
	WO 2005116025	A3	20060223		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	GB 2004-11791	A	20040526		

OS MARPAT 144:36367

AB The present invention relates to 2-substituted 4-thiazolylpyrimidines (shown as I; variables defined below; e.g. (3-methylsulfonylphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine (shown as II)), their preparation, pharmaceutical compns. containing them and their use as inhibitors of  $\geq 1$  protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders. For I: 1 of X1 and X2 is S, and the other is N; Z is NH, NHCO, NHCOCH2, NHSO2, NHCH2, CH2, CH2CH2, CH:CH, O, S, SO2, or SO; R1, R2, R3, R4, R5, R6, R7 and R8 = H, alkyl, alkyl-R9, aryl, aryl-R9, aralkyl, aralkyl-R9, halo, et al. or two of R4-R8 are linked to form a cyclic ether containing  $\geq 1$  oxygens; R9 = solubilizing group = mono, di- or polyhydroxylated alicyclic, di- or polyhydroxylated aliphatic or aromatic, carbohydrate derivative, O- and/or S-containing heterocyclic group, et al.; addnl.

details including provisos are given in the claims. Protein kinase inhibition properties of many I for many kinases are tabulated. Although the methods of preparation are not claimed, preps. and/or characterization data for 220 examples of I are included. For example, [4-(2-tert-butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methyl-3-nitrophenyl)amine was prepared by condensation of 1-(2-tert-butylamino-4-methylthiazol-5-yl)-3-dimethylaminopropenone and N-(4-methyl-3-nitrophenyl)guanidine nitrate. Compds. I are also claimed useful in an assay for identifying further candidate compds. capable of inhibiting various enzymes.

IT 870780-10-2P, 1-[4-[3-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone  
 870780-83-9P, 1-[4-[4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-


2-yl]amino]phenyl]piperazin-1-yl]ethanone 870780-84-0P,  
 1-[4-[4-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870781-42-3P,  
 N-[3-[[4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide

RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);  
 RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL  
 (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES  
 (Uses)

(drug candidate; preparation of 2-substituted 4-thiazolylpyrimidines as  
 protein kinase inhibitors with improved solubility properties)


RN 870780-10-2 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870780-83-9 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870780-84-0 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870781-42-3 CAPLUS

CN Acetamide, N-[[3-[[4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl)methyl]- (9CI) (CA INDEX NAME)



IT 870780-07-7P, [3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]acetic acid 2-methoxyethyl ester 870780-08-8P, [4-(2-tert-Butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl] (4-methyl-3-nitrophenyl)amine 870780-11-3P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3-methylsulfonylphenyl)amine 870780-12-4P, N-[3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]methanesulfonamide 870780-15-7P, N-[3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]methanesulfonamide 870780-16-8P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl] [3-(piperazin-1-yl)phenyl]amine 870780-17-9P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] [3-(piperazin-1-yl)phenyl]amine 870780-18-0P, N-[3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]benzamide 870780-19-1P, N-[3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]-1,1,1-trifluoromethanesulfonamide 870780-20-4P, N-[3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]-1,1,1-trifluoromethanesulfonamide 870780-23-7P, N-[3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]-1,1,1-trifluoromethanesulfonamide 870780-24-8P, N-[4-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]acetamide 870780-26-0P, N-[4-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzyl]acetamide 870780-27-1P, N-[4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]acetamide 870780-28-2P, N-[4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]acetamide 870780-29-3P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl] (4-methylsulfonylphenyl)amine 870780-30-6P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-31-7P, 3-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-32-8P, (4-Methylsulfonylphenyl) [4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 870780-33-9P, N-Methyl-3-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-35-1P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-methylbenzenesulfonamide 870780-36-2P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl] (3,4,5-trimethoxyphenyl)amine 870780-37-3P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl] (3,4,5-trimethoxyphenyl)amine 870780-38-4P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3,4,5-trimethoxyphenyl)amine 870780-39-5P, 3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-methylbenzenesulfonamide 870780-40-8P, (3-Methylsulfonylphenyl) [4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 870780-41-9P, [4-(2-Ethylamino-4-methylthiazol-5-

yl)pyrimidin-2-yl](3-methylsulfonylphenyl)amine 870780-42-0P,  
 N-Ethyl-3-[[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-44-2P, 3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-ethylbenzenesulfonamide 870780-45-3P, N-Ethyl-3-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-46-4P, N-(3-Methoxyphenyl)-3-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-49-7P, 3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-methylbenzenesulfonamide 870780-50-0P, 4-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-51-1P, 4-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-52-2P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-methyl-3-[(morpholin-4-yl)sulfonyl]phenyl]amine 870780-55-5P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl][4-methyl-3-[(morpholin-4-yl)sulfonyl]phenyl]amine 870780-56-6P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-methyl-3-[(morpholin-4-yl)sulfonyl]phenyl]amine 870780-57-7P, 4-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-58-8P, N-(2-Methoxyethyl)-4-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-59-9P, 4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-60-2P, (3-Bromo-4-methylphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 870780-63-5P, 4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-64-6P, [3-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]acetic acid 2-methoxyethyl ester 870780-65-7P, [3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]acetic acid 2-methoxyethyl ester 870780-66-8P, 1-[4-[3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870780-67-9P, [3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-5-hydroxymethylphenyl]methanol 870780-70-4P, [3-Hydroxymethyl-5-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]methanol 870780-71-5P, N-[3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]methanesulfonamide 870780-72-6P, (3-Bromophenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870780-75-9P, [4-(2-tert-Butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 870780-76-0P, N,N-Diethyl-4-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-78-2P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-80-6P, N-(2-Methoxyethyl)-3-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-81-7P, 3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-82-8P, 3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide 870780-85-1P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(piperazin-1-yl)phenyl]amine 870780-86-2P, [4-(4-Benzylpiperazin-1-yl)phenyl][4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870780-87-3P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(piperazin-1-yl)phenyl]amine 870780-88-4P, [3-[[4-[[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]sulfonyl]amino]phenyl]acetic acid ethyl ester 870780-90-8P, N-Acetyl-3-[[4-(4-methyl-



2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-92-0P, N-Acetyl-3-[[4-(2-amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-93-1P, 4-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870780-95-3P, 4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-ethylbenzenesulfonamide 870780-97-5P, N-(2-Hydroxyethyl)-4-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870780-98-6P, 4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870780-99-7P, 4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870781-00-3P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-isopropylbenzenesulfonamide 870781-02-5P, N-Benzyl-4-[[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-04-7P, N-Benzyl-4-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-05-8P, 4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-benzylbenzenesulfonamide 870781-06-9P, N-Benzyl-4-[[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-07-0P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870781-09-2P, N-(2-Hydroxyethyl)-3-[[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-10-5P, 3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870781-11-6P, 3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870781-13-8P, N-Benzyl-3-[[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-15-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-[(morpholin-4-yl)sulfonyl]phenyl]amine 870781-17-2P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-methyl-3-[(morpholin-4-yl)sulfonyl]phenyl]amine 870781-18-3P, 3-[[4-(2-(2-Methoxyethylamino)-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide 870781-20-7P, 3-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-N-(2-hydroxy-1,1-dimethylethyl)benzenesulfonamide 870781-29-6P, (3-Aminomethylphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870781-30-9P, Pyridine-2-carboxylic acid N-[3-[[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzyl]amide 870781-39-8P, [4-[2-(2-Ethylpyridin-4-yl)-4-methylthiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-41-2P, [4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-43-4P, 4-[[4-[2-(2-Ethylpyridin-4-yl)-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide 870781-44-5P, N-[4-[[4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-45-6P, N-[4-[[4-[2-(2-Ethylpyridin-4-yl)-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-46-7P, N-[3-[[4-[2-(2-Ethylpyridin-4-yl)-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-47-8P, [4-[4-Methyl-2-(6-methylpyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-49-0P, [4-[2-[3-(2-Methoxyethoxy)-5-trifluoromethylpyridin-2-yl]-4-methylthiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870781-51-4P, N-[3-[[4-[4-Methyl-2-(6-methylpyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide

870781-52-5P, N-[3-[[4-[2-(3-Chloro-5-trifluoromethylpyridin-2-yl)-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide  
870781-54-7P, N-(2-Methoxyethyl)-4-[[4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amino]benzenesulfonamide  
870781-56-9P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl] (4-methoxy-2-methylphenyl)amine 870781-58-1P,  
[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (4-methoxy-2-methylphenyl)amine 870781-59-2P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (5-methoxy-2-methylphenyl)amine 870781-61-6P,  
[4-(4-Benzylpiperazin-1-yl)phenyl] [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870781-62-7P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl] (5-methoxy-2-methylphenyl)amine 870781-63-8P,  
(3-Aminomethylphenyl) [4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870781-64-9P, [4-[2-[(Benzyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl] [4-(morpholin-4-yl)phenyl]amine 870781-66-1P,  
N-[3-[[4-[2-[(Benzyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-67-2P, 1-[4-[4-[[4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870781-68-3P, [4-[2-[(Ethyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl] [4-(morpholin-4-yl)phenyl]amine 870781-70-7P, [4-(2,6-Dimethylmorpholin-4-yl)phenyl] [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870781-72-9P,  
1-[4-[4-[[4-[2-[(Benzyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870781-74-1P,  
[4-[2-[(3,5-Dichlorophenyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl] [4-(morpholin-4-yl)phenyl]amine 870781-76-3P,  
[4-[2-[(4-Chlorophenyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl] [4-(morpholin-4-yl)phenyl]amine 870781-78-5P,  
N-[3-[[4-[2-[(3,5-Dichlorophenyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-79-6P,  
[3,5-Dichloro-4-(morpholin-4-yl)phenyl] [4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870781-81-0P,  
[3-Chloro-4-(morpholin-4-yl)phenyl] [4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870781-82-1P, [3-Chloro-4-(morpholin-4-yl)phenyl] [4-[2-[(3,5-dichlorophenyl)(methyl)amino]-4-methylthiazol-5-yl]pyrimidin-2-yl]amine 870781-83-2P, [4-[4-Methyl-2-(thiophen-2-yl)thiazol-5-yl]pyrimidin-2-yl] [4-(morpholin-4-yl)phenyl]amine 870781-84-3P, N-[3-[[4-[4-Methyl-2-(thiophen-2-yl)thiazol-5-yl]pyrimidin-2-yl]amino]benzyl]acetamide 870781-85-4P,  
1-[4-[4-[[4-[4-Methyl-2-(thiophen-2-yl)thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870781-86-5P,  
[5-[2-[(4-Dimethylaminophenyl)amino]pyrimidin-4-yl]-4-methylthiazol-2-yl]methanol 870781-89-8P, [3,5-Dichloro-4-(morpholin-4-yl)phenyl] [4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870781-90-1P, [3-Chloro-4-(morpholin-4-yl)phenyl] [4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870781-91-2P,  
[4-(4,2'-Dimethyl-[2,4']bithiazolyl-5-yl)pyrimidin-2-yl] [4-(morpholin-4-yl)phenyl]amine 870781-93-4P, [3-Chloro-4-(morpholin-4-yl)phenyl] [4-(4,2'-dimethyl-[2,4']bithiazolyl-5-yl)pyrimidin-2-yl]amine 870781-94-5P, [3,5-Dichloro-4-(morpholin-4-yl)phenyl] [4-(4,2'-dimethyl-[2,4']bithiazolyl-5-yl)pyrimidin-2-yl]amine 870781-95-6P,  
[4-[4-Methyl-2-[(thien-2-yl)sulfonyl]methyl]thiazol-5-yl]pyrimidin-2-yl] [4-(morpholin-4-yl)phenyl]amine 870781-97-8P,  
[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] [2-methyl-4-(morpholin-4-yl)phenyl]amine 870781-99-0P, [4-[2-(2,4-Dimethylphenyl)-4-methylthiazol-5-yl]pyrimidin-2-yl] [4-(morpholin-4-yl)phenyl]amine 870782-01-7P, [3-Chloro-4-(morpholin-4-yl)phenyl] [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870782-02-8P,

[3,5-Dichloro-4-(morpholin-4-yl)phenyl][4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870782-03-9P, [4-(2-tert-Butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-04-0P, [4-[2-(2-Methoxyethylamino)-4-methylthiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-05-1P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl][2-methyl-4-(morpholin-4-yl)phenyl]amine 870782-06-2P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][2-methyl-4-(morpholin-4-yl)phenyl]amine 870782-07-3P, [4-[4-Methyl-2-[4-(morpholin-4-yl)phenyl]thiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-09-5P, 1-[4-[4-[4-[4-Methyl-2-[4-(morpholin-4-yl)phenyl]thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870782-10-8P, N'-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N-methyl-2-trifluoromethylbenzene-1,4-diamine 870782-12-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][3-[(morpholin-4-yl)methyl]phenyl]amine 870782-14-2P, 4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-2-[(morpholin-4-yl)methyl]phenol 870782-16-4P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][3-(morpholin-4-yl)phenyl]amine 870782-18-6P, [4-[4-Methyl-2-[(methyl)(pyridin-3-yl)amino]thiazol-5-yl]pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-20-0P, [4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl](3,4,5-trimethoxyphenyl)amine 870782-21-1P, (3,5-Dimethoxyphenyl)[4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870782-22-2P, [3-Methoxy-4-(morpholin-4-yl)phenyl][4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870782-24-4P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methoxy-4-(morpholin-4-yl)phenyl]amine 870782-25-5P, [4-(4-Methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-27-7P, (3,5-Dimethoxyphenyl)[4-(4-methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-28-8P, (3,5-Dimethoxyphenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870782-29-9P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3,5-dimethoxyphenyl)amine 870782-30-2P, 1-[4-[4-[4-(4-Methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870782-31-3P, 1-[4-[4-[4-[4-Methyl-2-[(methyl)(pyridin-3-yl)amino]thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870782-32-4P, [4-(4-Methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl](3,4,5-trimethoxyphenyl)amine 870782-33-5P, [4-(4-Benzylpiperazin-1-yl)phenyl][4-(4-methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-34-6P, [4-(4-Methyl-2-phenylaminothiazol-5-yl)pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 870782-36-8P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3,4,5-trimethoxyphenyl)amine 870782-37-9P, [4-(2,6-Dimethylmorpholin-4-yl)phenyl][4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870782-38-0P, (3,5-Dimethoxyphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-39-1P, (3,5-Dimethoxyphenyl)[4-(4-methyl-2-phenylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-40-4P, 1-[4-[4-[4-(4-Methyl-2-phenylaminothiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone 870782-41-5P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][3-methoxy-4-(morpholin-4-yl)phenyl]amine 870782-42-6P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-[(morpholin-4-yl)methyl]phenyl]amine 870782-44-8P, (3,5-Dimethoxyphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 870782-45-9P, [4-(4-Benzylpiperazin-1-yl)phenyl][4-(4-methyl-2-phenylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-46-0P, (Benzodioxol-5-yl)[4-[4-


methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine  
 870782-47-1P, (Benzodioxol-5-yl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870782-48-2P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](benzodioxol-5-yl)amine 870782-49-3P, (2,3-Dihydrobenzo[1,4]dioxin-6-yl)[4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870782-50-6P, (2,3-Dihydrobenzo[1,4]dioxin-6-yl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 870782-51-7P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methoxy-4-(morpholin-4-yl)phenyl]amine 870782-52-8P, (2,3-Dihydrobenzo[1,4]dioxin-6-yl)[4-(4-methyl-2-phenethylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-53-9P, (4-Methoxy-3-methylphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 870782-55-1P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methoxy-3-methylphenyl)amine 870782-56-2P, (4-Methoxy-3-methylphenyl)[4-(4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870782-57-3P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methoxy-3-methylphenyl)amine 870782-58-4P, [4-Methyl-5-[2-[[4-(morpholin-4-yl)phenyl]amino]pyrimidin-4-yl]thiazol-2-yl]methanol 870782-59-5P  
 , 4-[4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylic acid ethyl ester 870782-61-9P, 2-[4-[4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]-N-isopropylacetamide 870782-63-1P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl][4-(4-methylpiperazin-1-yl)phenyl]amine 870782-64-2P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-(piperidin-1-yl)phenyl]amine 870782-66-4P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(piperidin-1-yl)phenyl]amine 870782-67-5P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(piperidin-1-yl)phenyl]amine 870782-68-6P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(4-methylpiperazin-1-yl)phenyl]amine 870782-69-7P, [4-Methyl-5-[2-[[4-(piperidin-1-yl)phenyl]amino]pyrimidin-4-yl]thiazol-2-yl]methanol 870782-70-0P, [4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl][4-(pyrrolidin-1-yl)phenyl]amine 870782-72-2P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-(pyrrolidin-1-yl)phenyl]amine 870782-73-3P, [5-[2-[[3-Methoxy-4-(morpholin-4-yl)phenyl]amino]pyrimidin-4-yl]-4-methylthiazol-2-yl]methanol 870782-74-4P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(4-thiomorpholinyl)phenyl]amine 870782-76-6P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-(4-thiomorpholinyl)phenyl]amine 870782-77-7P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][4-(4-thiomorpholinyl)phenyl]amine 870782-78-8P, [4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl][4-(4-thiomorpholinyl)phenyl]amine 870782-79-9P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(piperidin-1-yl)phenyl]amine 870782-81-3P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(piperidin-1-yl)phenyl]amine 870782-82-4P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(piperidin-1-yl)phenyl]amine 870782-83-5P, [3-Methyl-4-(piperidin-1-yl)phenyl][4-[4-methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl]amine 870782-84-6P, [4-Methyl-5-[2-[[3-methyl-4-(piperidin-1-yl)phenyl]amino]pyrimidin-4-yl]thiazol-2-yl]methanol 870782-85-7P, 5-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-2-(morpholin-4-yl)benzamide 870782-87-9P, 5-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-2-(morpholin-4-yl)benzamide 870782-88-0P, 5-[[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]-2-(morpholin-4-yl)benzamide 870782-89-1P, Cyclopropyl[4-[4-[[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-

yl]amino]phenyl]piperazin-1-yl]methanone 870782-91-5P,  
 [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-methyl-3-(morpholin-4-yl)phenyl]amine 870782-93-7P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-methoxy-3-[(morpholin-4-yl)methyl]phenyl]amine 870782-95-9P, [5-[2-[[3-Methoxy-4-(piperidin-1-yl)phenyl]amino]pyrimidin-4-yl]-4-methylthiazol-2-yl]methanol 870782-97-1P, [4-Methyl-5-[2-[[3-methyl-4-(morpholin-4-yl)phenyl]amino]pyrimidin-4-yl]thiazol-2-yl]methanol 870782-99-3P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(morpholin-4-yl)phenyl]amine 870783-00-9P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(morpholin-4-yl)phenyl]amine 870783-01-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][3-methyl-4-(morpholin-4-yl)phenyl]amine  
 RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2-substituted 4-thiazolylpyrimidines as protein kinase inhibitors with improved solubility properties)


RN 870780-07-7 CAPLUS

CN Benzeneacetic acid, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 870780-08-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(1,1-dimethylethyl)amino]-4-methyl-5-thiazolyl]-N-(4-methyl-3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 870780-11-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-12-4 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-15-7 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-16-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[3-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-17-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(1-piperazinyl)phenyl]-  
(9CI) (CA INDEX NAME)




RN 870780-18-0 CAPLUS

CN Benzamide, N-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-19-1 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 870780-20-4 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 870780-23-7 CAPLUS


CN Methanesulfonamide, N-[[3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 870780-24-8 CAPLUS


CN Acetamide, N-[[4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)






RN 870780-26-0 CAPLUS

CN Acetamide, N-[[4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-27-1 CAPLUS

CN Acetamide, N-[[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 870780-28-2 CAPLUS


CN Acetamide, N-[[4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 870780-29-3 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-

(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-30-6 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-31-7 CAPLUS

CN Benzenesulfonamide, 3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-32-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-33-9 CAPLUS

CN Benzenesulfonamide, N-methyl-3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-35-1 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 870780-36-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870780-37-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870780-38-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870780-39-5 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 870780-40-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-41-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-42-0 CAPLUS

CN Benzenesulfonamide, N-ethyl-3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-44-2 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-ethyl- (9CI) (CA INDEX NAME)




RN 870780-45-3 CAPLUS

CN Benzenesulfonamide, N-ethyl-3-[[4-[[4-methyl-2-(methyamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-46-4 CAPLUS

CN Benzenesulfonamide, N-(3-methoxyphenyl)-3-[[4-[[4-methyl-2-(methyamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-49-7 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 870780-50-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-[4-methyl-2-(methyamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-51-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(ethyamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-52-2 CAPLUS

CN Morpholine, 4-[[5-[[4-[2-(ethyamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-2-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870780-55-5 CAPLUS

CN Morpholine, 4-[[2-methyl-5-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870780-56-6 CAPLUS

CN Morpholine, 4-[[5-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 870780-57-7 CAPLUS


CN Benzenesulfonamide, 4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 870780-58-8 CAPLUS


CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)






RN 870780-59-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 870780-60-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromo-4-methylphenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 870780-63-5 CAPLUS


CN Benzenesulfonamide, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 870780-64-6 CAPLUS


CN Benzeneacetic acid, 3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-

pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 870780-65-7 CAPLUS

CN Benzeneacetic acid, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 870780-66-8 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870780-67-9 CAPLUS

CN 1,3-Benzenedimethanol, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-70-4 CAPLUS

CN 1,3-Benzenedimethanol, 5-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-71-5 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870780-72-6 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870780-75-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(1,1-dimethylethyl)amino]-4-methyl-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 870780-76-0 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-78-2 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 870780-80-6 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-81-7 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 870780-82-8 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 870780-85-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870780-86-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 870780-87-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(1-phenylmethyl)-1-piperazinyl]phenyl- (9CI) (CA INDEX NAME)




RN 870780-88-4 CAPLUS

CN Benzeneacetic acid, 3-[[[4-[[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]sulfonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 870780-90-8 CAPLUS

CN Acetamide, N-[[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870780-92-0 CAPLUS

CN Acetamide, N-[[3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870780-93-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 870780-95-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-ethyl- (9CI) (CA INDEX NAME)




RN 870780-97-5 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870780-98-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 870780-99-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 870781-00-3 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




pyrimidinyl]amino]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 870781-02-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 870781-04-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 870781-05-8 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 870781-06-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 870781-07-0 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 870781-09-2 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870781-10-5 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 870781-11-6 CAPLUS

CN Benzenesulfonamide, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 870781-13-8 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 870781-15-0 CAPLUS

CN Morpholine, 4-[[3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870781-17-2 CAPLUS

CN Morpholine, 4-[[5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 870781-18-3 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-[(2-methoxyethyl)amino]-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870781-20-7 CAPLUS

CN Benzenesulfonamide, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 870781-29-6 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 870781-30-9 CAPLUS

CN 2-Pyridinecarboxamide, N-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-39-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(2-ethyl-4-pyridinyl)-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-41-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-43-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-[2-(2-ethyl-4-pyridinyl)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 870781-44-5 CAPLUS

CN Acetamide, N-[[4-[[4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-45-6 CAPLUS

CN Acetamide, N-[[4-[[4-[2-(2-ethyl-4-pyridinyl)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-46-7 CAPLUS

CN Acetamide, N-[[3-[[4-[2-(2-ethyl-4-pyridinyl)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-47-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(6-methyl-3-pyridinyl)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-49-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[3-(2-methoxyethoxy)-5-(trifluoromethyl)-2-pyridinyl]-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870781-51-4 CAPLUS


CN Acetamide, N-[[3-[[4-[4-methyl-2-(6-methyl-3-pyridinyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 870781-52-5 CAPLUS


CN Acetamide, N-[[3-[[4-[2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)






RN 870781-54-7 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 870781-56-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870781-58-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870781-59-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(5-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870781-61-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 870781-62-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(5-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870781-63-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870781-64-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[(phenylmethyl)amino]-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-66-1 CAPLUS

CN Acetamide, N-[[3-[[4-[4-methyl-2-[(phenylmethyl)amino]-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-67-2 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870781-68-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylmethylamino)-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-70-7 CAPLUS

CN 2-Pyrimidinamine, N-[4-(2,6-dimethyl-4-morpholinyl)phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 870781-72-9 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-[methyl(phenylmethyl)amino]-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870781-74-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(3,5-dichlorophenyl)methylamino]-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-76-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(4-chlorophenyl)methylamino]-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-78-5 CAPLUS

CN Acetamide, N-[[[3-[[4-[2-[(3,5-dichlorophenyl)methylamino]-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-79-6 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-dichloro-4-(4-morpholinyl)phenyl]-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870781-81-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870781-82-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-4-[2-[(3,5-dichlorophenyl)methylamino]-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870781-83-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(2-thienyl)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-84-3 CAPLUS

CN Acetamide, N-[3-[[4-[4-methyl-2-(2-thienyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 870781-85-4 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-(2-thienyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870781-86-5 CAPLUS

CN 2-Thiazolemethanol, 5-[2-[[4-(dimethylamino)phenyl]amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 870781-89-8 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-dichloro-4-(4-morpholinyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 870781-90-1 CAPLUS


CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 870781-91-2 CAPLUS


CN 2-Pyrimidinamine, 4-(2',4'-dimethyl[2,4'-bithiazol]-5-yl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)






RN 870781-93-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-4-(2',4-dimethyl[2,4'-bithiazol]-5-yl)- (9CI) (CA INDEX NAME)




RN 870781-94-5 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-dichloro-4-(4-morpholinyl)phenyl]-4-(2',4-dimethyl[2,4'-bithiazol]-5-yl)- (9CI) (CA INDEX NAME)




RN 870781-95-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[(2-thienylsulfonyl)methyl]-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-97-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[2-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870781-99-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(2,4-dimethylphenyl)-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-01-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 870782-02-8 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-dichloro-4-(4-morpholinyl)phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 870782-03-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(1,1-dimethylethyl)amino]-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-04-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(2-methoxyethyl)amino]-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870782-05-1 CAPLUS


CN 2-Pyrimidinamine, 4-[4-methyl-2-(methyamino)-5-thiazolyl]-N-[2-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870782-06-2 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[2-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-07-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[4-(4-morpholinyl)phenyl]-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-09-5 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-[4-(4-morpholinyl)phenyl]-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870782-10-8 CAPLUS

CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1-methyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 870782-12-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-14-2 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 870782-16-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-18-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methyl-3-pyridinylamino)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-20-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870782-21-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-22-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-4-(4-morpholinyl)phenyl]-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-24-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[3-methoxy-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-25-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-27-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-28-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-29-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 870782-30-2 CAPLUS


CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870782-31-3 CAPLUS


CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-(methyl-3-pyridinylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)






RN 870782-32-4 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870782-33-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]-N-[4-(phenylmethyl)-1-piperazinyl]phenyl)- (9CI) (CA INDEX NAME)




RN 870782-34-6 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(phenylamino)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-36-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 870782-37-9 CAPLUS

CN 2-Pyrimidinamine, N-[4-(2,6-dimethyl-4-morpholinyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-38-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-39-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[4-methyl-2-(phenylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-40-4 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-(phenylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870782-41-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-methoxy-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-42-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-44-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 870782-45-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(phenylamino)-5-thiazolyl]-N-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 870782-46-0 CAPLUS

CN 2-Pyrimidinamine, N-1,3-benzodioxol-5-yl-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-47-1 CAPLUS

CN 2-Pyrimidinamine, N-1,3-benzodioxol-5-yl-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-48-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-1,3-benzodioxol-5-yl- (9CI) (CA INDEX NAME)




RN 870782-49-3 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-50-6 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-51-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[3-methoxy-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-52-8 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[4-methyl-2-[(2-phenylethyl)amino]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-53-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy-3-methylphenyl)-4-[4-methyl-2-(methylanino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-55-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-methoxy-3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870782-56-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy-3-methylphenyl)-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-57-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-methoxy-3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 870782-58-4 CAPLUS

CN 2-Thiazolemethanol, 4-methyl-5-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 870782-59-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 870782-61-9 CAPLUS

CN 1-Piperazineacetamide, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 870782-63-1 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylanino)-5-thiazolyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-64-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-66-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870782-67-5 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)






RN 870782-68-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-69-7 CAPLUS

CN 2-Thiazolemethanol, 4-methyl-5-[2-[[4-(1-piperidiny)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 870782-70-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870782-72-2 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870782-73-3 CAPLUS


CN 2-Thiazolemethanol, 5-[2-[[3-methoxy-4-(4-morpholinyl)phenyl]amino]-4-

pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 870782-74-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-76-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-77-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-78-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-[4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-79-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-methyl-4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-81-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[3-methyl-4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-82-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[3-methyl-4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-83-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-methyl-4-(1-piperidinyl)phenyl]-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870782-84-6 CAPLUS

CN 2-Thiazolemethanol, 4-methyl-5-[2-[[3-methyl-4-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 870782-85-7 CAPLUS

CN Benzamide, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 870782-87-9 CAPLUS

CN Benzamide, 5-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 870782-88-0 CAPLUS

CN Benzamide, 5-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 870782-89-1 CAPLUS

CN Piperazine, 1-(cyclopropylcarbonyl)-4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870782-91-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-methyl-3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-93-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-methoxy-3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870782-95-9 CAPLUS

CN 2-Thiazolemethanol, 5-[2-[[3-methoxy-4-(1-piperidiny)phenyl]amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 870782-97-1 CAPLUS

CN 2-Thiazolemethanol, 4-methyl-5-[2-[[3-methyl-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 870782-99-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[3-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 870783-00-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[3-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 870783-01-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:1262395 CAPLUS  
 DN 144:22936  
 TI Preparation of aminopyrimidine derivatives as aurora 2 kinase inhibitors  
 for treatment of cancer  
 IN Tomozane, Hideo; Ando, Ryoichi; Oike, Shinsuke  
 PA Mitsubishi Pharma Corporation, Japan  
 SO PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005113550	A1	20051201	WO 2005-JP9119	20050519
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2004-150962 A 20040520

OS MARPAT 144:22936

AB The title aminopyrimidine derivs. I [wherein R1 and R2 = independently halo, alkyl, OH, alkoxy, amino, alkylamino, or acylamino; R3 and R4 = independently H, halo, alkyl, OH, or alkoxy; R5 = H, alkyl, or acyl; R6 and R7 = independently H, halo, alkyl, OH, etc.; R8 = (un)substituted COH, CO2H, CONH2, etc.; R9 = H, alkyl, OH, alkoxy, etc.], or pharmaceutically acceptable salts, hydrates, or solvates thereof were prepared as aurora 2 kinase inhibitors for the treatment of cancer. For example, the compound II was prepared in a multi-step synthesis. II inhibited aurora 2 kinase with IC50 of 4 nM.

IT 870458-86-9P 870459-09-9P 870459-17-9P

870459-18-0P 870459-19-1P 870459-20-4P

870459-21-5P 870459-24-8P 870459-30-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of aminopyrimidine derivs. as aurora 2 kinase inhibitors for treatment of cancer)

RN 870458-86-9 CAPLUS


CN 1,3-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N'-hydroxy- (9CI) (CA INDEX NAME)






RN 870459-09-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-17-9 CAPLUS

CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 870459-18-0 CAPLUS


CN Benzenemethanesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-19-1 CAPLUS


CN Butanamide, 4-bromo-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-20-4 CAPLUS

CN Carbamic acid, [2-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 870459-21-5 CAPLUS

CN Carbamic acid, [3-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 870459-24-8 CAPLUS

CN Propanamide, 3-amino-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-30-6 CAPLUS

CN Urea, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




IT 693229-35-5P 870458-87-0P 870458-88-1P  
 870458-89-2P 870458-90-5P 870458-91-6P  
 870458-92-7P 870458-93-8P 870458-94-9P  
 870458-95-0P 870458-96-1P 870458-97-2P  
 870458-98-3P 870458-99-4P 870459-00-0P  
 870459-01-1P 870459-02-2P 870459-03-3P  
 870459-04-4P 870459-05-5P 870459-06-6P  
 870459-07-7P 870459-08-8P 870459-10-2P  
 870459-11-3P 870459-12-4P 870459-13-5P  
 870459-14-6P 870459-15-7P 870459-16-8P  
 870459-22-6P 870459-23-7P 870459-25-9P  
 870459-26-0P 870459-27-1P 870459-28-2P  
 870459-29-3P 870459-31-7P 870459-32-8P  
 870459-33-9P 870459-34-0P 870459-35-1P  
 870459-36-2P 870459-37-3P 870459-38-4P  
 870459-39-5P 870459-40-8P 870459-41-9P  
 870459-42-0P 870459-43-1P 870459-44-2P  
 870459-45-3P 870459-46-4P 870459-47-5P  
 870459-48-6P 870459-49-7P 870459-50-0P  
 870459-51-1P 870459-52-2P 870459-53-3P  
 870459-54-4P 870459-57-7P 870459-59-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidine derivs. as aurora 2 kinase inhibitors for treatment of cancer)


RN 693229-35-5 CAPLUS

CN Acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870458-87-0 CAPLUS

CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 870458-88-1 CAPLUS

CN Acetamide, N-(acetyloxy)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 870458-89-2 CAPLUS

CN Butanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 870458-90-5 CAPLUS

CN Butanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-(1-oxobutoxy)- (9CI) (CA INDEX NAME)




RN 870458-91-6 CAPLUS

CN Benzamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 870458-92-7 CAPLUS

CN Benzamide, N-(benzoyloxy)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870458-93-8 CAPLUS

CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870458-94-9 CAPLUS

CN Butanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870458-95-0 CAPLUS

CN Propanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 870458-96-1 CAPLUS

CN Benzamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870458-97-2 CAPLUS

CN Benzeneacetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870458-98-3 CAPLUS


CN Benzenepropanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870458-99-4 CAPLUS


CN Cyclopropanecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-00-0 CAPLUS

CN Cyclohexanecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-01-1 CAPLUS

CN Pentanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-02-2 CAPLUS


CN Octanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)






RN 870459-03-3 CAPLUS

CN 2-Thiophenecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-04-4 CAPLUS

CN 2-Thiopheneacetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-05-5 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-06-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-07-7 CAPLUS

CN 2-Thiophenecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 870459-08-8 CAPLUS

CN 5-Thiazolecarboxamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 870459-10-2 CAPLUS

CN Acetamide, 2-chloro-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-11-3 CAPLUS

CN Methanesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-12-4 CAPLUS

CN 1-Butanesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-13-5 CAPLUS

CN Benzenesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-14-6 CAPLUS

CN 4-Morpholineacetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-15-7 CAPLUS


CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2-[(2-hydroxyethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 870459-16-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 870459-22-6 CAPLUS

CN Carbamic acid, [4-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 870459-23-7 CAPLUS


CN Acetamide, 2-amino-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 870459-25-9 CAPLUS

CN Butanamide, 4-amino-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-26-0 CAPLUS

CN Acetamide, 2-(acetylamino)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-27-1 CAPLUS

CN Propanamide, 3-(acetylamino)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-28-2 CAPLUS

CN Butanamide, 4-(acetylamino)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-29-3 CAPLUS


CN Ethanesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 870459-31-7 CAPLUS  
 CN Glycine, N-[[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 870459-32-8 CAPLUS  
 CN Glycine, N-[[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 870459-33-9 CAPLUS  
 CN Propanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-3,3,3-trifluoro- (9CI) (CA INDEX NAME)




RN 870459-34-0 CAPLUS  
 CN Butanamide, 4-(dimethylamino)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 870459-35-1 CAPLUS

CN Thiourea, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 870459-36-2 CAPLUS


CN Thiourea, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 870459-37-3 CAPLUS


CN 3-Pyridinepropanamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)






RN 870459-38-4 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-39-5 CAPLUS

CN 4-Morpholinepropanesulfonamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-40-8 CAPLUS

CN Benzenesulfonamide, 4-(bromomethyl)-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-41-9 CAPLUS

CN Carbamic acid, [3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 870459-42-0 CAPLUS

CN Carbamic acid, [3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 870459-43-1 CAPLUS


CN Acetamide, N-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-44-2 CAPLUS


CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-

methylphenyl]- (9CI) (CA INDEX NAME)




RN 870459-45-3 CAPLUS

CN Acetamide, N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 870459-46-4 CAPLUS

CN Acetamide, N-[5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 870459-47-5 CAPLUS

CN Acetamide, N-[3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-48-6 CAPLUS

CN Acetamide, N-[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-49-7 CAPLUS

CN Methanesulfonamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-50-0 CAPLUS


CN Ethanesulfonamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 870459-51-1 CAPLUS


CN Benzenemethanesulfonamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-52-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 870459-53-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 870459-54-4 CAPLUS


CN 4-Morpholineacetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 870459-57-7 CAPLUS


CN Acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2-[(2-hydroxyethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 870459-59-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




IT 364333-82-4P 364334-16-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aminopyrimidine derivs. as aurora 2 kinase inhibitors for treatment of cancer)


RN 364333-82-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-16-7 CAPLUS

CN 1,3-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:1155926 CAPLUS  
 DN 144:165710  
 TI Evaluation of phenylaminopyrimidines as antifungal protein kinase inhibitors  
 AU Pillonel, Christian  
 CS Syngenta Crop Protection AG, Basel, CH-4002, Switz.  
 SO Pest Management Science (2005), 61(11), 1069-1076  
 CODEN: PMSFCF; ISSN: 1526-498X  
 PB John Wiley & Sons Ltd.  
 DT Journal  
 LA English  
 AB The effects of diverse phenylaminopyrimidines (PAP), namely PAP-pyridines (type A), PAP-pyrazoles (type B) and PAP-thiazoles (type C), on *Neurospora crassa* has been investigated. Type A strongly inhibit the in vitro growth of *N. crassa*, whereas types B and C are much less active. A significant correlation was observed between the *Neurospora* growth inhibition and the intrinsic activity of type A compds. on the cyclin-dependent protein kinase p34CDC2 of starfish, suggesting that the target of phenylaminopyrimidines in fungi is a cyclin-dependent protein kinase (CDK). The phenylaminopyrimidine-binding CDKs Phoss (major band) and CDC2 (minor band) involved in phosphorus uptake, glycogen synthesis and the cell cycle were identified from *N. crassa* by affinity chromatog. on phenylaminopyrimidine-sepharose. Comparative expts. with different protein kinases revealed the importance of the side chain of phenylaminopyrimidines for their target selectivity. A type B compound was found to selectively inhibit the MAP-kinase OS-2 involved in the osmoregulatory pathway of *Neurospora*.  
 IT 509086-68-4 509086-73-1 509086-76-4  
 509086-77-5 509086-80-0 509086-84-4  
 509087-07-4 509087-28-9 874810-54-5  
 874810-55-6  
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (phenylaminopyrimidines as antifungal protein kinase inhibitors)  
 RN 509086-68-4 CAPLUS  
 CN Benzenemethanol, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




RN 509086-73-1 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)






RN 509086-76-4 CAPLUS

CN Benzenemethanol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]-α-methyl- (9CI) (CA INDEX NAME)




RN 509086-77-5 CAPLUS

CN Phenol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509086-80-0 CAPLUS

CN Ethanone, 1-[3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)




RN 509086-84-4 CAPLUS

CN Benzoic acid, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 509087-07-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 509087-28-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(3-methylphenyl)-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 874810-54-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[4-(4-fluorophenyl)-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 874810-55-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:823700 CAPLUS  
 DN 143:229876  
 TI Preparation of thiazolyl-substituted pyrimidineamines as protein kinase inhibitors  
 IN Duncan, Kenneth; Gibson, Darren; Wang, Shudong; Zheleva, Daniella; Fischer, Peter  
 PA Cyclacel Limited, UK  
 SO PCT Int. Appl., 77 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005075468	A2	20050818	WO 2005-GB405	20050207
	WO 2005075468	A3	20051013		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 2004-2653	A	20040206		

OS MARPAT 143:229876

AB Title compds. I [Z1 = N, CH; Z2-3 = N, CR7; R1-7 = H, hydrocarbaryl, halo, etc.; Z1 = CH or Z2 = N or Z1 = CH and Z2 = N with some exceptions] are prepared For instance, (6-chloropyridin-3-yl)(4-(thiazol-2-yl)pyrimidin-2-yl)amine (II) is prepared from 3-dimethylamino-1-(thiazol-2-yl)propenone and 6-chloropyridin-3-ylamine and aqueous cyanamide solution. II has Ki = 0.016 for protein kinase GSK3. I are useful for the treatment of one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.

IT 862592-85-6P, (6-Chloropyridin-3-yl)(4-(thiazol-2-yl)pyrimidin-2-yl)amine 862592-86-7P, N-[4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl]benzene-1,3-diamine 862592-87-8P, 3-[[4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl]amino]phenol 862592-88-9P, [4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl](3-trifluoromethylphenyl)amine 862592-89-0P, [4-Chloro-3-(trifluoromethyl)phenyl][4-(4,5-dimethylthiazol-2-yl)pyrimidin-2-yl]amine 862592-90-3P, [4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl](3-nitrophenyl)amine 862592-91-4P, (6-Methoxypyridin-3-yl)[4-(thiazol-2-yl)pyrimidin-2-yl]amine 862592-92-5P, [4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl](6-methoxypyridin-3-yl)amine 862592-93-6P, (6-Chloropyridin-3-yl)[4-(4,5-dimethylthiazol-2-yl)pyrimidin-2-yl]amine 862592-94-7P, [4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl][4-(morpholin-4-yl)phenyl]amine 862592-95-8P, [4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl](4-methyl-3-nitrophenyl)amine 862592-96-9P, 4-[[4-(4,5-Dimethylthiazol-2-yl)pyrimidin-2-yl]amino]phenol 862592-97-0P, [6-(Pyrrolidin-1-yl)pyridin-3-yl][4-(thiazol-2-yl)pyrimidin-2-yl]amine 862592-98-1P, (6-Chloro-5-methylpyridin-3-yl)[4-(thiazol-2-yl)pyrimidin-2-yl]amine 862593-02-0P, 1-[2-[2-(4-Chlorophenylamino)pyrimidin-4-yl]-4-


methylthiazol-5-yl]ethanone 862593-04-2P, (4-Chlorophenyl)[4-(4-methylthiazol-2-yl)pyrimidin-2-yl]amine 862593-05-3P, 2-[2-(4-Chlorophenylamino)pyrimidin-4-yl]-4-hydroxythiazole-5-carboxylic acid ethyl ester 862593-06-4P, 1-[2-[2-(6-Chloropyridin-3-ylamino)pyrimidin-4-yl]-4-methylthiazol-5-yl]ethanone 862593-08-6P, 2-[2-(6-Chloropyridin-3-ylamino)pyrimidin-4-yl]-4-hydroxythiazole-5-carboxylic acid ethyl ester 862593-10-0P, 2-[2-(6-Chloropyridin-3-ylamino)pyrimidin-4-yl]-5-methylthiazol-4-ol 862593-11-1P, 2-[2-(6-Chloropyridin-3-ylamino)pyrimidin-4-yl]-5-(2-hydroxyethyl)thiazol-4-ol 862593-18-8P, (4-Chlorophenyl)[4-(4-phenylthiazol-2-yl)pyrimidin-2-yl]amine 862593-20-2P, 2-[2-(4-Chlorophenylamino)pyrimidin-4-yl]-4-methylthiazole-5-carboxylic acid ethyl ester 862593-22-4P, [2-[2-(4-Chlorophenylamino)pyrimidin-4-yl]thiazol-4-yl]acetic acid methyl ester

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazolyl-substituted pyrimidineamines as protein kinase inhibitors)


RN 862592-85-6 CAPLUS

CN 2-Pyrimidinamine, N-(6-chloro-3-pyridinyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 862592-86-7 CAPLUS

CN 1,3-Benzenediamine, N-[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 862592-87-8 CAPLUS

CN Phenol, 3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 862592-88-9 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 862592-89-0 CAPLUS

CN 2-Pyrimidinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4,5-dimethyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 862592-90-3 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 862592-91-4 CAPLUS

CN 2-Pyrimidinamine, N-(6-methoxy-3-pyridinyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 862592-92-5 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 862592-93-6 CAPLUS

CN 2-Pyrimidinamine, N-(6-chloro-3-pyridinyl)-4-(4,5-dimethyl-2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 862592-94-7 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-[4-(4-morpholinyl)phenyl]-  
(9CI) (CA INDEX NAME)




RN 862592-95-8 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-(4-methyl-3-nitrophenyl)-  
(9CI) (CA INDEX NAME)




RN 862592-96-9 CAPLUS

CN Phenol, 4-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA  
INDEX NAME)




RN 862592-97-0 CAPLUS

CN 2-Pyrimidinamine, N-[6-(1-pyrrolidinyl)-3-pyridinyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 862592-98-1 CAPLUS

CN 2-Pyrimidinamine, N-(6-chloro-5-methyl-3-pyridinyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 862593-02-0 CAPLUS


CN Ethanone, 1-[2-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 862593-04-2 CAPLUS


CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)






RN 862593-05-3 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 862593-06-4 CAPLUS

CN Ethanone, 1-[2-[2-[(6-chloro-3-pyridinyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 862593-08-6 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(6-chloro-3-pyridinyl)amino]-4-pyrimidinyl]-4-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 862593-10-0 CAPLUS

CN 4-Thiazolol, 2-[2-[(6-chloro-3-pyridinyl)amino]-4-pyrimidinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 862593-11-1 CAPLUS

CN 5-Thiazoleethanol, 2-[2-[(6-chloro-3-pyridinyl)amino]-4-pyrimidinyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 862593-18-8 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(4-phenyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 862593-20-2 CAPLUS


CN 5-Thiazolecarboxylic acid, 2-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 862593-22-4 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)


10/809,946




L8 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:821022 CAPLUS  
 DN 143:367267  
 TI Expedient parallel synthesis of 2-amino-4-heteroarylpyrimidines  
 AU Bursavich, Matthew G.; Lombardi, Sabrina; Gilbert, Adam M.  
 CS Exploratory Medicinal Chemistry, Chemical and Screening Sciences, Wyeth  
 Research, Pearl River, NY, 10965, USA  
 SO Organic Letters (2005), 7(19), 4113-4116  
 CODEN: ORLEF7; ISSN: 1523-7060  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 143:367267  
 AB An expedient synthesis of diverse 2-amino-4-heteroarylpyrimidines via a  
 2-chloropyrimidine intermediate is described. A series of potentially  
 biol. active analogs were synthesized in two parallel steps to afford  
 focused arrays.  
 IT 477769-42-9P 477769-45-2P 477769-51-0P  
 477769-60-1P 477769-75-8P 866112-02-9P  
 866112-03-0P 866112-04-1P 866112-05-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of 2-anilino- and 2-amino acid-4-heteroarylpyrimidines via  
 nucleophilic substitution)  
 RN 477769-42-9 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI)  
 (CA INDEX NAME)



RN 477769-45-2 CAPLUS  
 CN 2-Pyrimidinamine, N-(4-nitrophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX  
 NAME)




RN 477769-51-0 CAPLUS  
 CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX  
 NAME)




RN 477769-60-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477769-75-8 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 866112-02-9 CAPLUS

CN 2-Pyrimidinamine, N-phenyl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 866112-03-0 CAPLUS


CN 2-Pyrimidinamine, N-(2-methylphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 866112-04-1 CAPLUS


CN Acetamide, N-[4-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/809,946



RN 866112-05-2 CAPLUS

CN 2-Pyrimidinamine, N-[4-(4-morpholinyl)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:493687 CAPLUS  
 DN 143:40009  
 TI Homology model of CDK4 kinase for use in screening and design of drugs for treating proliferative disorders  
 IN McInnes, Campbell; Thomas, Mark; Wang, Shudong; McLachlan, Janice; Meades, Christopher; Kontopidis, George; Wood, Gavin; Fischer, Peter  
 PA Cyclacel Limited, UK  
 SO PCT Int. Appl., 152 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005052147	A2	20050609	WO 2004-GB4793	20041111
	WO 2005052147	A3	20051124		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI GB 2003-27380 A 20031125  
 AB The present invention relates to a homol. model for CDK4 kinase, and the use thereof in assays for the identification of small mol. CDK4 kinase modulators. The atomic structure coordinates of the CDK4 kinase homol. model are provided. The invention further relates to CDK4 kinase modulators identified by said assays, and their use in the treatment of CDK4 kinase-related disorders such as proliferative disorders, e.g., cancer. Preparation of CDK4 kinase-modulating aminopyrimidine compds. is reported.  
 IT 693228-65-8P 693229-61-7P 693230-49-8P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of CDK4 kinase modulators; homol. model of CDK4 kinase for use in screening and design of drugs for treating proliferative disorders)  
 RN 693228-65-8 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]-(9CI) (CA INDEX NAME)




RN 693229-61-7 CAPLUS  
 CN Acetamide, N-[[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-

pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 693230-49-8 CAPLUS

CN 1,4-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



IT 693228-73-8P 693228-77-2P 693228-83-0P


693229-59-3P 693229-65-1P 693229-69-5P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of CDK4 kinase modulators; homol. model of CDK4 kinase for use in screening and design of drugs for treating proliferative disorders)

RN 693228-73-8 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-77-2 CAPLUS

CN 1-Piperazineethanol, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)







RN 693228-83-0 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 693229-59-3 CAPLUS  
 CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(1-methylpiperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-65-1 CAPLUS  
 CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-69-5 CAPLUS  
 CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)


thiazolyl]- (9CI) (CA INDEX NAME)



IT 693228-71-6 693229-57-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of CDK4 kinase modulators; homol. model of CDK4 kinase for use  
 in screening and design of drugs for treating proliferative disorders)  
 RN 693228-71-6 CAPLUS  
 CN Piperazine, 1-acetyl-4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-  
 pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 693229-57-1 CAPLUS  
 CN Piperazine, 1-acetyl-4-[4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-  
 pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:451562 CAPLUS

DN 143:3240

TI Use of crystal structure of Plk1 kinase in screening for inhibitors for treatment of cancer, glomerulonephritis, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disorder

IN McInnes, Campbell; McLachlan, Janice; Mezna, Mokdad; Fischer, Peter

PA Cyclacel Limited, UK

SO PCT Int. Appl., 184 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047526	A2	20050526	WO 2004-GB4762	20041112
WO 2005047526	A3	20051208		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI GB 2003-26396 A 20031112

AB The preset invention provides use of crystal structure of protein Plk1 kinase in screening for inhibitors for treatment of cancer, glomerulonephritis, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disorder. Plk1 kinase inhibitors include 5'-thioadenosine, staurosporine, wortmannin, purvalanol A, LY294002, quercetin, morin hydrate and their derivs. and 4-[4-(4-methyl-2-

methylaminothiazol-5-yl)-pyrimidin-2-ylamino]-phenol, 4-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol, and 4-[4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol.


IT 364334-10-1 364334-30-5 364334-83-8

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(as protein Plk1 kinase inhibitor; crystal structure of Plk1 kinase and its use in screening for inhibitors in treating cancer, glomerulonephritis, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disorder)

RN 364334-10-1 CAPLUS


CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 364334-30-5 CAPLUS  
 CN Phenol, 4-[[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-  
 (9CI) (CA INDEX NAME)



RN 364334-83-8 CAPLUS  
 CN Phenol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
 (CA INDEX NAME)



L8 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:409513 CAPLUS

DN 142:463748

TI Preparation of pyrimidinylthiazolone compounds as protein kinase inhibitors

IN Wang, Shudong; Wood, Gavin; Duncan, Kenneth W.; Meades, Christopher; Gibson, Darren; McLachlan, Janice C.; Perry, Alex; Blake, David; Zheleva, Daniella I.; Fischer, Peter M.

PA Cyclacel Limited, UK

SO PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042525	A1	20050512	WO 2004-GB4465	20041021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285745	A1	20050512	AU 2004-285745	20041021
CA 2542880	AA	20050512	CA 2004-2542880	20041021
EP 1678171	A1	20060712	EP 2004-768981	20041021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI GB 2003-24599	A	20031021		
GB 2003-30013	A	20031224		
WO 2004-GB4465	W	20041021		

OS MARPAT 142:463748


AB Title compds. I [wherein R1, R5 = H or (un)substituted hydrocarbyl; R2 - R4 = H, (un)substituted alkyl or alkenyl; etc., or pharmaceutically acceptable salts thereof] were prepared as inhibitors of one or more protein kinases. For example, cyclization of NH2COSK with 3-chloropentane-2,4-dione in acetone to a thiazolone (100% yield) II (R = H) followed by N-alkylation with iodoethane in the presence of KOH afforded II (R = Et) (64% yield). This ketone underwent condensation with DMF di-Me acetal (30% yield) and subsequent cyclization with N-(6-methoxypyridin-3-yl)guanidine nitrate to give III. Biol. data showed that the invented compds. were inhibitors of CDK and GSK enzymes and so on. Therefore, I and their pharmaceutical compns. are useful for treating diseases, such as proliferative disorders and diabetes.

IT 851439-16-2P, 4-Methyl-5-[2-(3-nitrophenylamino)pyrimidin-4-yl]-3H-thiazol-2-one 851439-17-3P, 4-Methyl-5-[2-(4-methyl-3-nitrophenylamino)pyrimidin-4-yl]-3H-thiazol-2-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(kinase inhibitor; preparation of pyrimidinylthiazolone compds. as protein kinase inhibitors)

RN 851439-16-2 CAPLUS

CN 2(3H)-Thiazolone, 4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 851439-17-3 CAPLUS  
CN 2(3H)-Thiazolone, 4-methyl-5-[2-[(4-methyl-3-nitrophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:120927 CAPLUS  
 DN 142:219301  
 TI Preparation of pyridinylaminopyrimidine derivatives as protein kinase inhibitors  
 IN Wang, Shudong; Meades, Christopher; Gibson, Darren; Fischer, Peter  
 PA Cyclacel Limited, UK  
 SO PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012298	A1	20050210	WO 2004-GB3282	20040730
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004261482	A1	20050210	AU 2004-261482	20040730
	CA 2533870	AA	20050210	CA 2004-2533870	20040730
	EP 1648887	A1	20060426	EP 2004-743608	20040730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	GB 2003-17842	A	20030730		
	GB 2003-18347	A	20030805		
	WO 2004-GB3282	W	20040730		
OS	MARPAT 142:219301				
AB	Title compds. I [R1 = O; R2, R5-6 = R7; R10 = H, alkyl; X = S, O, (un)substituted amino; Y = N, (un)substituted alkyl; one of Z1-3 = amino, ammonium or (un)substituted alkyl; R7 = H, halo, amino, alkoxy, etc.] are prepared For instance, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][pyridin-3-yl]amine (II) is prepared from 3-dimethylamino-1-(2,4-dimethylthiazol-5-yl)propenone and N-(pyridin-3-yl)guanidine (2-methoxyethanol, reflux, 18 h) in 24% yield. II has Ki = 0.11 µM for CDK2/cyclin E. I are useful in the treatment of proliferative, viral, and CNS disorders as well as for the treatment of strokes, alopecia and/or diabetes.				
IT	837420-17-4P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][pyridin-3-yl]amine 837420-18-5P, 3-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-1-methylpyridinium iodide 837420-20-9P, (6-Chloropyridin-3-yl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 837420-21-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](6-methoxypyridin-3-yl)amine 837420-22-1P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](6-methoxypyridin-3-yl)amine 837420-23-2P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](6-chloropyridin-3-yl)amine 837420-24-3P, (6-Methoxypyridin-3-yl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 837420-25-4P, (6-Chloropyridin-3-yl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 837420-26-5P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](6-methoxypyridin-3-yl)amine 837420-28-7P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](6-methoxypyridin-3-				


yl)amine 837420-29-8P, [4-[2-((2-Methoxyethyl)amino)-4-methylthiazol-5-yl]pyrimidin-2-yl](6-methoxypyridin-3-yl)amine 837420-30-1P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](6-(pyrrolidin-1-yl)pyridin-3-yl)amine 837420-31-2P, [4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-yl][6-(4-methylpiperazin-1-yl)pyridin-3-yl]amine 837420-32-3P, (6-Methoxypyridin-3-yl)[4-(4-methyl-2-(morpholin-4-yl)thiazol-5-yl)pyrimidin-2-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridinylaminopyrimidine derivs. as protein kinase inhibitors)


RN 837420-17-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 837420-18-5 CAPLUS

CN Pyridinium, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-1-methyl-, iodide (9CI) (CA INDEX NAME)




● I<sup>-</sup>

RN 837420-20-9 CAPLUS


CN 2-Pyrimidinamine, N-(6-chloro-3-pyridinyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)






RN 837420-21-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 837420-22-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 837420-23-2 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(6-chloro-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 837420-24-3 CAPLUS  
 CN 2-Pyrimidinamine, N-(6-methoxy-3-pyridinyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 837420-25-4 CAPLUS  
 CN 2-Pyrimidinamine, N-(6-chloro-3-pyridinyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 837420-26-5 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 837420-28-7 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 837420-29-8 CAPLUS  
 CN 2-Pyrimidinamine, 4-[2-[(2-methoxyethyl)amino]-4-methyl-5-thiazolyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 837420-30-1 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[6-(1-pyrrolidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 837420-31-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 837420-32-3 CAPLUS

CN 2-Pyrimidinamine, N-(6-methoxy-3-pyridinyl)-4-[4-methyl-2-(4-morpholinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:1124644 CAPLUS  
 DN 142:74589  
 TI 2-Aminopyrimidine derivatives as Raf kinase inhibitors, process for their preparation, and their use, e.g., in the treatment of proliferative diseases such as cancer  
 IN Batt, David Bryant; Ramsey, Timothy Michael; Sabio, Michael Lloyd  
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
 SO PCT Int. Appl., 69 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110452	A1	20041223	WO 2004-EP6317	20040611
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004246800	A1	20041223	AU 2004-246800	20040611
	CA 2529090	AA	20041223	CA 2004-2529090	20040611
	EP 1635835	A1	20060322	EP 2004-739809	20040611
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1805748	A	20060719	CN 2004-80016328	20040611
PRAI	US 2003-478709P	P	20030613		
	WO 2004-EP6317	W	20040611		

OS MARPAT 142:74589


AB The application discloses compds. that inhibit Raf kinase, having formula I [wherein R1 is an (un)substituted Ph or heteroaryl radical; and R2 is an (un)substituted Ph radical; or an N-oxide or pharmaceutically acceptable salt thereof]. Also disclosed are methods of treating diseases characterized by excessive signaling through the MAP kinase pathway by administering a RAF kinase-inhibiting amount of a compound I. In particular, I are useful for the treatment of proliferative diseases such as cancer. Over 30 compds. I were prepared. For instance, amidation of 4-methyl-N3-[4-(pyrazin-2-yl)pyrimidin-2-yl]benzene-1,3-diamine with 3-CF3C6H4CO2H using BOP reagent and DIEA in DMF gave invention compound II. The prepared compds. I inhibited human Raf proteins as follows (IC50): wild-type C-Raf 0.01-0.7 µM; wild-type B-Raf 0.04-1.5 µM; and mutant B-Raf (V599E) 0.006-1.6 µM.

IT 812699-79-9P, N-[4-Methyl-3-[[4-(thiazol-2-yl)pyrimidin-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidine derivs. as Raf kinase inhibitors for treatment of proliferative diseases such as cancer)

RN 812699-79-9 CAPLUS  
 CN Benzamide, N-[4-methyl-3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-3-

(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 812700-18-8, 4-Methyl-N3-[4-(thiazol-2-yl)pyrimidin-2-yl]benzene-1,3-diamine

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of aminopyrimidine derivs. as Raf kinase inhibitors for treatment of proliferative diseases such as cancer)

RN 812700-18-8 CAPLUS

CN 1,3-Benzenediamine, 4-methyl-N3-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RE.CNT 10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:857595 CAPLUS

DN 141:350190

TI Preparation of thiazoles as inhibitors of protein kinases

IN Brenchley, Guy; Farmer, Luc J.; Harrington, Edmund Martin; Knegetel, Ronald; O'Donnell, Michael; Salituro, Francesco G.; Studley, John R.; Wang, Jian

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 139 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087699	A2	20041014	WO 2004-US9166	20040325
	WO 2004087699	A3	20041209		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004225977	A1	20041014	AU 2004-225977	20040325
	CA 2523126	AA	20041014	CA 2004-2523126	20040325
	US 2005004150	A1	20050106	US 2004-809946	20040325
	EP 1605946	A2	20051221	EP 2004-758338	20040325
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-457468P	P	20030325		
	WO 2004-US9166	W	20040325		
OS	MARPAT 141:350190				
AB	The title compds. [I; R1, R2 = R, halo, CN, NO2, etc.; R = H, (un)substituted alkyl; Ar1 = (un)substituted aryl, heteroaryl, etc.; R3, R4 = ZR7; or R3 and R4 are taken together to form (un)substituted (un)saturated 3-8 membered ring having 0-3 heteroatoms; Z = a bond, alkylidene, etc.; R7 = halo, CN, NO2, etc.], useful of inhibitors of protein kinases, were prepared E.g., a multi-step synthesis of II, starting from benzothiazole, was given. The compds. I were tested against SYK and ZAP-70 kinases (data given for representative compds. I). The invention also provides pharmaceutically acceptable compns. comprising said compds. I and methods of using the compns. in the treatment of various disease, conditions, or disorders.				
IT	774229-46-8P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of thiazoles as inhibitors of protein kinases)				
RN	774229-46-8 CAPLUS				
CN	2-Pyrimidinamine, 4-(5-chloro-2-thiazolyl)-N-(3,4,5-trimethoxyphenyl)-(9CI) (CA INDEX NAME)				



IT 774228-01-2P 774228-02-3P 774228-03-4P  
 774228-04-5P 774228-05-6P 774228-06-7P  
 774228-07-8P 774228-08-9P 774228-09-0P  
 774228-10-3P 774228-11-4P 774228-12-5P  
 774228-13-6P 774228-14-7P 774228-15-8P  
 774228-16-9P 774228-17-0P 774228-18-1P  
 774228-19-2P 774228-20-5P 774228-21-6P  
 774228-22-7P 774228-23-8P 774228-24-9P  
 774228-25-0P 774228-26-1P 774228-27-2P  
 774228-28-3P 774228-29-4P 774228-30-7P  
 774228-31-8P 774228-32-9P 774228-33-0P  
 774228-34-1P 774228-35-2P 774228-36-3P  
 774228-37-4P 774228-38-5P 774228-39-6P  
 774228-40-9P 774228-41-0P 774228-42-1P  
 774228-43-2P 774228-44-3P 774228-45-4P  
 774228-46-5P 774228-47-6P 774228-48-7P  
 774228-49-8P 774228-50-1P 774228-51-2P  
 774228-52-3P 774228-53-4P 774228-54-5P  
 774228-55-6P 774228-56-7P 774228-57-8P  
 774228-58-9P 774228-59-0P 774228-60-3P  
 774228-61-4P 774228-62-5P 774228-63-6P  
 774228-64-7P 774228-65-8P 774228-66-9P  
 774228-67-0P 774228-68-1P 774228-69-2P  
 774228-70-5P 774228-71-6P 774228-72-7P  
 774228-73-8P 774228-74-9P 774228-75-0P  
 774228-76-1P 774228-77-2P 774228-78-3P  
 774228-79-4P 774228-80-7P 774228-82-9P  
 774228-83-0P 774228-84-1P 774228-85-2P  
 774228-86-3P 774228-87-4P 774228-88-5P  
 774228-89-6P 774228-90-9P 774228-91-0P  
 774228-92-1P 774228-93-2P 774228-94-3P  
 774228-95-4P 774228-96-5P 774228-97-6P  
 774228-98-7P 774228-99-8P 774229-00-4P  
 774229-01-5P 774229-02-6P 774229-03-7P  
 774229-04-8P 774229-05-9P 774229-06-0P  
 774229-07-1P 774229-08-2P 774229-09-3P  
 774229-10-6P 774229-11-7P 774229-13-9P  
 774229-14-0P 774229-15-1P 774229-16-2P  
 774229-17-3P 774229-18-4P 774229-19-5P  
 774229-21-9P 774229-23-1P 774229-25-3P  
 774229-26-4P 774229-28-6P 774229-29-7P  
 774229-30-0P 774229-31-1P 774229-33-3P  
 774229-34-4P 774229-35-5P 774229-36-6P  
 774229-37-7P 774229-38-8P 774229-39-9P  
 774229-40-2P 774229-41-3P 774229-42-4P  
 774229-43-5P 774229-44-6P 774229-45-7P  
 774229-47-9P 774229-48-0P 774229-49-1P  
 774229-50-4P 774229-51-5P 774229-52-6P




774229-53-7P 774229-54-8P 774229-55-9P  
 774229-56-0P 774229-57-1P 774229-58-2P  
 774229-59-3P 774229-60-6P 774229-61-7P  
 774229-62-8P 774229-63-9P 774229-64-0P  
 774229-65-1P 774229-66-2P 774229-67-3P  
 774229-68-4P 774229-69-5P 774229-70-8P  
 774229-71-9P 774229-72-0P 774229-73-1P  
 774229-74-2P 774229-75-3P 774229-76-4P  
 774229-77-5P 774229-78-6P 774229-79-7P  
 774229-80-0P 774229-81-1P 774229-82-2P  
 774229-83-3P 774229-84-4P 774229-85-5P  
 774229-86-6P 774229-87-7P 774229-88-8P  
 774229-89-9P 774229-90-2P 774229-91-3P  
 774229-92-4P 774229-93-5P 774229-94-6P  
 774229-95-7P 774229-96-8P 774229-97-9P  
 774229-98-0P 774229-99-1P 774230-00-1P  
 774230-01-2P 774230-02-3P 774230-03-4P  
 774230-04-5P 774230-05-6P 774230-06-7P  
 774230-07-8P 774230-08-9P 774230-09-0P  
 774230-10-3P 774230-11-4P 774230-12-5P  
 774230-13-6P 774230-14-7P 774230-15-8P  
 774230-16-9P 774230-17-0P 774230-18-1P  
 774230-19-2P 774230-20-5P 774230-21-6P  
 774230-22-7P 774230-23-8P 774230-24-9P  
 774230-25-0P 774230-26-1P 774230-27-2P  
 774230-28-3P 774230-29-4P 774230-30-7P  
 774230-31-8P 774230-32-9P 774230-33-0P  
 774230-34-1P 774230-35-2P 774230-36-3P  
 774230-37-4P 774230-38-5P 774230-39-6P  
 774230-40-9P 774230-41-0P 774230-42-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of thiazoles as inhibitors of protein kinases)


RN 774228-01-2 CAPLUS  
 CN 1H-Benzimidazol-5-amine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]-2-  
 (trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774228-02-3 CAPLUS  
 CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI)  
 (CA INDEX NAME)




RN 774228-03-4 CAPLUS  
 CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-04-5 CAPLUS  
 CN 2-Pyrimidinamine, N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-05-6 CAPLUS  
 CN 2-Pyrimidinamine, N-(3-fluoro-4-methoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-06-7 CAPLUS  
 CN 2-Pyrimidinamine, N-[3-[(3-aminophenyl)sulfonyl]phenyl]-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-07-8 CAPLUS  
 CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 774228-08-9 CAPLUS  
 CN 2-Pyrimidinamine, N-(3-bromo-4-methylphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-09-0 CAPLUS  
 CN 1H-Indazol-6-amine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-10-3 CAPLUS  
 CN Phenol, 2-[(diethylamino)methyl]-4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-11-4 CAPLUS  
 CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-(5-methyl-2-thiazolyl)-  
 (9CI) (CA INDEX NAME)




RN 774228-12-5 CAPLUS  
 CN 1,4-Benzenediamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]-N'-phenyl-  
 (9CI) (CA INDEX NAME)




RN 774228-13-6 CAPLUS  
 CN 2-Pyrimidinamine, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-14-7 CAPLUS  
 CN 2-Pyrimidinamine, N-(4-ethoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-15-8 CAPLUS  
 CN Benzamide, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-16-9 CAPLUS  
 CN 2-Pyrimidinamine, N-(6-methoxy[1,1'-biphenyl]-3-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 774228-17-0 CAPLUS  
 CN Phenol, 2-methoxy-5-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-18-1 CAPLUS  
 CN 1H-Indol-5-amine, 2-methyl-N-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-19-2 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxy[1,1'-biphenyl]-4-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-20-5 CAPLUS

CN 1H-Indol-5-amine, 2,3-dihydro-1-(methylsulfonyl)-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-21-6 CAPLUS

CN 8-Quinolinamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-22-7 CAPLUS

CN 2H-1-Benzopyran-2-one, 4-(methoxymethyl)-7-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-23-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 774228-24-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 774228-25-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-26-1 CAPLUS

CN 9H-Carbazol-3-amine, 9-ethyl-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-27-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-28-3 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 774228-29-4 CAPLUS


CN 2-Pyrimidinamine, N-(4-chloro-3-methylphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 774228-30-7 CAPLUS


CN Ethanone, 1-[3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)






RN 774228-31-8 CAPLUS

CN 1H-Indol-5-amine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-32-9 CAPLUS

CN 1,3-Benzenediamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-33-0 CAPLUS

CN Phosphonic acid, [[4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 774228-34-1 CAPLUS

CN 2H-1-Benzopyran-2-one, 4-methyl-7-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-35-2 CAPLUS

CN Acetamide, N-[2-methyl-4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774228-36-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-37-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774228-38-5 CAPLUS

CN Benzeneacetonitrile, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-39-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-benzothiazolyl)-N-(3-phenoxycarbonylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-40-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-benzothiazolyl)-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774228-41-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-42-1 CAPLUS

CN 2-Pyrimidinamine, 4-(4-bromo-2-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-43-2 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 774228-44-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[(dimethylamino)methyl]-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-45-4 CAPLUS

CN 1,3-Propanediamine, N'-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 774228-46-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(1-piperidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-47-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[(4-ethyl-1-piperazinyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-48-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(4-morpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-49-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 774228-50-1 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1H-inden-5-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-51-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dichlorophenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-52-3 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-53-4 CAPLUS

CN 1,3-Propanediamine, N'-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 774228-54-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-(1-piperidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-55-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-[(4-ethyl-1-piperazinyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-56-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-(4-morpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774228-57-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-[(dimethylamino)methyl]-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-58-9 CAPLUS

CN 3-Pyrrolidinol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 774228-59-0 CAPLUS


CN 4-Piperidinol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 774228-60-3 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 774228-61-4 CAPLUS

CN 1-Piperazineethanol, 4-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 774228-62-5 CAPLUS

CN 4-Thiazolecarbonitrile, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-63-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-benzothiazolyl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-64-7 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(bromomethyl)-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-65-8 CAPLUS

CN 4-Thiazoleacetonitrile, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-66-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-(methoxymethyl)-2-thiazolyl]-(9CI) (CA INDEX NAME)




RN 774228-67-0 CAPLUS

CN Glycine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 774228-68-1 CAPLUS

CN Glycine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 774228-69-2 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-(9CI) (CA INDEX NAME)




RN 774228-70-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(4,5-dimethyl-2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 774228-71-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-bromo-2-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI)  
(CA INDEX NAME)




RN 774228-72-7 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-,  
acetate (ester) (9CI) (CA INDEX NAME)




RN 774228-73-8 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[[3-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 774228-74-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(1-piperidinyl)-2-thiazolyl]-  
(9CI) (CA INDEX NAME)




RN 774228-75-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(5-ethyl-2-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 774228-76-1 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(aminomethyl)-2-thiazolyl]-N-(3,5-dimethylphenyl)-  
(9CI) (CA INDEX NAME)




RN 774228-77-2 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-,  
carbamate (ester) (9CI) (CA INDEX NAME)




RN 774228-78-3 CAPLUS

CN Acetamide, N-[3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-  
(9CI) (CA INDEX NAME)




RN 774228-79-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(4-nitrophenyl)- (9CI) (CA  
INDEX NAME)




RN 774228-80-7 CAPLUS

CN Benzonitrile, 4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 774228-82-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-(5-methyl-2-  
thiazolyl)- (9CI) (CA INDEX NAME)




RN 774228-83-0 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774228-84-1 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774228-85-2 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(5-propyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 774228-86-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774228-87-4 CAPLUS

CN Ethanol, 2-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]methylamino]- (9CI) (CA INDEX NAME)




RN 774228-88-5 CAPLUS

CN 1-Propanol, 3-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 774228-89-6 CAPLUS

CN 1,3-Benzenediamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774228-90-9 CAPLUS

CN Benzonitrile, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 774228-91-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[4-(4-morpholinyl)phenyl]-  
(9CI) (CA INDEX NAME)



RN 774228-92-1 CAPLUS


CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774228-93-2 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(1-piperazinyl)-2-thiazolyl]-  
(9CI) (CA INDEX NAME)






RN 774228-94-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(dimethylamino)-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774228-95-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 774228-96-5 CAPLUS


CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 774228-97-6 CAPLUS


CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-(5-methyl-2-thiazolyl)- (9CI)

(CA INDEX NAME)




RN 774228-98-7 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774228-99-8 CAPLUS

CN Benzeneacetonitrile, 4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774229-00-4 CAPLUS

CN 2-Pyrimidinamine, N-(2,6-dimethylphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774229-01-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-ethylphenyl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774229-02-6 CAPLUS

CN Phenol, 2-methyl-4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 774229-03-7 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(2-propylphenyl)- (9CI) (CA  
INDEX NAME)




RN 774229-04-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[2-(phenylmethyl)phenyl]-  
(9CI) (CA INDEX NAME)




RN 774229-05-9 CAPLUS

CN Benzoic acid, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-, methyl  
ester (9CI) (CA INDEX NAME)




RN 774229-06-0 CAPLUS

CN Benzoic acid, 2-methyl-4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 774229-07-1 CAPLUS

CN Benzoic acid, 2-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-, butyl ester (9CI) (CA INDEX NAME)




RN 774229-08-2 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[[3-methyl-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-09-3 CAPLUS

CN Phenol, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774229-10-6 CAPLUS

CN Carbamic acid, [4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 774229-11-7 CAPLUS

CN Benzenemethanol, 3-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774229-13-9 CAPLUS

CN 5-Benzothiazolamine, 2-methyl-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-14-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 774229-15-1 CAPLUS

CN Ethanone, 1-[4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-  
(9CI) (CA INDEX NAME)




RN 774229-16-2 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1H-inden-2-yl)-4-(5-methyl-2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 774229-17-3 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 774229-18-4 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-19-5 CAPLUS

CN 2-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-(5-methyl-2-thiazolyl)-(9CI) (CA INDEX NAME)




RN 774229-21-9 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 774229-23-1 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-(3,4,5-trimethoxyphenyl)-(9CI) (CA INDEX NAME)




RN 774229-25-3 CAPLUS

CN 5-Thiazoleethanol, 2-[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 774229-26-4 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[(3-pyridinylamino)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774229-28-6 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[(4-pyridinylamino)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)






RN 774229-29-7 CAPLUS

CN 1(3H)-Isobenzofuranone, 6-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 774229-30-0 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774229-31-1 CAPLUS

CN 1H-Benzotriazol-5-amine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 774229-33-3 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[3-(methylthio)phenyl]- (9CI)  
(CA INDEX NAME)




RN 774229-34-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-[4-(methylthio)phenyl]- (9CI)  
(CA INDEX NAME)




RN 774229-35-5 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-5-(methylthio)-, methyl ester (9CI) (CA INDEX NAME)



RN 774229-36-6 CAPLUS


CN 4-Thiazolecarboxylic acid, 2-[2-[[3-bromo-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-5-(methylthio)-, methyl ester (9CI) (CA INDEX NAME)




RN 774229-37-7 CAPLUS

CN Piperazine, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-


thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 774229-38-8 CAPLUS


CN 6-Benzothiazolamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)

RN 774229-39-9 CAPLUS

CN 1H-Indazol-5-amine, 3-methyl-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)


RN 774229-40-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-N-  
phenyl- (9CI) (CA INDEX NAME)




RN 774229-41-3 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-aminoethyl)-2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774229-42-4 CAPLUS


CN 1H-Benzimidazol-2-amine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 774229-43-5 CAPLUS


CN 1,4-Benzenediamine, N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774229-44-6 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[(phenylamino)methyl]-2-

thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-45-7 CAPLUS

CN 1,2-Ethanediamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-47-9 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[[3-hydroxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-48-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(1-piperazinyl)-2-thiazolyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774229-49-1 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[[3-hydroxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-50-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-chloro-2-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774229-51-5 CAPLUS

CN 1,3-Benzenediamine, 5-methyl-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-52-6 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[[2-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 774229-53-7 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[[2-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774229-54-8 CAPLUS


CN 2-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-4-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 774229-55-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-2-thiazolyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 774229-56-0 CAPLUS

CN Carbamic acid, [3-[[4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 774229-57-1 CAPLUS

CN Acetamide, N-[3-methyl-5-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774229-58-2 CAPLUS

CN Methanesulfonamide, N-[3-methyl-5-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774229-59-3 CAPLUS

CN 1,3-Benzenediamine, 5-(methoxymethyl)-N-[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 774229-60-6 CAPLUS


CN Acetamide, N-[4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-  
(9CI) (CA INDEX NAME)

RN 774229-61-7 CAPLUS


CN Benzoic acid, 4-[[[4-[[4-(5-methyl-2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 774229-62-8 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(5-nitro-2-thiazolyl)- (9CI)  
(CA INDEX NAME)

RN 774229-63-9 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-2-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI)  
(CA INDEX NAME)


RN 774229-64-0 CAPLUS

CN Ethanol, 2-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 774229-65-1 CAPLUS

CN 1-Propanol, 3-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 774229-66-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[[2-(1-piperidinyl)ethyl]amino]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-67-3 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[[2-(1-piperazinyl)ethyl]amino]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-68-4 CAPLUS

CN 4-Morpholineethanamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-69-5 CAPLUS

CN Ethanol, 2-[[2-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 774229-70-8 CAPLUS

CN 1,2-Ethanediamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 774229-71-9 CAPLUS

CN 1,2-Ethanediamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 774229-72-0 CAPLUS

CN 1,2-Ethanediamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 774229-73-1 CAPLUS

CN 1,2-Ethanediamine, N-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]-N'-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 774229-74-2 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(methylthio)-, ethyl ester (9CI) (CA INDEX NAME)




RN 774229-75-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(methylthio)- (9CI) (CA INDEX NAME)




RN 774229-76-4 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 774229-77-5 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-(1-piperidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774229-78-6 CAPLUS


CN 2-Pyrimidinamine, 4-[4-[(cyclohexylamino)methyl]-5-(methylthio)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774229-79-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-(4-morpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-80-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-(1-piperazinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-81-1 CAPLUS

CN Ethanol, 2-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(methylthio)-4-thiazolyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 774229-82-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-[[2-(1-piperazinyl)ethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-83-3 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-[[phenylmethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774229-84-4 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methylthio)-4-[[3-pyridinylmethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774229-85-5 CAPLUS


CN 4-Thiazolecarboxamide, 5-[(cyclohexylmethyl)amino]-2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 774229-86-6 CAPLUS

CN 4-Thiazolecarboxamide, 5-(cyclohexylamino)-2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774229-87-7 CAPLUS


CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 774229-88-8 CAPLUS


CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-

(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 774229-89-9 CAPLUS

CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 774229-90-2 CAPLUS

CN 4-Thiazolecarboxamide, 5-(dimethylamino)-2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-91-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 774229-92-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 774229-93-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 774229-94-6 CAPLUS

CN 5-Thiazolecarbonitrile, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774229-95-7 CAPLUS

CN Methanedianiline, N'-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 774229-96-8 CAPLUS

CN 1,2-Ethanediamine, N'-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 774229-97-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(1-piperazinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-98-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[(4-methyl-1-piperazinyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774229-99-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[[[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-00-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[[[2-(1H-imidazol-1-yl)ethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-01-2 CAPLUS

CN Ethanol, 2-[[2-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-thiazolyl]methyl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 774230-02-3 CAPLUS


CN Phenol, 3-[[4-[5-(4-morpholinylmethyl)-2-thiazolyl]-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 774230-03-4 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[2-[2-[[3-hydroxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774230-04-5 CAPLUS

CN Phenol, 3-[[4-[5-(1-piperidinylmethyl)-2-thiazolyl]-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 774230-05-6 CAPLUS


CN Phenol, 3-[[4-[5-(1-piperazinylmethyl)-2-thiazolyl]-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 774230-06-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[5-(4-morpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)






RN 774230-07-8 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[2-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-5-thiazolyl]methyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774230-08-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[5-(1-piperazinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-09-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[5-(1-piperidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-10-3 CAPLUS

CN Phenol, 3-[[4-[5-[[[(tetrahydro-2-furanyl)methoxy]methyl]-2-thiazolyl]-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774230-11-4 CAPLUS

CN Phenol, 3-[[4-(4-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774230-12-5 CAPLUS

CN Phenol, 3-[[4-[4-methyl-5-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-thiazolyl]-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774230-13-6 CAPLUS

CN 5-Thiazoleethanol, 2-[2-[[3-hydroxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 774230-14-7 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-bis(trifluoromethyl)phenyl]-4-(5-ethenyl-4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774230-15-8 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-bis(trifluoromethyl)phenyl]-4-[5-(2-methoxyethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-16-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-bromo-5-(trifluoromethyl)phenyl]-4-(5-ethenyl-4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 774230-17-0 CAPLUS


CN 2-Pyrimidinamine, N-[3-bromo-5-(trifluoromethyl)phenyl]-4-[5-(2-methoxyethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774230-18-1 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(5-ethenyl-4-methyl-2-

thiazolyl)- (9CI) (CA INDEX NAME)




RN 774230-19-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(2-methoxyethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-20-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-(5-ethenyl-4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 774230-21-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[5-(2-methoxyethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-22-7 CAPLUS

CN 2-Pyrimidinamine, N-[3,5-bis(trifluoromethyl)phenyl]-4-[4-methyl-5-[2-(4-morpholinyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-23-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[2-(dimethylamino)ethyl]-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774230-24-9 CAPLUS

CN Phenol, 3-[[4-(5-ethenyl-4-methyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774230-25-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-[2-(4-morpholinyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-26-1 CAPLUS

CN 5-Thiazoleethanol, 4-methyl-2-[2-[[3-methyl-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774230-27-2 CAPLUS

CN 5-Thiazoleethanol, 4-methyl-2-[2-[[3-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774230-28-3 CAPLUS

CN 5-Thiazoleethanol, 2-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 774230-29-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-ethenyl-4-methyl-2-thiazolyl)-N-[3-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 774230-30-7 CAPLUS


CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[4-methyl-5-[2-(4-morpholinyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774230-31-8 CAPLUS


CN Ethanol, 2-[[2-[2-[2-[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]ethyl]amino]- (9CI) (CA INDEX NAME)






RN 774230-32-9 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-(methylthio)-, methyl ester (9CI) (CA INDEX NAME)




RN 774230-33-0 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-[3-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 774230-34-1 CAPLUS


CN Phenol, 3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 774230-35-2 CAPLUS


CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-[3-methyl-5-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774230-36-3 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 774230-37-4 CAPLUS

CN 5-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 774230-38-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[(dimethylamino)methyl]-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774230-39-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-(4-morpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-40-9 CAPLUS

CN Ethanol, 2-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]methylamino]- (9CI) (CA INDEX NAME)




RN 774230-41-0 CAPLUS

CN Ethanol, 2-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 774230-42-1 CAPLUS

CN 1-Piperazineethanol, 4-[2-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




IT 774230-43-2P 774230-44-3P 774230-45-4P  
 774230-46-5P 774230-47-6P 774230-48-7P  
 774230-49-8P 774230-50-1P 774230-51-2P  
 774230-52-3P 774230-53-4P 774230-54-5P  
 774230-55-6P 774230-56-7P 774230-57-8P  
 774230-58-9P 774230-59-0P 774230-60-3P  
 774230-61-4P 774230-62-5P 774230-63-6P  
 774230-64-7P 774230-65-8P 774230-66-9P  
 774230-67-0P 774230-68-1P 774230-69-2P  
 774230-70-5P 774230-71-6P 774230-72-7P  
 774230-73-8P 774230-74-9P 774230-75-0P  
 774230-76-1P 774230-77-2P 774230-78-3P  
 774230-79-4P 774230-80-7P 774230-81-8P  
 774230-82-9P 774230-83-0P 774230-84-1P  
 774230-85-2P 774230-86-3P 774230-87-4P  
 774230-88-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazoles as inhibitors of protein kinases)


RN 774230-43-2 CAPLUS

CN 1-Propanol, 3-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 774230-44-3 CAPLUS

CN 1,2-Ethanediol, 1-[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-45-4 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 774230-46-5 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-ethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 774230-47-6 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 774230-48-7 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 774230-49-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 774230-50-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-[(4-methyl-1-piperazinyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-51-2 CAPLUS

CN Cyclohexanol, 4-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 774230-52-3 CAPLUS

CN 4-Piperidinol, 1-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 774230-53-4 CAPLUS


CN 2-Pyrimidinamine, 4-[5-([1,4'-bipiperidin]-1'-ylmethyl)-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 774230-54-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[(cyclohexylmethylamino)methyl]-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)






RN 774230-55-6 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774230-56-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-[(methylamino)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-57-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-(1-piperazinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-58-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 774230-59-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-[(diethylamino)methyl]-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774230-60-3 CAPLUS

CN Ethanol, 2-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 774230-61-4 CAPLUS

CN Ethanol, 2-[2-[[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 774230-62-5 CAPLUS


CN 1,2-Ethanediamine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 774230-63-6 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-[[[3-

ethoxyphenyl)amino]methyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-64-7 CAPLUS

CN 1,2-Ethanediamine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 774230-65-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-[[[2-(2-pyridinyl)ethyl]amino]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774230-66-9 CAPLUS


CN 1-Piperazineethanol, 4-[3-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 774230-67-0 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774230-68-1 CAPLUS

CN Ethanol, 2-[[3-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]propyl]methylamino]- (9CI) (CA INDEX NAME)




RN 774230-69-2 CAPLUS

CN Ethanol, 2-[[3-[3-[[4-(4,5-dimethyl-2-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 774230-70-5 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-[3-[3-(4-methyl-1-piperazinyl)propoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774230-71-6 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 774230-72-7 CAPLUS

CN 4-Thiazolemethanol, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-5-ethyl- (9CI) (CA INDEX NAME)




RN 774230-73-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[4-methyl-5-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-74-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(aminomethyl)-4-methyl-2-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 774230-75-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-(1-pyrrolidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-76-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[4-methyl-5-(1-piperidinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 774230-77-2 CAPLUS


CN 4-Morpholineethanamine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)






RN 774230-78-3 CAPLUS

CN 3-Piperidinemethanol, 1-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 774230-79-4 CAPLUS

CN 1-Piperazineethanol, 4-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 774230-80-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(methoxymethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-81-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-(ethoxymethyl)-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 774230-82-9 CAPLUS

CN Ethanol, 2-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]methoxy]- (9CI) (CA INDEX NAME)




RN 774230-83-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-N,N,4-trimethyl- (9CI) (CA INDEX NAME)




RN 774230-84-1 CAPLUS

CN 5-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)




RN 774230-85-2 CAPLUS

CN Glycine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 774230-86-3 CAPLUS

CN Glycine, N-[[2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-4-methyl-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 774230-87-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 774230-88-5 CAPLUS

CN 4-Thiazolecarboxaldehyde, 2-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



L8 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:857594 CAPLUS  
 DN 141:332212  
 TI Preparation of aminopyrimidinyl-substituted thiazoles useful as inhibitors of protein kinases  
 IN Farmer, Luc J.; Harrington, Edmund Martin; Salituro, Francesco G.; Wang, Jian  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 76 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087698	A2	20041014	WO 2004-US9061	20040325
	WO 2004087698	A3	20041209		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004225965	A1	20041014	AU 2004-225965	20040325
	CA 2523125	AA	20041014	CA 2004-2523125	20040325
	US 2004235834	A1	20041125	US 2004-809944	20040325
	EP 1610793	A2	20060104	EP 2004-758287	20040325
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-457218P	P	20030325		
	WO 2004-US9061	W	20040325		
OS	CASREACT 141:332212; MARPAT 141:332212				
AB	Title compds. I [R1-2 = halo, CN, NO2, etc.; Ar1 = aryl, etc.; R3-4 = ZR7; Z = bond, alkylidene; R7 = halo, NO2, CN, alkoxy, etc.] are prepared General procedures are provided, e.g., [4-[2-((3,5-dimethylphenyl)amino)pyrimidin-4-yl]thiazol-2-yl]methanol. Selected example compds. of the invention exhibit $K_i < 5 \mu\text{M}$ for Syk kinase. I are useful for the treatment of autoimmune disorders.				
IT	769933-80-4P 769933-81-5P 769933-83-7P 769933-84-8P 769933-85-9P 769933-86-0P 769933-87-1P 769933-88-2P 769933-89-3P 769933-90-6P 769933-91-7P 769933-92-8P 769933-93-9P 769933-94-0P 769933-95-1P 769933-96-2P 769933-97-3P 769933-98-4P 769933-99-5P 769934-00-1P 769934-01-2P 769934-02-3P 769934-03-4P 769934-04-5P 769934-05-6P 769934-06-7P 769934-07-8P 769934-08-9P 769934-09-0P 769934-10-3P 769934-11-4P 769934-12-5P 769934-13-6P 769934-14-7P 769934-15-8P 769934-16-9P 769934-17-0P 769934-18-1P 769934-19-2P 769934-20-5P 769934-21-6P 769934-22-7P 769934-23-8P 769934-24-9P 769934-25-0P				


769934-26-1P 769934-27-2P 769934-28-3P  
 769934-29-4P 769934-30-7P 769934-31-8P  
 769934-32-9P 769934-33-0P 769934-34-1P  
 769934-35-2P 769934-36-3P 769934-37-4P  
 769934-38-5P 769934-39-6P 769934-40-9P  
 769934-41-0P 769934-43-2P 769934-44-3P  
 769934-45-4P 769934-46-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of aminopyrimidinyl-substituted thiazoles useful as inhibitors  
 of protein kinases for autoimmune disorders)


RN 769933-80-4 CAPLUS

CN Ethanone, 1-[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]-  
 (9CI) (CA INDEX NAME)




RN 769933-81-5 CAPLUS

CN 2-Thiazolemethanol, 4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 769933-83-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(4-thiazolyl)- (9CI) (CA INDEX  
 NAME)




RN 769933-84-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-(4-thiazolyl)-  
 (9CI) (CA INDEX NAME)




RN 769933-85-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(4-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 769933-86-0 CAPLUS

CN Phenol, 3-[[4-(4-thiazolyl)-2-pyrimidinyl]amino]-5-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)




RN 769933-87-1 CAPLUS

CN 1H-Benzimidazol-5-amine, N-[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]-2-  
(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 769933-88-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-(2-methyl-4-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 769933-89-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-90-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-91-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluoro-4-methoxyphenyl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 769933-92-8 CAPLUS


CN 2-Pyrimidinamine, N-[3-[(3-aminophenyl)sulfonyl]phenyl]-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)






RN 769933-93-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methyl-4-thiazolyl)-N-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 769933-94-0 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromo-4-methylphenyl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-95-1 CAPLUS

CN 1H-Indazol-5-amine, N-[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769933-96-2 CAPLUS

CN Phenol, 2-[(diethylamino)methyl]-4-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 769933-97-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769933-98-4 CAPLUS

CN 1,4-Benzenediamine, N-[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 769933-99-5 CAPLUS

CN 2-Pyrimidinamine, N-1,3-benzodioxol-5-yl-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769934-00-1 CAPLUS

CN 2-Pyrimidinamine, N-(4-ethoxyphenyl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 769934-01-2 CAPLUS


CN Benzamide, 3-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 769934-02-3 CAPLUS


CN 2-Pyrimidinamine, N-(6-methoxy[1,1'-biphenyl]-3-yl)-4-(4-thiazolyl)- (9CI)

(CA INDEX NAME)




RN 769934-03-4 CAPLUS

CN Phenol, 2-methoxy-5-[[4-(4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 769934-04-5 CAPLUS

CN Ethanone, 1-[4-[2-[(2-methyl-1H-indol-5-yl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 769934-05-6 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxy[1,1'-biphenyl]-4-yl)-4-(4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769934-06-7 CAPLUS

CN 1H-Indol-5-amine, 1-(methylsulfonyl)-N-[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769934-07-8 CAPLUS

CN Ethanone, 1-[4-[2-(8-quinolinylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI)  
(CA INDEX NAME)




RN 769934-08-9 CAPLUS

CN 2H-1-Benzopyran-2-one, 4-(methoxymethyl)-7-[[4-(4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 769934-09-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methyl-4-thiazolyl)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 769934-10-3 CAPLUS

CN 2-Pyrimidinamine, 4-(4-thiazolyl)-N-[4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 769934-11-4 CAPLUS

CN 2-Thiazolemethanol, 4-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 769934-12-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-(4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769934-13-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-chloro-3-methylphenyl)-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769934-14-7 CAPLUS

CN Ethanone, 1-[3-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 769934-15-8 CAPLUS

CN 2-Thiazolemethanol, 4-[2-(1H-indol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769934-16-9 CAPLUS

CN 1,3-Benzenediamine, N-[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769934-17-0 CAPLUS

CN Phosphonic acid, [[4-[[4-(4-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 769934-18-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 769934-19-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methyl-4-thiazolyl)-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 769934-20-5 CAPLUS

CN Benzeneacetonitrile, 3-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 769934-21-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-bromo-4-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI)  
(CA INDEX NAME)




RN 769934-22-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(dimethylamino)methyl]-4-thiazolyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 769934-23-8 CAPLUS


CN 1,3-Propanediamine, N'-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 769934-24-9 CAPLUS  
 CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[2-(1-piperidinylmethyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 769934-25-0 CAPLUS  
 CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[2-[(4-ethyl-1-piperazinyl)methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 769934-26-1 CAPLUS  
 CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[2-(4-morpholinylmethyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 769934-27-2 CAPLUS  
 CN 3-Pyrrolidinol, 1-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 769934-28-3 CAPLUS  
 CN 4-Piperidinol, 1-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)






RN 769934-29-4 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769934-30-7 CAPLUS

CN 1-Piperazineethanol, 4-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 769934-31-8 CAPLUS

CN 2-Thiazolecarbonitrile, 4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769934-32-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(bromomethyl)-4-thiazolyl]-N-(3,5-dimethylphenyl)-  
(9CI) (CA INDEX NAME)




RN 769934-33-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[2-(methoxymethyl)-4-thiazolyl]-  
(9CI) (CA INDEX NAME)




RN 769934-34-1 CAPLUS

CN Glycine, N-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 769934-35-2 CAPLUS

CN Glycine, N-[[4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 769934-36-3 CAPLUS

CN 2-Thiazoleacetic acid, 4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 769934-37-4 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(2,5-dimethyl-4-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 769934-38-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[2-(1-piperidinyl)-4-thiazolyl]-  
(9CI) (CA INDEX NAME)




RN 769934-39-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(2-ethyl-4-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 769934-40-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methyl-4-thiazolyl)-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 769934-41-0 CAPLUS

CN Benzonitrile, 4-[[4-(2-methyl-4-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 769934-43-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 769934-44-3 CAPLUS

CN 2-Thiazolemethanol, 4-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 769934-45-4 CAPLUS

CN 2-Thiazolecarboxylic acid, 4-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 769934-46-5 CAPLUS

CN 2-Thiazolecarboxylic acid, 4-[2-[[3-methoxy-5-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:756664 CAPLUS  
 DN 141:243576  
 TI Preparation of macrocycle amino compounds and compositions as  
 cyclin-dependent protein kinase inhibitors  
 IN Ren, Pingda; Adrian, Francisco; Gray, Nathanael S.; Wang, Xia  
 PA IRM LLC, Bermuda  
 SO PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004078682	A2	20040916	WO 2004-US6947	20040305
	WO 2004078682	A3	20051208		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

	US 2004235841	A1	20041125	US 2004-794454	20040305
PRAI	US 2003-452633P	P	20030305		

OS MARPAT 141:243576


AB The invention provides a novel class of cyclic compds. I, wherein n is 0-3; R1 hydrogen and alkyl; R2-R3 are independently substituted arylene and hetero-arylene; R4 4 is -XIR6(CH2)mNR7C(O)-, -XNR6(CH2)mNR7C(O)CH2-, -XR6(CH2)mNR7(CH2)mNR7C(O)-, -O(CH2)mNR7C(O)-, -NR6(CH2)mO- and -XNR6(CH2)mNR7CH2-; wherein X is a bond or C-alkylene; m is 1-6; R6 and R7 independently are hydrogen and alkyl; and R5 is halo, alkyl, halo-substituted alkyl, alkoxy and halo-substituted alkoxy and heterocycloalkyl; wherein any heterocycloalkyl of R5 is substituted with a group halo, alkyl, halo-substituted alkyl, alkoxy, halo-substituted alkoxy, heterocycloalkyl-alkyl and -XNR8R9, wherein X is a bond or alkylene; R8 and R9 are independently hydrogen and alkyl; or a salt thereof pharmaceutical compns. comprising such cyclic compds. and methods of using such compds. to treat or prevent diseases and disorders associated with cyclin-dependent kinases (CDKs) activity, particularly diseases associated with the activity of CDK2 and CDK5. Thus, macrocycle II was prepared and tested as CDK2 and CDK5 inhibitors.

IT 752245-59-3P 752245-60-6P 752245-61-7P  
 752245-62-8P 752245-63-9P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of macrocycle amino compds. and compns. as cyclin-dependent protein kinase inhibitors)


RN 752245-59-3 CAPLUS

CN Benzoic acid, 3-[[4-[2-amino-4-(trifluoromethyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 752245-60-6 CAPLUS

CN Benzoic acid, 3-[[4-[2-chloro-4-(trifluoromethyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 752245-61-7 CAPLUS

CN Benzoic acid, 3-[[4-[2-[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]butyl]amino]-4-(trifluoromethyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 752245-62-8 CAPLUS

CN Benzoic acid, 3-[[4-[2-[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]butyl]amino]-4-(trifluoromethyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 752245-63-9 CAPLUS

CN Benzoic acid, 3-[[4-[2-[(4-aminobutyl)amino]-4-(trifluoromethyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)





L8 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:546415 CAPLUS

DN 141:89104

TI Preparation of 2-substituted 4-heteroarylpyrimidines as GSK3 inhibitors for the treatment of diabetes

IN Wang, Shudong; Meades, Christopher; Wood, Gavin; Duncan, Kenneth; Zhevela, Daniella; Fischer, Peter

PA Cyclacel Limited, UK

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056368	A1	20040708	WO 2003-GB5558	20031218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2502138	AA	20040708	CA 2003-2502138	20031218
	AU 2003292444	A1	20040714	AU 2003-292444	20031218
	EP 1572211	A1	20050914	EP 2003-768023	20031218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016703	A	20051018	BR 2003-16703	20031218
	CN 1720049	A	20060111	CN 2003-80104697	20031218
	JP 2006515588	T2	20060601	JP 2004-561646	20031218
	US 2005282843	A1	20051222	US 2005-140136	20050526
PRAI	GB 2002-29581	A	20021219		
	WO 2003-GB5558	W	20031218		

OS MARPAT 141:89104

AB Heteroarylpyrimidines of formula I [X, Y = S, (substituted) N, (substituted) C; R1 = alkyl, aryl, heteroaryl, halo, CF3, CN, (substituted) NH2, alkoxycarbonyl, etc.; R2-R4 = H, alkyl, aryl, heteroaryl, halo, CF3, NO2, OH, alkoxy, acyl, alkoxycarbonyl, (substituted) NH2, SO2-alkyl, etc.] are prepared for use in a medicament for treating diabetes. The compds. of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke. Thus, II was prepared, and had IC50 of 0.005  $\mu$ M against GSK3 $\beta$ .


IT 364334-42-9P 507487-89-OP 717111-31-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylpyrimidines as GSK3 inhibitors)


RN 364334-42-9 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-  
(9CI) (CA INDEX NAME)



RN 717111-31-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2-chloro-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-  
(9CI) (CA INDEX NAME)




IT 507488-21-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heteroarylpyrimidines as GSK3 inhibitors)

RN 507488-21-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methoxy-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-  
(9CI) (CA INDEX NAME)



10/809,946

L8 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:430798 CAPLUS  
 DN 141:7130  
 TI Preparation of pyrimidine derivs. as inhibitors of cyclin-dependent kinases  
 IN Wang, Shudong; Meades, Christopher; Wood, Gavin; O'Boyle, Janice; McInnes, Campbell; Fischer, Peter  
 PA Cyclacel Limited, UK  
 SO PCT Int. Appl., 127 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004043953	A1	20040527	WO 2003-GB4973	20031114
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2502190	AA	20040527	CA 2003-2502190	20031114
	AU 2003301977	A1	20040603	AU 2003-301977	20031114
	EP 1567522	A1	20050831	EP 2003-811029	20031114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016152	A	20050927	BR 2003-16152	20031114
	CN 1711258	A	20051221	CN 2003-80103318	20031114
	JP 2006514619	T2	20060511	JP 2004-550846	20031114
	US 2005192300	A1	20050901	US 2004-991942	20041117
PRAI	GB 2002-26583	A	20021114		
	WO 2003-GB4973	W	20031114		

OS MARPAT 141:7130

AB The tile compds. I [X1 = S, X2 = N or (substituted)amino or X2 = S, X1 = N or (substituted)amino; Z = NH, NHCO, NHSO<sub>2</sub>, NHCH<sub>2</sub>, CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, CH=CH, SO<sub>2</sub>, or SO; R<sub>2</sub> = OXO, or H, (substituted)alkyl, (substituted)aryl, (substituted)aralkyl, halo, NO<sub>2</sub>, CN, OH, etc.; R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, and R<sub>8</sub> = H, (substituted)alkyl, (substituted)aryl, (substituted)aralkyl, halo, NO<sub>2</sub>, CN, OH, etc.] were prepared as inhibitors of cyclin-dependent kinases (CDKs) for the treatment of proliferative disorders and/or viral disorders. For example, condensation of N'-[5-(3-dimethylamino-acryloyl)-4-methyl-thiazol-2-yl]-N,N-dimethyl-formamidine and N-(4-morpholin-4-yl-phenyl)-guanidine nitrate afforded compound II. In an assay against multiple kinases, II selectively inhibited CDKs, showing an IC<sub>50</sub> of 0.48 μM against CDK2/cyclin E, and 0.44 μM against CDK2/cyclin A. Addnl. bioassays indicated II possessed anti-proliferative activity against human cancer cell lines, A549, HT29, Saos-2 with IC<sub>50</sub> 2.1, 1.7, and 1.9 μM, resp.


IT 507488-50-8P 693228-71-6P 693228-73-8P  
 693228-97-6P 693228-99-8P 693229-41-3P  
 693229-57-1P 693229-61-7P 693229-63-9P  
 693229-69-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyrimidine derivs. as CDKs inhibitors)


RN 507488-50-8 CAPLUS

CN Acetamide, 2-chloro-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693228-71-6 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693228-73-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-97-6 CAPLUS

CN Propanamide, 3-amino-N-[4-methyl-5-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693228-99-8 CAPLUS

CN Propanamide, 3-bromo-N-[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-41-3 CAPLUS

CN Acetamide, 2-chloro-N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-57-1 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-61-7 CAPLUS

CN Acetamide, N-[[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 693229-63-9 CAPLUS

CN Acetamide, N-[[3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 693229-69-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)



IT 507488-47-3P 507488-51-9P 693228-63-6P  
693228-65-8P 693228-67-0P 693228-69-2P


693228-74-9P 693228-75-0P 693228-77-2P  
 693228-79-4P 693228-81-8P 693228-83-0P  
 693228-85-2P 693228-87-4P 693228-89-6P  
 693228-91-0P 693228-93-2P 693228-95-4P  
 693229-01-5P 693229-03-7P 693229-05-9P  
 693229-07-1P 693229-09-3P 693229-11-7P  
 693229-13-9P 693229-15-1P 693229-17-3P  
 693229-19-5P 693229-23-1P 693229-25-3P  
 693229-27-5P 693229-28-6P 693229-30-0P  
 693229-31-1P 693229-33-3P 693229-35-5P  
 693229-37-7P 693229-39-9P 693229-42-4P  
 693229-43-5P 693229-45-7P 693229-47-9P  
 693229-49-1P 693229-51-5P 693229-53-7P  
 693229-55-9P 693229-59-3P 693229-65-1P  
 693229-67-3P 693229-70-8P 693229-72-0P  
 693229-74-2P 693229-76-4P 693229-78-6P  
 693229-80-0P 693229-82-2P 693229-84-4P  
 693229-86-6P 693229-88-8P 693229-90-2P  
 693229-92-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of pyrimidine derivs. as CDKs inhibitors)


RN 507488-47-3 CAPLUS

CN Methanesulfonamide, N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-  
 2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 507488-51-9 CAPLUS


CN Acetamide, 2-chloro-N-[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-  
 methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 693228-63-6 CAPLUS




CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-65-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-67-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-69-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-74-9 CAPLUS

CN Ethanol, 2-[2-[4-[4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 693228-75-0 CAPLUS

CN 1-Piperazinepropanol, 4-[4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693228-77-2 CAPLUS

CN 1-Piperazineethanol, 4-[4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693228-79-4 CAPLUS

CN Piperazine, 1-[4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 693228-81-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 693228-83-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 693228-85-2 CAPLUS


CN Propanamide, 3-amino-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 693228-87-4 CAPLUS

CN Propanamide, 2-amino-3-hydroxy-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 693228-89-6 CAPLUS

CN Butanamide, 2-amino-3-hydroxy-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]-, (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 693228-91-0 CAPLUS

CN Butanamide, 2-amino-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 693228-93-2 CAPLUS


CN Butanamide, 2-amino-3-hydroxy-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 693228-95-4 CAPLUS

CN Butanamide, 4-amino-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-01-5 CAPLUS

CN 4-Morpholinepropanamide, N-[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-03-7 CAPLUS

CN 4-Morpholinepropanamide, N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-05-9 CAPLUS

CN 1-Piperazinepropanamide, 4-methyl-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-07-1 CAPLUS

CN Acetamide, 2-chloro-N-[5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-09-3 CAPLUS

CN Acetamide, 2-chloro-N-[5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-11-7 CAPLUS

CN Acetamide, 2-chloro-N-[5-[2-[[4-(dimethylamino)phenyl]amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-13-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 693229-15-1 CAPLUS


CN Acetamide, N-[5-[2-[[4-(dimethylamino)phenyl]amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]-2-[[2-(2-hydroxyethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-17-3 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[6-[[3-[[4-methyl-5-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-2-thiazolyl]amino]-3-oxopropyl]amino]-6-oxohexyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B






RN 693229-19-5 CAPLUS

CN Methanesulfonamide, N-[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-23-1 CAPLUS

CN Acetamide, 2-chloro-N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-25-3 CAPLUS

CN 4-Morpholinepropanamide, N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-27-5 CAPLUS

CN Propanamide, N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]-3-[[2-(diethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-28-6 CAPLUS

CN Propanamide, N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]-3-[[2-(4-morpholinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-30-0 CAPLUS

CN 4-Morpholinepropanamide, N-[5-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-31-1 CAPLUS

CN 4-Morpholinepropanamide, N-[5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-33-3 CAPLUS

CN 1-Piperazinepropanamide, N-[5-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 693229-35-5 CAPLUS

CN Acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-37-7 CAPLUS

CN Acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 693229-39-9 CAPLUS

CN 1-Piperazineethanol, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- $\alpha$ -methyl- (9CI) (CA INDEX NAME)


RN 693229-42-4 CAPLUS

CN 4-Morpholineacetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-43-5 CAPLUS

CN 1H-1,2,4-Triazole-1-acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-45-7 CAPLUS

CN 1-Pyrrolidineacetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-47-9 CAPLUS

CN 1H-Imidazole-1-acetamide, N-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 693229-49-1 CAPLUS

CN Phenol, 3-[[4-[4-methyl-2-(4-morpholinyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-51-5 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(4-morpholinyl)-5-thiazolyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-53-7 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-[4-methyl-2-(4-morpholinyl)-5-thiazolyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 693229-55-9 CAPLUS

CN Benzenethanol, 4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-59-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-65-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693229-67-3 CAPLUS

CN Acetamide, N-[[3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 693229-70-8 CAPLUS

CN Benzenemethanol, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-72-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(4-morpholinyl)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 693229-74-2 CAPLUS


CN Benzenemethanol, 2-chloro-5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 693229-76-4 CAPLUS


CN Benzenemethanol, 2-chloro-5-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 693229-78-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-80-0 CAPLUS

CN 2-Pyrimidinamine, N-[4-(2-methoxyethoxy)-3-nitrophenyl]-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 693229-82-2 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-[[2-(4-morpholinyl)ethoxy]methyl]phenyl]- (9CI) (CA INDEX NAME)






RN 693229-84-4 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 693229-86-6 CAPLUS

CN Methanesulfonamide, N-[[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 693229-88-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-90-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 693229-92-4 CAPLUS

CN Benzenemethanol, 3-[[4-[[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




IT 364334-85-0 507487-89-0 507487-92-5  
507488-00-8 693230-34-1 693230-36-3  
693230-39-6 693230-42-1 693230-44-3  
693230-49-8 693230-80-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyrimidine derivs. as CDKs inhibitors)


RN 364334-85-0 CAPLUS

CN Benzenemethanol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507487-92-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-chlorophenyl)-  
(9CI) (CA INDEX NAME)




RN 507488-00-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-fluorophenyl)-  
(9CI) (CA INDEX NAME)




RN 693230-34-1 CAPLUS

CN Propanamide, 3-chloro-N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693230-36-3 CAPLUS

CN Propanamide, 3-bromo-N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693230-39-6 CAPLUS

CN Propanamide, 3-amino-N-[5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693230-42-1 CAPLUS

CN Propanamide, 3-bromo-N-[5-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693230-44-3 CAPLUS

CN Propanamide, 3-bromo-N-[5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693230-49-8 CAPLUS

CN 1,4-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 693230-80-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(aminomethyl)-4-methyl-5-thiazolyl]-N-(4-fluoro-3-nitrophenyl)- (9CI) (CA INDEX NAME)




IT 693230-19-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of pyrimidine derivs. as CDKs inhibitors)

RN 693230-19-2 CAPLUS

CN Carbamic acid, [3-[[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:430750 CAPLUS  
 DN 141:7129  
 TI Preparation of 4-heteroarylpyrimidines as specific cyclin-dependent kinase inhibitors for treating viruses  
 IN Wang, Shudong; Meades, Christopher; Wood, Gavin; Blake, David; Fischer, Peter  
 PA Cyclacel Limited, UK  
 SO PCT Int. Appl., 142 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004043467	A1	20040527	WO 2003-GB4977	20031114
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003283585	A1	20040603	AU 2003-283585	20031114
	EP 1581231	A1	20051005	EP 2003-775562	20031114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005288307	A1	20051229	US 2005-129198	20050513
PRAI	GB 2002-26582	A	20021114		
	WO 2003-GB4977	W	20031114		

OS MARPAT 141:7129

AB Title compds. I [wherein one of X1 and X2 = S, and the other of X1 and X2 = N so as to form a thiazolyl ring, R2 = independently as defined below for R1 and R3; one of X1 and X2 = S, and the other of X1 and X2 = NH and derivs. so as to form a 4,5-dihydrothiazolyl ring; R2 = oxo; the bond between C and R2 = double; Z = NH, NHCO, NHSO2, NHCH2, CH2, CH2CH2, CH:CH; R1, R3 = independently H, halo, NO2, CN, OH and derivs., NH2 and derivs., CO2H and derivs., CONH2 and derivs., SO3H, (un)substituted ar/alkyl, aryl, heterocyclyl, etc.; R4, R5, R6, R7, R8 = independently H, halo, NO2, CN, OH and derivs., NH2 and derivs., alkylheteroaryl, SO3H, SO2NH2, CF3, (un)substituted lower alkyl; and their pharmaceutically acceptable salts] were prepared for use in the treatment of viral disorders. For example, II was prepared by cyclocondensation of 3-Dimethylamino-1-(2,4-dimethylthiazol-5-yl)propanone (preparation given) with N-(3-Nitrophenyl)guanidine nitrate (preparation given) in 2-methoxyethanol in the presence of NaOH. Selected I showed high degree of selectivity for inhibition of CDKs. II displayed an average IC50 of 0.23  $\mu$ M against CDK2-Cyclin E1 kinase. Thus, I are useful for treating cytomegalovirus, herpes simplex, HIV-I, and varicella-zoster virus.

IT 364333-82-4P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 364334-85-0P, [3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]methanol 364334-88-3P, N,N-Dimethyl-N'-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]benzene-1,4-diamine 507487-89-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-00-8P, [4-(2-Amino-4-


methylthiazol-5-yl]pyrimidin-2-yl](4-fluorophenyl)amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(anti-viral agent; preparation of 4-heteroarylpyrimidines as specific cyclin-dependent kinase inhibitors for treating viruses)


RN 364333-82-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI)  
(CA INDEX NAME)




RN 364334-85-0 CAPLUS

CN Benzenemethanol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 364334-88-3 CAPLUS


CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)





RN 507488-00-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-fluorophenyl)-  
(9CI) (CA INDEX NAME)

IT 364333-75-5P, (2-Chlorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-76-6P, (4-Chlorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-77-7P, (3-Chlorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-81-3P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (2-nitrophenyl)amine 364333-83-5P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (4-nitrophenyl)amine 364333-88-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (2-fluorophenyl)amine 364333-89-1P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (4-fluorophenyl)amine 364333-90-4P, (2,4-Difluorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-91-5P, (3,5-Difluorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-92-6P, (3,5-Dichlorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-93-7P, (2,4-Dichlorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-94-8P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3-trifluoromethylphenyl)amine 364333-95-9P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (2-trifluoromethylphenyl)amine 364333-96-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (4-trifluoromethylphenyl)amine 364333-97-1P, (2-Bromophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-98-2P, (3-Bromophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-99-3P, (4-Bromophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364334-00-9P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (2-iodophenyl)amine 364334-01-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3-iodophenyl)amine 364334-02-1P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (4-iodophenyl)amine 364334-04-3P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3-fluorophenyl)amine 364334-05-4P, (3,4-Difluorophenyl) [4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364334-06-5P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (2-methoxyphenyl)amine 364334-07-6P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl] (3-

methoxyphenyl)amine 364334-08-7P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](4-methoxyphenyl)amine 364334-09-8P, 3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-10-1P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-14-5P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]-2-nitrophenol 364334-16-7P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]benzene-1,3-diamine 364334-17-8P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzonitrile 364334-18-9P, 3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzonitrile 364334-19-0P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid methyl ester 364334-20-3P, (3-Chloro-4-methylphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364334-21-4P, (3-Chloro-4-methoxyphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364334-22-5P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid 364334-23-6P, [4-Bromo-6-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 364334-24-7P, [4-(2,4-Dimethylthiazol-5-yl)-6-phenylpyrimidin-2-yl](3-nitrophenyl)amine 364334-25-8P, 4-[4-(2,4-Dimethylthiazol-5-yl)-6-phenylpyrimidin-2-ylamino]phenol 364334-26-9P, (3,4-Difluorophenyl)[4-(4-methyl-2-phenylthiazol-5-yl)pyrimidin-2-yl]amine 364334-27-0P, 4-[4-(4-Methyl-2-phenylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-28-1P, [4-(2,4-Dimethylthiazol-5-yl)-6-phenylpyrimidin-2-yl](4-fluorophenyl)amine 364334-29-2P, (4-Fluorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-30-5P, 4-[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-31-6P, [4-(2,4-Dimethylthiazol-5-yl)-6-(4-trifluoromethylphenyl)pyrimidin-2-yl](4-fluorophenyl)amine 364334-32-7P, (4-Chlorophenyl)[4-(2,4-dimethylthiazol-5-yl)-6-(4-trifluoromethylphenyl)pyrimidin-2-yl]amine 364334-33-8P, 4-[4-(2,4-Dimethylthiazol-5-yl)-6-(4-trifluoromethylphenyl)pyrimidin-2-ylamino]-2-nitrophenol 364334-34-9P, (4-Fluorophenyl)[4-(4-methyl-2-(pyridin-3-yl)thiazol-5-yl)pyrimidin-2-yl]amine 364334-35-0P, [4-(2,4-Dimethylthiazol-5-yl)-6-(3-trifluoromethylphenyl)pyrimidin-2-yl](4-fluorophenyl)amine 364334-36-1P, 4-[6-(2,4-Dimethylthiazol-5-yl)-2-(4-fluorophenylamino)pyrimidin-4-yl]-2,6-dimethoxyphenol 364334-37-2P, 4-[6-(2,4-Dimethylthiazol-5-yl)-2-(4-fluorophenylamino)pyrimidin-4-yl]phenol 364334-38-3P, [4-[4-Methyl-2-(pyridin-3-yl)thiazol-5-yl]pyrimidin-2-yl](3-nitrophenyl)amine 364334-39-4P, (4-Iodophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-41-8P, 4-[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-ylamino]-2-nitrophenol 364334-42-9P, 2-Chloro-4-[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-ylamino]benzoic acid ethyl ester 364334-43-0P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 364334-44-1P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 364334-45-2P, 3-[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-46-3P, 2-Chloro-4-[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid ethyl ester 364334-47-4P, 4-Chloro-3-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid 2-methoxyethyl ester 364334-48-5P, 2-Chloro-4-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid 2-methoxyethyl ester 364334-49-6P, 4-Chloro-3-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid 364334-51-0P, [4-(2-Allylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 364334-52-1P, (3-Bromophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-53-2P,

[4-(2-Allylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine  
 364334-54-3P, 3-[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-55-4P, (4-Bromophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-56-5P, (4-Chlorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-57-6P, (3-Methoxyphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-58-7P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 364334-59-8P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl](3-trifluoromethylphenyl)amine 364334-60-1P, 2-Chloro-5-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid ethyl ester 364334-61-2P, 3-Chloro-2-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid ethyl ester 364334-62-3P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](2-fluoro-4-iodophenyl)amine 364334-63-4P, 2-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]-5-methoxyphenol 364334-64-5P, (3-Chloro-4-iodophenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364334-66-7P, 2-Chloro-4-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-67-8P, 5-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]-2-fluorobenzoic acid 2-methoxyethyl ester 364334-68-9P, 2-Chloro-5-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid methyl ester 364334-69-0P, 4-Chloro-3-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid methyl ester 364334-70-3P, 2-Chloro-4-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzoic acid methyl ester 364334-71-4P, (3-Iodophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-72-5P, (3-Fluorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-73-6P, (3,4-Difluorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-74-7P, (2,4-Difluorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-75-8P, (3,5-Difluorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-76-9P, (4-Chloro-3-trifluoromethylphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-77-0P, (3-Chlorophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-78-1P, (4-Methoxyphenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-79-2P, (4-Fluoro-3-nitrophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 364334-80-5P, 4-[4-[2-(4-Nitrophenylamino)thiazol-5-yl]pyrimidin-2-yl]amino]phenol 364334-81-6P, N-[5-[2-(4-Hydroxyphenylamino)pyrimidin-4-yl]-4-methylthiazol-2-yl]acetamide 364334-82-7P, (4-Fluorophenyl)[4-[2-(4-nitrophenylamino)thiazol-5-yl]pyrimidin-2-yl]amine 364334-83-8P, 4-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-84-9P, N-[3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]guanidine 364334-86-1P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl][4-[(pyridin-4-yl)methyl]phenyl]amine 364334-87-2P, [3-(2-Diethylaminoethoxymethyl)phenyl][4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 507487-91-4P, N-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]-N',N'-dimethylbenzene-1,4-diamine 507487-92-5P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-chlorophenyl)amine 507487-93-6P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-methoxyphenyl)amine 507487-94-7P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-fluorophenyl)amine 507487-95-8P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 507487-96-9P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methoxyphenyl)amine 507487-97-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-


chlorophenyl)amine 507487-98-1P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-iodophenyl)amine 507487-99-2P,  
 [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-iodophenyl)amine 507488-01-9P, 3-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenol 507488-02-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-iodo-3-nitrophenyl)amine 507488-03-1P,  
 2-[4-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]ethanol 507488-04-2P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-bromophenyl)amine 507488-05-3P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-bromophenyl)amine 507488-06-4P,  
 [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-chloro-3-trifluoromethylphenyl)amine 507488-08-6P, [4-(2-Diethylaminoethoxy)phenyl][4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 507488-09-7P, 2-[4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]ethanol 507488-10-0P,  
 2-[[4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]ethylamino]ethanol 507488-11-1P, 1-(3,4-Dimethoxyphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 507488-12-2P, 5-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]-2-methoxyphenol 507488-13-3P, N'-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N,N-dimethyl-2-nitrobenzene-1,4-diamine 507488-14-4P, 2-Chloro-N'-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]-N,N-dimethylbenzene-1,4-diamine 507488-15-5P,  
 N'-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N,N-dimethyl-2-trifluoromethylbenzene-1,4-diamine 507488-16-6P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-4-methoxy-N',N'-dimethylbenzene-1,3-diamine 507488-17-7P, N,N-Dimethyl-N'-[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]benzene-1,4-diamine 507488-18-8P, (4-Iodo-3-nitrophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 507488-29-1P,  
 (3-Iodo-4-methylphenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-30-4P, (4-Fluoro-3-methylphenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-33-7P,  
 [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-35-9P, (4-Chlorophenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-36-0P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 507488-37-1P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-methoxyphenyl)amine 507488-38-2P, (3-Chlorophenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-39-3P,  
 [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methyl-3-nitrophenyl)amine 507488-40-6P, [4-(2-Butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 507488-42-8P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-44-0P, (4-Chlorophenyl)[4-(2-dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-45-1P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 507488-46-2P, (3-Chlorophenyl)[4-(2-dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-48-4P, 2-[[4-Methyl-5-[2-(3-nitrophenylamino)pyrimidin-4-yl]thiazol-2-yl]amino]ethanol 507488-49-5P, 2-[[5-[2-(4-Fluorophenylamino)pyrimidin-4-yl]-4-methylthiazol-2-yl]amino]ethanol 507488-52-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-nitrophenyl)amine 507488-53-1P, N-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]phenylamine 507488-55-3P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzenesulfonic acid 674333-60-9P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]phenylamine 693290-45-8P, [4-[4-(2,4-Dimethylthiazol-5-

yl)pyrimidin-2-ylamino]phenyl]trimethylammonium iodide  
 693290-46-9P, 4-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]benzenesulfonic acid 693290-47-0P, N-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]benzene-1,3-diamine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anti-viral agent; preparation of 4-heteroarylpyrimidines as specific cyclin-dependent kinase inhibitors for treating viruses)


RN 364333-75-5 CAPLUS

CN 2-Pyrimidinamine, N-(2-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
 (CA INDEX NAME)




RN 364333-76-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
 (CA INDEX NAME)




RN 364333-77-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
 (CA INDEX NAME)




RN 364333-81-3 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-nitrophenyl)- (9CI)  
 (CA INDEX NAME)




RN 364333-83-5 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-nitrophenyl)- (9CI)  
 (CA INDEX NAME)



RN 364333-88-0 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-fluorophenyl)- (9CI)  
 (CA INDEX NAME)




RN 364333-89-1 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)- (9CI)  
 (CA INDEX NAME)




RN 364333-90-4 CAPLUS  
 CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-


(9CI) (CA INDEX NAME)



RN 364333-91-5 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)

RN 364333-92-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dichlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)


RN 364333-93-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-dichlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 364333-94-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-95-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-96-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)







RN 364333-97-1 CAPLUS  
CN 2-Pyrimidinamine, N-(2-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 364333-98-2 CAPLUS  
CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
(CA INDEX NAME)



RN 364333-99-3 CAPLUS  
CN 2-Pyrimidinamine, N-(4-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 364334-00-9 CAPLUS  
CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-iodophenyl)- (9CI)  
(CA INDEX NAME)




RN 364334-01-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-iodophenyl)- (9CI)  
(CA INDEX NAME)




RN 364334-02-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-iodophenyl)- (9CI)  
(CA INDEX NAME)



RN 364334-04-3 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-fluorophenyl)- (9CI)  
(CA INDEX NAME)




RN 364334-05-4 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-


(9CI) (CA INDEX NAME)




RN 364334-06-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-methoxyphenyl)- (9CI)  
(CA INDEX NAME)

RN 364334-07-6 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-methoxyphenyl)- (9CI)  
(CA INDEX NAME)

RN 364334-08-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-methoxyphenyl)- (9CI)  
(CA INDEX NAME)


RN 364334-09-8 CAPLUS

CN Phenol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-10-1 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-14-5 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-nitro- (9CI) (CA INDEX NAME)




RN 364334-16-7 CAPLUS

CN 1,3-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 364334-17-8 CAPLUS

CN Benzonitrile, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 364334-18-9 CAPLUS

CN Benzonitrile, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)



RN 364334-19-0 CAPLUS


CN Benzoic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 364334-20-3 CAPLUS


CN 2-Pyrimidinamine, N-(3-chloro-4-methylphenyl)-4-(2,4-dimethyl-5-thiazolyl)-

(9CI) (CA INDEX NAME)




RN 364334-21-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 364334-22-5 CAPLUS

CN Benzoic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-23-6 CAPLUS


CN 2-Pyrimidinamine, 4-bromo-6-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-24-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)-6-phenyl-  
(9CI) (CA INDEX NAME)

RN 364334-25-8 CAPLUS


CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-6-phenyl-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)

RN 364334-26-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(4-methyl-2-phenyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)


RN 364334-27-0 CAPLUS

CN Phenol, 4-[[4-(4-methyl-2-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 364334-28-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-phenyl-  
(9CI) (CA INDEX NAME)




RN 364334-29-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(methylamino)-5-  
thiazolyl]- (9CI) (CA INDEX NAME)



RN 364334-30-5 CAPLUS

CN Phenol, 4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 364334-31-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[4-




(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-32-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-33-8 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-6-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]-2-nitro- (9CI) (CA INDEX NAME)




RN 364334-34-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-35-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-36-1 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 364334-37-2 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 364334-38-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-39-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-iodophenyl)-4-[4-methyl-2-(methyamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-41-8 CAPLUS

CN Phenol, 4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-2-nitro- (9CI) (CA INDEX NAME)




RN 364334-42-9 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-43-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 364334-44-1 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-45-2 CAPLUS

CN Phenol, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-46-3 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-47-4 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-48-5 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-49-6 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-51-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(2-propenylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-52-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-53-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(2-propenylamino)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 364334-54-3 CAPLUS


CN Phenol, 3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 364334-55-4 CAPLUS


CN 2-Pyrimidinamine, N-(4-bromophenyl)-4-[4-methyl-2-(methylamino)-5-

thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-56-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-57-6 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 364334-58-7 CAPLUS


CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)






RN 364334-59-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-60-1 CAPLUS

CN Benzoic acid, 2-chloro-5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-61-2 CAPLUS

CN Benzoic acid, 3-chloro-2-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-62-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-fluoro-4-iodophenyl)- (9CI) (CA INDEX NAME)




RN 364334-63-4 CAPLUS

CN Phenol, 2-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-5-methoxy-  
(9CI) (CA INDEX NAME)




RN 364334-64-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-iodophenyl)-4-(2,4-dimethyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 364334-66-7 CAPLUS

CN Phenol, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 364334-67-8 CAPLUS

CN Benzoic acid, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-fluoro-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-68-9 CAPLUS

CN Benzoic acid, 2-chloro-5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-69-0 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-70-3 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-71-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-iodophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-72-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-73-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-74-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-75-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-76-9 CAPLUS

CN 2-Pyrimidinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-77-0 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-78-1 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-79-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluoro-3-nitrophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-80-5 CAPLUS

CN Phenol, 4-[[4-[2-[(4-nitrophenyl)amino]-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-81-6 CAPLUS

CN Acetamide, N-[5-[2-[(4-hydroxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-82-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[2-[(4-nitrophenyl)amino]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-83-8 CAPLUS

CN Phenol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-84-9 CAPLUS

CN Guanidine, [3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-  
(9CI) (CA INDEX NAME)


RN 364334-86-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 364334-87-2 CAPLUS


CN 2-Pyrimidinamine, N-[3-[[2-(diethylamino)ethoxy]methyl]phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)



RN 507487-91-4 CAPLUS


CN 1,4-Benzenediamine, N'-[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]-  
N,N-dimethyl- (9CI) (CA INDEX NAME)






RN 507487-92-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-chlorophenyl)-  
(9CI) (CA INDEX NAME)




RN 507487-93-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-methoxyphenyl)-  
(9CI) (CA INDEX NAME)



RN 507487-94-7 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-fluorophenyl)-  
(9CI) (CA INDEX NAME)




RN 507487-95-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507487-96-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-methoxyphenyl)-  
(9CI) (CA INDEX NAME)


RN 507487-97-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-chlorophenyl)-  
(9CI) (CA INDEX NAME)


RN 507487-98-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-iodophenyl)- (9CI)  
(CA INDEX NAME)

RN 507487-99-2 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-iodophenyl)- (9CI)  
(CA INDEX NAME)

RN 507488-01-9 CAPLUS

CN Phenol, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)


RN 507488-02-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-iodo-3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-03-1 CAPLUS

CN Benzeneethanol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-04-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-bromophenyl)-  
(9CI) (CA INDEX NAME)




RN 507488-05-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-bromophenyl)-  
(9CI) (CA INDEX NAME)



RN 507488-06-4 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-chloro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507488-08-6 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-4-(2,4-dimethyl-5-


thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-09-7 CAPLUS

CN Benzeneethanol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)


RN 507488-10-0 CAPLUS

CN Ethanol, 2-[[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]ethylamino]-  
(9CI) (CA INDEX NAME)


RN 507488-11-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-(2,4-dimethyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)


RN 507488-12-2 CAPLUS  
 CN Phenol, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methoxy-  
 (9CI) (CA INDEX NAME)




RN 507488-13-3 CAPLUS  
 CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl-2-nitro- (9CI) (CA INDEX NAME)



RN 507488-14-4 CAPLUS  
 CN 1,4-Benzenediamine, 2-chloro-N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)




RN 507488-15-5 CAPLUS  
 CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 507488-16-6 CAPLUS

CN 1,3-Benzenediamine, N1-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-4-methoxy-N3,N3-dimethyl- (9CI) (CA INDEX NAME)




RN 507488-17-7 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 507488-18-8 CAPLUS


CN 2-Pyrimidinamine, N-(4-iodo-3-nitrophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 507488-29-1 CAPLUS


CN 2-Pyrimidinamine, N-(3-iodo-4-methylphenyl)-4-(2-methoxy-4-methyl-5-

thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-30-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-iodo-3-methylphenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-33-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 507488-35-9 CAPLUS


CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)






RN 507488-36-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507488-37-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 507488-38-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-39-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-methyl-3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-40-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(butylamino)-4-methyl-5-thiazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 507488-42-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 507488-44-0 CAPLUS


CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[2-(dimethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 507488-45-1 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(4-

fluorophenyl)- (9CI) (CA INDEX NAME)




RN 507488-46-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[2-(dimethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-48-4 CAPLUS

CN Ethanol, 2-[[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-49-5 CAPLUS


CN Ethanol, 2-[[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 507488-52-0 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-nitrophenyl)-  
(9CI) (CA INDEX NAME)

RN 507488-53-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-phenyl- (9CI) (CA  
INDEX NAME)


RN 507488-55-3 CAPLUS

CN Benzenesulfonic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 674333-60-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-phenyl- (9CI) (CA INDEX  
NAME)




RN 693290-45-8 CAPLUS

CN Benzenaminium, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)




RN 693290-46-9 CAPLUS

CN Benzenesulfonic acid, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 693290-47-0 CAPLUS

CN 1,3-Benzenediamine, N-[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:324510 CAPLUS  
 DN 142:51189  
 TI Structural Determinants of CDK4 Inhibition and Design of Selective ATP  
 Competitive Inhibitors  
 AU McInnes, Campbell; Wang, Shudong; Anderson, Sian; O'Boyle, Janice;  
 Jackson, Wayne; Kontopidis, George; Meades, Christopher; Mezna, Mokdad;  
 Thomas, Mark; Wood, Gavin; Lane, David P.; Fischer, Peter M.  
 CS Cyclacel Limited, Dundee, DD1 5JJ, UK  
 SO Chemistry & Biology (2004), 11(4), 525-534  
 CODEN: CBOLE2; ISSN: 1074-5521  
 PB Cell Press  
 DT Journal  
 LA English  
 AB A number of selective inhibitors of the CDK4/cyclin D1 complex have been  
 reported recently. Due to the absence of an exptl. CDK4 structure, the  
 ligand and protein determinants contributing to CDK4 selectivity are  
 poorly understood at present. Here, we report the use of computational  
 methods to elucidate the characteristics of selectivity and to derive the  
 structural basis for specific, high-affinity binding of inhibitors to the  
 CDK4 active site. From these data, the hypothesis emerged that  
 appropriate incorporation of an ionizable function into a CDK2 inhibitor  
 results in more favorable binding to CDK4. This knowledge was applied to  
 the design of compds. in the otherwise CDK2-selective 2-anilino-4-(thiazol-  
 5-yl)pyrimidine pharmacophore that are potent and highly selective ATP  
 antagonists of CDK4/cyclin D1. The findings of this study also have  
 significant implications in the design of CDK4 mimic structures based on  
 CDK2.  
 IT 693229-69-5P  
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic  
 preparation); BIOL (Biological study); PREP (Preparation)  
 (PI; mol. modeling of CDK4 kinase inhibition and design of selective  
 ATP competitive inhibitors)  
 RN 693229-69-5 CAPLUS  
 CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[4-methyl-2-(methylamino)-5-  
 thiazolyl]- (9CI) (CA INDEX NAME)




IT 693228-63-6P 693228-65-8P 693228-73-8P  
 693228-77-2P 693228-83-0P 693229-59-3P  
 693229-61-7P 693229-65-1P 693230-49-8P  
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic  
 preparation); BIOL (Biological study); PREP (Preparation)  
 (mol. modeling of CDK4 kinase inhibition and design of selective ATP  
 competitive inhibitors)  
 RN 693228-63-6 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-  
 morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693228-65-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]-  
(9CI) (CA INDEX NAME)




RN 693228-73-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(1-piperazinyl)phenyl]-  
(9CI) (CA INDEX NAME)



RN 693228-77-2 CAPLUS


CN 1-Piperazineethanol, 4-[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 693228-83-0 CAPLUS




CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-59-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 693229-61-7 CAPLUS

CN Acetamide, N-[[3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 693229-65-1 CAPLUS


CN 2-Pyrimidinamine, N-[3-(aminomethyl)phenyl]-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 693230-49-8 CAPLUS

CN 1,4-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:102824 CAPLUS  
 DN 140:270811  
 TI 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR  
 Analysis, X-ray Crystallography, and Biological Activity  
 AU Wang, Shudong; Meades, Christopher; Wood, Gavin; Osnowski, Andrew;  
 Anderson, Sian; Yuill, Rhoda; Thomas, Mark; Mezna, Mokdad; Jackson, Wayne;  
 Midgley, Carol; Griffiths, Gary; Fleming, Ian; Green, Simon; McNae, Iain;  
 Wu, Su-Ying; McInnes, Campbell; Zheleva, Daniella; Walkinshaw, Malcolm D.;  
 Fischer, Peter M.  
 CS Cyclacel Limited, Dundee, DD1 5JJ, UK  
 SO Journal of Medicinal Chemistry (2004), 47(7), 1662-1675  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 140:270811  
 AB Following the identification through virtual screening of  
 4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-ylamines as moderately potent  
 inhibitors of cyclin-dependent kinase-2 (CDK2), a CDK inhibitor analog  
 program was initiated. The first aims were to optimize potency and to  
 evaluate the cellular mode of action of lead candidate mols. Here the  
 synthetic chemical, the structure-guided design approach, and the  
 structure-activity relationships (SARs) that led to the discovery of  
 2-anilino-4-(thiazol-5-yl)pyrimidine ATP-antagonistic CDK2 inhibitors,  
 many with very low nM Kis against CDK2, are reported. Furthermore, X-ray  
 crystal structures of four representative analogs from our chemical series in  
 complex with CDK2 are presented, and these structures are used to  
 rationalize the observed biochem. SARs. Finally results are reported that  
 show, using the most potent CDK2 inhibitor compound from the current series,  
 that the observed antiproliferative and proapoptotic effects are consistent  
 with cellular CDK2 and CDK9 inhibition.  
 IT 364334-09-8DP, complex with CDK2 364334-30-5DP, complex  
 with CDK2 364334-88-3DP, complex with CDK2 507487-89-ODP  
 , complex with CDK2  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (crystal structure of)  
 RN 364334-09-8 CAPLUS  
 CN Phenol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA  
 INDEX NAME)




RN 364334-30-5 CAPLUS  
 CN Phenol, 4-[[4-[4-methyl-2-(methyamino)-5-thiazolyl]-2-pyrimidinyl]amino]-  
 (9CI) (CA INDEX NAME)




RN 364334-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




IT 364333-75-5P, (2-Chlorophenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-76-6P, (4-Chlorophenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-77-7P, (3-Chlorophenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 364333-82-4P 364333-83-5P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](4-nitrophenyl)amine 364333-88-0P 364333-89-1P 364333-94-8P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](3-trifluoromethylphenyl)amine 364333-95-9P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](2-trifluoromethylphenyl)amine 364333-96-0P, [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 364334-04-3P 364334-09-8P, 3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-10-1P, 4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-16-7P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]benzene 1,3-diamine 364334-18-9P, 3-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino]benzonitrile 364334-30-5P, 4-[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-

ylamino]phenol 364334-44-1P, [4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 364334-45-2P, 3-[4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-53-2P, [4-(2-Allylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 364334-54-3P, 3-[4-(4-Methyl-2-methylaminothiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-83-8P, 4-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenol 364334-88-3P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]N',N'-dimethylbenzene-1,4-diamine 507487-89-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507487-91-4P, N-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]N',N'-dimethylbenzene-1,4-diamine 507488-13-3P 507488-14-4P 507488-42-8P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 674333-60-9P 674333-61-0P 674333-62-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of 2-anilino-4-(thiazol-5-yl)pyrimidines as CDK inhibitors)


RN 364333-75-5 CAPLUS

CN 2-Pyrimidinamine, N-(2-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 364333-76-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 364333-77-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 364333-82-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI)  
(CA INDEX NAME)




RN 364333-83-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-nitrophenyl)- (9CI)  
(CA INDEX NAME)



RN 364333-88-0 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-fluorophenyl)- (9CI)  
(CA INDEX NAME)



RN 364333-89-1 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)- (9CI)

(CA INDEX NAME)




RN 364333-94-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-95-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-96-0 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-04-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-fluorophenyl)- (9CI)  
(CA INDEX NAME)

RN 364334-09-8 CAPLUS

CN Phenol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA  
INDEX NAME)


RN 364334-10-1 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA  
INDEX NAME)

RN 364334-16-7 CAPLUS


CN 1,3-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)






RN 364334-18-9 CAPLUS

CN Benzonitrile, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 364334-30-5 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)



RN 364334-44-1 CAPLUS


CN 2-Pyrimidinamine, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-3-nitrophenyl)- (9CI)  
(CA INDEX NAME)



RN 364334-45-2 CAPLUS


CN Phenol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)

(9CI) (CA INDEX NAME)




RN 364334-53-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(2-propenylamino)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-54-3 CAPLUS

CN Phenol, 3-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-83-8 CAPLUS

CN Phenol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507487-91-4 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507488-13-3 CAPLUS

CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl-2-nitro- (9CI) (CA INDEX NAME)




RN 507488-14-4 CAPLUS

CN 1,4-Benzenediamine, 2-chloro-N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)




RN 507488-42-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 674333-60-9 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 674333-61-0 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-methylphenyl)- (9CI)

(CA INDEX NAME)



RN 674333-62-1 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(2-pyridinyl)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:282567 CAPLUS  
 DN 138:304297  
 TI Preparation of thiazolyl substituted aminopyrimidines as plant protection agents  
 IN Mueller, Urs; Eberle, Martin; Pillonel, Christian; Lutz, William; Stanetty, Peter  
 PA Syngenta Participations Ag, Switz.  
 SO PCT Int. Appl., 128 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003029249	A1	20030410	WO 2002-IB3868	20020919
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2460160	AA	20030410	CA 2002-2460160	20020919
	EP 1434776	A1	20040707	EP 2002-800204	20020919
	EP 1434776	B1	20060628		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013010	A	20041005	BR 2002-13010	20020919
	US 2005038059	A1	20050217	US 2004-491231	20040924
PRAI	GB 2001-23589	A	20011001		
	WO 2002-IB3868	W	20020919		

OS MARPAT 138:304297


AB The title compds. [I; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, haloalkyl, etc.; NR1R2 = (un)substituted (un)saturated ring which may contain O or S as a ring member, or form N:CR9NR10R11; R3 = H, halo, alkyl; R4 = H, alkyl, haloalkyl, etc.; R5 = H, OH, halo, etc.; R6 = H, alkyl, haloalkyl; R7 = (un)substituted thienyl, pyridyl, aryl; R8 = H, alkyl, alkenyl, etc.; R9 = H, alkyl, haloalkyl, etc.; R10 = alkyl, haloalkyl, alkoxyalkyl, etc.; R11 = alkyl, cycloalkyl, aryl, etc.], useful as fungicides, were prepared. Thus, a multi-step synthesis of I [NR1R2 = N:C(Me)NMe2; R3-R6 = H; R7 = Ph; R8 = H], starting from 4-methyl-2-methylthiopyrimidine and Me benzoate, was given. The compds. I showed good activity in twelve different tests (biol. data given).

IT 509086-70-8P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of thiazolyl substituted aminopyrimidines as plant protection agents)

RN 509086-70-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-phenyl- (9CI) (CA INDEX NAME)




IT 509086-63-9P 509086-64-0P 509086-65-1P  
 509086-66-2P 509086-67-3P 509086-68-4P  
 509086-69-5P 509086-71-9P 509086-72-0P  
 509086-73-1P 509086-74-2P 509086-75-3P  
 509086-76-4P 509086-77-5P 509086-78-6P  
 509086-79-7P 509086-80-0P 509086-81-1P  
 509086-82-2P 509086-83-3P 509086-84-4P  
 509086-85-5P 509086-86-6P 509086-87-7P  
 509086-88-8P 509086-89-9P 509086-90-2P  
 509086-91-3P 509086-92-4P 509086-93-5P  
 509086-94-6P 509086-95-7P 509086-96-8P  
 509086-97-9P 509086-98-0P 509086-99-1P  
 509087-00-7P 509087-01-8P 509087-02-9P  
 509087-03-0P 509087-04-1P 509087-05-2P  
 509087-06-3P 509087-07-4P 509087-08-5P  
 509087-09-6P 509087-11-0P 509087-12-1P  
 509087-14-3P 509087-15-4P 509087-16-5P  
 509087-17-6P 509087-18-7P 509087-19-8P  
 509087-20-1P 509087-21-2P 509087-23-4P  
 509087-24-5P 509087-25-6P 509087-26-7P  
 509087-27-8P 509087-28-9P 509087-29-0P  
 509087-30-3P 509087-32-5P 509087-43-8P  
 509087-44-9P 509087-45-0P 509087-46-1P  
 509087-47-2P 509087-48-3P 509087-80-3P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazolyl substituted aminopyrimidines as plant protection agents)


RN 509086-63-9 CAPLUS

CN Ethanimidamide, N,N-dimethyl-N'-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-64-0 CAPLUS

CN Acetamide, N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-65-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-[(3-methylbutyl)amino]-4-phenyl-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 509086-66-2 CAPLUS


CN 3-Butyn-2-ol, 4-[3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 509086-67-3 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3',4'-dimethoxy[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)






RN 509086-68-4 CAPLUS

CN Benzenemethanol, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-  
 $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




RN 509086-69-5 CAPLUS

CN Benzenemethanol, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-  
 (9CI) (CA INDEX NAME)




RN 509086-71-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-chlorophenyl)-  
 (9CI) (CA INDEX NAME)




RN 509086-72-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-fluorophenyl)-  
(9CI) (CA INDEX NAME)




RN 509086-73-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-methoxyphenyl)-  
(9CI) (CA INDEX NAME)



RN 509086-74-2 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(4-methyl-1-piperazinyl)-4-phenyl-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 509086-75-3 CAPLUS


CN Benzonitrile, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-

(9CI) (CA INDEX NAME)




RN 509086-76-4 CAPLUS

CN Benzenemethanol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]-α-methyl- (9CI) (CA INDEX NAME)




RN 509086-77-5 CAPLUS

CN Phenol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509086-78-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 509086-79-7 CAPLUS

CN Ethanone, 1-[3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509086-80-0 CAPLUS

CN Ethanone, 1-[3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)




RN 509086-81-1 CAPLUS

CN Benzenemethanol, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- $\alpha$ -methyl- (9CI) (CA INDEX NAME)




RN 509086-82-2 CAPLUS

CN 1(3H)-Isobenzofuranone, 6-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509086-83-3 CAPLUS

CN Ethanone, 1-[3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, O-methyloxime (9CI) (CA INDEX NAME)




RN 509086-84-4 CAPLUS

CN Benzoic acid, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 509086-85-5 CAPLUS

CN Phenol, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 509086-86-6 CAPLUS

CN Phenol, 5-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)




RN 509086-87-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 509086-88-8 CAPLUS

CN Ethanone, 1-[3-[[4-[2-(ethylamino)-4-phenyl-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509086-89-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-phenyl-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 509086-90-2 CAPLUS

CN Acetamide, N-[5-[2-[(1,3-dihydro-3-oxo-5-isobenzofuranyl)amino]-4-pyrimidinyl]-4-phenyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-91-3 CAPLUS


CN Propanamide, N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-92-4 CAPLUS  
 CN Butanamide, 3-methyl-N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 509086-93-5 CAPLUS  
 CN Butanamide, N-[5-[2-[[3-(ethylamino)phenyl]amino]-4-pyrimidinyl]-4-phenyl-2-thiazolyl]-2,2,3,3,4,4,4-heptafluoro- (9CI) (CA INDEX NAME)




RN 509086-94-6 CAPLUS  
 CN Propanamide, 2,2,3,3,3-pentafluoro-N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-95-7 CAPLUS  
 CN Acetamide, 2,2,2-trifluoro-N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)






RN 509086-96-8 CAPLUS

CN Ethanehydrazonamide, N,N-dimethyl-N'-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509086-97-9 CAPLUS

CN Methanehydrazonamide, N,N-dimethyl-N'-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 509086-98-0 CAPLUS


CN Cyclopropanecarboxamide, N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 509086-99-1 CAPLUS


CN Propanamide, 3-chloro-2,2-dimethyl-N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509087-00-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-morpholinyl)-4-phenyl-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 509087-01-8 CAPLUS

CN Benzonitrile, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-02-9 CAPLUS

CN Benzenemethanol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 509087-03-0 CAPLUS

CN Benzenemethanol, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-04-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 509087-05-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 509087-06-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 509087-07-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 509087-08-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 509087-09-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-[3-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 509087-11-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 509087-12-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-(4-fluorophenyl)-5-thiazolyl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 509087-14-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[2-(ethylamino)-4-(4-fluorophenyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509087-15-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-[4-(4-fluorophenyl)-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509087-16-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-methoxyphenyl)-5-thiazolyl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 509087-17-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-methoxyphenyl)-5-thiazolyl]-N-phenyl-  
(9CI) (CA INDEX NAME)




RN 509087-18-7 CAPLUS

CN Benzonitrile, 3-[[4-[2-amino-4-(4-methoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-19-8 CAPLUS

CN Ethanone, 1-[3-[[4-[2-amino-4-(4-methoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509087-20-1 CAPLUS

CN Benzoic acid, 3-[[4-[2-amino-4-(4-methoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 509087-21-2 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-(4-methoxyphenyl)-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 509087-23-4 CAPLUS


CN Benzoic acid, 3-[[4-[2-amino-4-(4-methylphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)






RN 509087-24-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(3,4-dimethoxyphenyl)-5-thiazolyl]-N-phenyl-  
(9CI) (CA INDEX NAME)




RN 509087-25-6 CAPLUS

CN Benzonitrile, 3-[[4-[2-amino-4-(3,4-dimethoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-26-7 CAPLUS

CN Ethanone, 1-[3-[[4-[2-amino-4-(3,4-dimethoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509087-27-8 CAPLUS

CN Benzoic acid, 3-[[4-[2-amino-4-(3,4-dimethoxyphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 509087-28-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(3-methylphenyl)-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 509087-29-0 CAPLUS

CN Benzonitrile, 3-[[4-[2-amino-4-(3-methylphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-30-3 CAPLUS

CN Ethanone, 1-[3-[[4-[2-amino-4-(3-methylphenyl)-5-thiazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509087-32-5 CAPLUS

CN Butanamide, 2,2,3,3,4,4,4-heptafluoro-N-[4-(3-methylphenyl)-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509087-43-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 509087-44-9 CAPLUS

CN Ethanone, 1-[3-[[4-(2-amino-4-(4-fluorophenyl)-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 509087-45-0 CAPLUS

CN Benzonitrile, 3-[[4-(2-amino-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-46-1 CAPLUS

CN Acetamide, N-[5-[2-[[3-[(acetyloxy)methyl]phenyl]amino]-4-pyrimidinyl]-4-(4-fluorophenyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 509087-47-2 CAPLUS

CN Benzeneacetonitrile, 3-[[4-(2-amino-4-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 509087-48-3 CAPLUS

CN Benzeneacetonitrile, 3-[[4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 509087-80-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-amino-4-(4-fluorophenyl)-5-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




IT 509087-34-7P 509087-38-1P 509087-39-2P  
509087-40-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of thiazolyl substituted aminopyrimidines as plant protection  
agents)


RN 509087-34-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-phenyl-5-thiazolyl)-N-(3-iodophenyl)- (9CI)  
(CA INDEX NAME)




RN 509087-38-1 CAPLUS

CN Carbamic acid, [4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 509087-39-2 CAPLUS

CN Carbamic acid, [5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-4-phenyl-2-  
thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 509087-40-5 CAPLUS

CN Carbamic acid, [5-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-4-phenyl-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:282566 CAPLUS  
 DN 138:304296  
 TI Preparation of N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines  
 as specific cyclin-dependent kinase inhibitors useful as antitumor agents  
 IN Wang, Shudong; Meades, Christopher; Wood, Gavin; Osnowski, Andrew;  
 Fischer, Peter Martin  
 PA Cyclacel Limited, UK  
 SO PCT Int. Appl., 84 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003029248	A1	20030410	WO 2002-GB4383	20020927
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2460909	AA	20030410	CA 2002-2460909	20020927
	EP 1430051	A1	20040623	EP 2002-762582	20020927
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012944	A	20041013	BR 2002-12944	20020927
	JP 2005508931	T2	20050407	JP 2003-532496	20020927
	CN 1617870	A	20050518	CN 2002-818729	20020927
	NZ 531596	A	20050826	NZ 2002-531596	20020927
	US 2004259894	A1	20041223	US 2004-810767	20040326
PRAI	GB 2001-23377	A	20010928		
	GB 2001-23629	A	20011002		
	WO 2002-GB4383	W	20020927		

AB The present invention relates to sixty-two 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compns. containing them

and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like. 72-H MTT in vitro cytotoxicity and CDK2/E and CDK4/D1 inhibition IC50 values are reported for most of the 62 claimed compds. Kinase specificity for N4-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]-N1,N1-dimethyl-2-nitrobenzene-1,4-diamine and 2-[N-(4-N,N-Dimethylamino-3-chlorophenyl)]-4-(2,4-dimethylthiazol-5-yl)pyrimidinamine was tested for 16 kinases. In vitro antiproliferative activity of [4-(2-amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-iodophenyl)amine, 2-[4-[4-(2-amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino]phenyl]ethanol and [4-(2-amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-bromophenyl)amine are tabulated for 26 cell lines. Although the methods of preparation are not claimed, 18 example preps. and characterization data for .apprx.60 compds. are included.

IT 364334-88-3P, N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N',N'-dimethylbenzene-1,4-diamine 507487-89-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine




507488-00-8P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of N-thiazolpyrimidinyl-N-phenylamines as specific cyclin-dependent kinase inhibitors useful as antitumor agents)


RN 364334-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507487-89-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 507488-00-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



IT 507487-91-4P, N-[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]-N',N'-dimethylbenzene-1,4-diamine 507487-92-5P,  
[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-chlorophenyl)amine 507487-93-6P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-methoxyphenyl)amine 507487-94-7P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-fluorophenyl)amine 507487-95-8P,


[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 507487-96-9P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methoxyphenyl)amine 507487-97-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-chlorophenyl)amine 507487-98-1P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-iodophenyl)amine 507487-99-2P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-iodophenyl)amine 507488-01-9P, 3-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenol 507488-02-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-iodo-3-nitrophenyl)amine 507488-03-1P, 2-[4-[[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]ethanol 507488-04-2P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-bromophenyl)amine 507488-05-3P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-bromophenyl)amine 507488-06-4P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-chloro-3-trifluoromethylphenyl)amine 507488-08-6P 507488-09-7P, 2-[4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl]ethanol 507488-10-0P, 2-[[4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]phenyl](ethyl)amino]ethanol 507488-11-1P, (3,4-Dimethoxyphenyl)[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]amine 507488-12-2P, 5-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]-2-methoxyphenol 507488-13-3P, N4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N1,N1-dimethyl-2-nitrobenzene-1,4-diamine 507488-14-4P 507488-15-5P, N4-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N1,N1-dimethyl-2-trifluoromethylbenzene-1,4-diamine 507488-16-6P, N1-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-4-methoxy-N3,N3-dimethylbenzene-1,3-diamine 507488-17-7P, N,N-Dimethyl-N'-[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]benzene-1,4-diamine 507488-18-8P, (4-Iodo-3-nitrophenyl)[4-(4-methyl-2-methylaminothiazol-5-yl)pyrimidin-2-yl]amine 507488-19-9P, 4-[[4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenol 507488-21-3P, [4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-22-4P, (4-Iodophenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-23-5P, (4-Fluorophenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-24-6P, (4-Chlorophenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-25-7P, [4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methoxyphenyl)amine 507488-26-8P, 3-[[4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amino]phenol 507488-27-9P, (4-Fluoro-3-nitrophenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-28-0P, (4-Chloro-3-methylphenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-29-1P, (3-Iodo-4-methylphenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-30-4P, (4-Fluoro-3-methylphenyl)[4-(2-methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-31-5P, [4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methyl-3-nitrophenyl)amine 507488-32-6P, N-[4-(2-Methoxy-4-methylthiazol-5-yl)pyrimidin-2-yl]-N',N'-dimethylbenzene-1,4-diamine 507488-33-7P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-35-9P, (4-Chlorophenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-36-0P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-trifluoromethylphenyl)amine 507488-37-1P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-methoxyphenyl)amine 507488-38-2P, (3-Chlorophenyl)[4-(2-ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-39-3P, [4-(2-Ethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-methyl-3-

nitrophenyl)amine 507488-40-6P, [4-(2-Butylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 507488-42-8P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine 507488-44-0P, (4-Chlorophenyl)[4-(2-dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-45-1P, [4-(2-Dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-fluorophenyl)amine 507488-46-2P, (3-Chlorophenyl)[4-(2-dimethylamino-4-methylthiazol-5-yl)pyrimidin-2-yl]amine 507488-47-3P, N-[4-Methyl-5-[2-(3-nitrophenylamino)pyrimidin-4-yl]thiazol-2-yl]methanesulfonamide 507488-48-4P, 2-[[4-Methyl-5-[2-(3-nitrophenylamino)pyrimidin-4-yl]thiazol-2-yl]amino]ethanol 507488-49-5P, 2-[[5-[2-(4-Fluorophenylamino)pyrimidin-4-yl]-4-methylthiazol-2-yl]amino]ethanol 507488-50-8P, 2-Chloro-N-[4-methyl-5-[2-(3-nitrophenylamino)pyrimidin-4-yl]thiazol-2-yl]acetamide 507488-51-9P, 2-Chloro-N-[5-[2-(4-fluorophenylamino)pyrimidin-4-yl]-4-methylthiazol-2-yl]acetamide 507488-52-0P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](4-nitrophenyl)amine 507488-53-1P, [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](phenyl)amine 507488-55-3P, 4-[[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonic acid  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N-thiazolpyrimidinyl-N-phenylamines as specific cyclin-dependent kinase inhibitors useful as antitumor agents)


RN 507487-91-4 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 507487-92-5 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 507487-93-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-methoxyphenyl)-

(9CI) (CA INDEX NAME)




RN 507487-94-7 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-fluorophenyl)-  
(9CI) (CA INDEX NAME)

RN 507487-95-8 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507487-96-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-methoxyphenyl)-  
(9CI) (CA INDEX NAME)


RN 507487-97-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-chlorophenyl)-  
(9CI) (CA INDEX NAME)

RN 507487-98-1 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-iodophenyl)- (9CI)  
(CA INDEX NAME)

RN 507487-99-2 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-iodophenyl)- (9CI)  
(CA INDEX NAME)


RN 507488-01-9 CAPLUS

CN Phenol, 3-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 507488-02-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-iodo-3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-03-1 CAPLUS

CN Benzeneethanol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 507488-04-2 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-bromophenyl)- (9CI) (CA INDEX NAME)



RN 507488-05-3 CAPLUS


CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-bromophenyl)- (9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)




RN 507488-06-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-[4-chloro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507488-08-6 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-09-7 CAPLUS


CN Benzeneethanol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-10-0 CAPLUS  
 CN Ethanol, 2-[[4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)



RN 507488-11-1 CAPLUS  
 CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-12-2 CAPLUS  
 CN Phenol, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)




RN 507488-13-3 CAPLUS  
 CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl-2-nitro- (9CI) (CA INDEX NAME)






RN 507488-14-4 CAPLUS

CN 1,4-Benzenediamine, 2-chloro-N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)




RN 507488-15-5 CAPLUS

CN 1,4-Benzenediamine, N4-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N1,N1-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 507488-16-6 CAPLUS


CN 1,3-Benzenediamine, N1-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-4-methoxy-N3,N3-dimethyl- (9CI) (CA INDEX NAME)



RN 507488-17-7 CAPLUS


CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-[4-methyl-2-(methylamino)-5-

thiazolyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 507488-18-8 CAPLUS

CN 2-Pyrimidinamine, N-(4-iodo-3-nitrophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-19-9 CAPLUS

CN Phenol, 4-[[4-(2-methoxy-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-21-3 CAPLUS


CN 2-Pyrimidinamine, 4-(2-methoxy-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-22-4 CAPLUS  
CN 2-Pyrimidinamine, N-(4-iodophenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 507488-23-5 CAPLUS  
CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)



RN 507488-24-6 CAPLUS  
CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 507488-25-7 CAPLUS  
CN 2-Pyrimidinamine, 4-(2-methoxy-4-methyl-5-thiazolyl)-N-(4-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 507488-26-8 CAPLUS

CN Phenol, 3-[[4-(2-methoxy-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 507488-27-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluoro-3-nitrophenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)- (9CI) (CA INDEX NAME)



RN 507488-28-0 CAPLUS


CN 2-Pyrimidinamine, N-(4-chloro-3-methylphenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)- (9CI) (CA INDEX NAME)



RN 507488-29-1 CAPLUS


CN 2-Pyrimidinamine, N-(3-iodo-4-methylphenyl)-4-(2-methoxy-4-methyl-5-

thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-30-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluoro-3-methylphenyl)-4-(2-methoxy-4-methyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 507488-31-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2-methoxy-4-methyl-5-thiazolyl)-N-(4-methyl-3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-32-6 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2-methoxy-4-methyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 507488-33-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-35-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-36-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 507488-37-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 507488-38-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[2-(ethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-39-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-methyl-3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 507488-40-6 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(butylamino)-4-methyl-5-thiazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 507488-42-8 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-44-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[2-(dimethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-45-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(dimethylamino)-4-methyl-5-thiazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 507488-46-2 CAPLUS


CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[2-(dimethylamino)-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)






RN 507488-47-3 CAPLUS

CN Methanesulfonamide, N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-48-4 CAPLUS

CN Ethanol, 2-[[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-49-5 CAPLUS

CN Ethanol, 2-[[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 507488-50-8 CAPLUS

CN Acetamide, 2-chloro-N-[4-methyl-5-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-51-9 CAPLUS

CN Acetamide, 2-chloro-N-[5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 507488-52-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 507488-53-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 507488-55-3 CAPLUS

CN Benzenesulfonic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:273687 CAPLUS  
 DN 139:127415  
 TI Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS  
 Structural Basis for Ligand-Induced Disordering of the Activation Loop  
 AU Wu, Su Ying; McNae, Iain; Kontopidis, George; McClue, Steven J.; McInnes,  
 Campbell; Stewart, Kevin J.; Wang, Shudong; Zheleva, Daniella I.;  
 Marriage, Howard; Lane, David P.; Taylor, Paul; Fischer, Peter M.;  
 Walkinshaw, Malcolm D.  
 CS Structural Biochemistry Group, The University of Edinburgh, Edinburgh, EH9  
 3JR, UK  
 SO Structure (Cambridge, MA, United States) (2003), 11(4), 399-410  
 CODEN: STRUE6; ISSN: 0969-2126  
 PB Cell Press  
 DT Journal  
 LA English  
 OS CASREACT 139:127415  
 AB A family of 4-heteroaryl-2-amino-pyrimidine CDK2 inhibitor lead compds.  
 was discovered with the new database-mining program LIDAEUS through in  
 silico screening. Four compds. with IC50 values ranging from 17 to 0.9  
 µM were selected for x-ray crystal anal. Two distinct binding modes  
 are observed, one of which resembles the hydrogen bonding pattern of bound  
 ATP. In the second binding mode, the ligands trigger a conformational  
 change in the activation T loop by inducing movement of Lys33 and Asp145  
 side chains. The family of mols. discovered provides an excellent  
 starting point for the design and synthesis of tight binding inhibitors,  
 which may lead to a new class of antiproliferative drugs.  
 IT 364333-96-0  
 RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action);  
 PRP (Properties); BIOL (Biological study)  
 (CDK inhibitors discovery using LIDAEUS program detailing structural  
 basis for ligand-induced disordering of activation loop)  
 RN 364333-96-0 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-  
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 364333-96-0D, complexed with CDK2  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (CDK inhibitors discovery using LIDAEUS program detailing structural  
 basis for ligand-induced disordering of activation loop)  
 RN 364333-96-0 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-  
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:117808 CAPLUS  
 DN 138:170248  
 TI Preparation of 4-(thiazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors  
 IN Fraley, Mark E.; Hoffman, William F.; Hartman, George D.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 97 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011838	A1	20030213	WO 2002-US23882	20020727
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004181066	A1	20040916	US 2004-485291	20040129
PRAI	US 2001-309407P	P	20010801		
	WO 2002-US23882	W	20020727		

OS MARPAT 138:170248

AB The present invention relates to title compds. I [wherein R1a = H, (un)substituted alkyl, OR8, or N(R8)2; R1 and R2 = independently H, halo, CF3, (CH2)tr9COR8, COR9, (CH2)tor8, CN, (CH2)tNR7R8, (CH2)CONR7R8, CO2R8, (CH2)tSOO-2(CH2)tNR7R8, or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, alkenyl, or alkynyl; R3 = H, CN, halo, N(R8)2, OR8, or (un)substituted (ar)alkyl or aryl; R7 = H or (un)substituted (ar)alkyl; R8 = independently H or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, or aralkyl; or NR7R8 = (un)substituted heterocyclyl; R9 = independently (un)substituted alkyl, heterocyclyl, or aryl; W = aryl or heterocyclyl; m = 0-2; n = independently 0-6; p = 0-4; t = independently 0-6; or pharmaceutically acceptable salts, hydrates, or stereoisomers thereof], which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compns. which contain these compds., and methods of using them to treat tyrosine kinase-dependent diseases and conditions. For example, cyclization of 2-bromo-1-[2-(methylthio)pyrimidin-4-yl]ethanone (3-step preparation given) with thiourea in EtOH gave 5-bromo-4-[2-(methylthio)pyrimidin-4-yl]-1,3-thiazol-2-amine•HBr. Oxidation to the methylsulfinyl derivative using oxone followed by substitution with 3,5-dimethylaniline afforded II. In bioassays, I inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC values between 0.01 M and 5.0 M. Thus, I are useful for the treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals (no data).


IT 496913-75-8P, 4-(2-Amino-5-bromo-1,3-thiazol-4-yl)-N-(3,5-dimethylphenyl)pyrimidin-2-amine 496913-80-5P, 4-(2-Amino-1,3-thiazol-4-yl)-N-(3,5-dimethylphenyl)pyrimidin-2-amine 496913-88-3P, 4-(2-Amino-5-phenyl-1,3-thiazol-4-yl)-N-(3,5-dimethylphenyl)pyrimidin-2-amine 496913-96-3P,

2-Amino-4-[2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl]-1,3-thiazole-5-carbonitrile 496914-06-8P, 4-[2-[(3,5-Dimethylphenyl)amino]pyrimidin-4-yl]-1,3-thiazole-5-carbonitrile  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tyrosine kinase inhibitor; preparation of (thiazolyl)pyrimidinamine tyrosine kinase inhibitors by reacting (methylsulfinyl)- or (methylsulfonyl) (thiazolyl)pyrimidines with amines)


RN 496913-75-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-5-bromo-4-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 496913-80-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-4-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 496913-88-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2-amino-5-phenyl-4-thiazolyl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 496913-96-3 CAPLUS

CN 5-Thiazolecarbonitrile, 2-amino-4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 496914-06-8 CAPLUS

CN 5-Thiazolecarbonitrile, 4-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L8 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:927427 CAPLUS  
 DN 138:14054  
 TI Preparation of thiazole compounds as inhibitors of protein kinases  
 IN Cochran, John; Nanthakumar, Suganthini; Harrington, Edmund; Wang, Jian  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 75 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096905	A1	20021205	WO 2002-US16352	20020523
	WO 2002096905	C1	20050728		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2446756	AA	20021205	CA 2002-2446756	20020523
	US 2003119856	A1	20030626	US 2002-154118	20020523
	US 6762179	B2	20040713		
	EP 1392684	A1	20040303	EP 2002-737123	20020523
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2006516110	T2	20060622	JP 2003-500084	20020523
	US 2005004152	A1	20050106	US 2004-891912	20040713
PRAI	US 2001-295158P	P	20010601		
	US 2002-154118	A3	20020523		
	WO 2002-US16352	W	20020523		
OS	MARPAT 138:14054				
AB	Thiazole compds. [I; wherein R1 = H, (substituted) (C1-C6)alkyl, CN, halogen, NO2, (substituted) (C1-C4)alkylidene; Ar1 = (substituted) 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially saturated,				
or	aryl ring, 3-7 membered heterocyclic ring, 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring] were prepared For example, (II) was prepared in three steps from 2-acetylthiazole. These compds. are inhibitors of protein kinases, particularly inhibitors of GSK3, Aurora2, and Syk mammalian protein kinases. For example, compound II showed IC50 ≤ 0.5 μM against Syk mammalian protein kinase.				
IT	477769-08-7P	477769-09-8P	477769-10-1P		
	477769-11-2P	477769-12-3P	477769-13-4P		
	477769-14-5P	477769-15-6P	477769-16-7P		
	477769-17-8P	477769-18-9P	477769-19-0P		
	477769-20-3P	477769-21-4P	477769-22-5P		
	477769-23-6P	477769-24-7P	477769-25-8P		
	477769-26-9P	477769-27-0P	477769-28-1P		
	477769-29-2P	477769-30-5P	477769-31-6P		
	477769-33-8P	477769-34-9P	477769-35-0P		
	477769-36-1P	477769-37-2P	477769-38-3P		
	477769-39-4P	477769-40-7P	477769-41-8P		
	477769-42-9P	477769-43-0P	477769-44-1P		


477769-45-2P 477769-46-3P 477769-47-4P  
 477769-48-5P 477769-49-6P 477769-50-9P  
 477769-51-0P 477769-52-1P 477769-53-2P  
 477769-54-3P 477769-55-4P 477769-56-5P  
 477769-57-6P 477769-58-7P 477769-59-8P  
 477769-60-1P 477769-61-2P 477769-62-3P  
 477769-63-4P 477769-64-5P 477769-65-6P  
 477769-66-7P 477769-67-8P 477769-68-9P  
 477769-69-0P 477769-70-3P 477769-71-4P  
 477769-72-5P 477769-73-6P 477769-74-7P  
 477769-75-8P 477769-76-9P 477769-77-0P  
 477769-78-1P 477769-79-2P 477769-80-5P  
 477769-81-6P 477769-82-7P 477769-83-8P  
 477769-84-9P 477769-85-0P 477769-86-1P  
 477769-87-2P 477769-88-3P 477769-89-4P  
 477769-90-7P 477769-91-8P 477769-92-9P  
 477769-93-0P 477769-94-1P 477769-95-2P  
 477769-96-3P 477769-97-4P 477769-98-5P  
 477769-99-6P 477770-00-6P 477770-01-7P  
 477770-02-8P 477770-03-9P 477770-04-0P  
 477770-05-1P 477770-06-2P 477770-07-3P  
 477770-08-4P 477770-09-5P 477770-10-8P  
 477770-11-9P 477770-12-0P 477770-13-1P  
 477770-14-2P 477770-15-3P 477770-16-4P  
 477770-17-5P 477770-18-6P 477770-19-7P  
 477770-20-0P 477770-21-1P 477770-22-2P  
 477770-23-3P 477770-24-4P 477770-25-5P  
 477770-26-6P 477770-27-7P 477770-28-8P  
 477770-29-9P 477770-30-2P 477770-31-3P  
 477770-32-4P 477770-33-5P 477770-34-6P  
 477770-35-7P 477770-36-8P 477770-37-9P  
 477770-38-0P 477770-39-1P 477770-40-4P  
 477770-41-5P 477770-42-6P 477770-43-7P  
 477770-44-8P 477770-45-9P 477770-46-0P  
 477770-47-1P 477770-48-2P 477770-49-3P  
 477770-50-6P 477770-51-7P 477770-52-8P  
 477770-53-9P 477770-54-0P 477770-55-1P  
 477770-56-2P 477770-57-3P 477770-58-4P  
 477770-59-5P 477770-60-8P 477770-61-9P  
 477770-62-0P 477770-63-1P 477770-64-2P  
 477770-65-3P 477770-66-4P 477770-67-5P  
 477770-68-6P 477770-69-7P 477770-70-0P  
 477770-71-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of thiazole compds. as inhibitors of protein kinases)


RN 477769-08-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3,4-dichlorophenyl)methoxy]phenyl]-4-(2-  
 thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-09-8 CAPLUS

CN 2-Pyrimidinamine, N-(2'-methyl[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 477769-10-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-phenoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-11-2 CAPLUS

CN 2-Pyrimidinamine, N-{3-[[4-(methylsulfonyl)phenyl]methoxy]phenyl}-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-12-3 CAPLUS

CN 2-Pyrimidinamine, N-(2'-fluoro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 477769-13-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-(phenylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-14-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-(4-pyridinylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-15-6 CAPLUS

CN 2-Pyrimidinamine, N-(4'-phenoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-16-7 CAPLUS

CN 2-Pyrimidinamine, N-[4-(phenylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-17-8 CAPLUS

CN Phenol, 3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477769-18-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 477769-19-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-phenoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-20-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3-aminophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-21-4 CAPLUS

CN 2-Pyrimidinamine, N-(3'-fluoro-5'-methoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-22-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-nitrophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-23-6 CAPLUS

CN 2-Pyrimidinamine, N-[3-(1,3-benzodioxol-5-ylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-24-7 CAPLUS

CN 2-Pyrimidinamine, N-(2',4'-difluoro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-25-8 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-26-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-(2-pyridinylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI)  
(CA INDEX NAME)


RN 477769-27-0 CAPLUS

CN 2-Pyrimidinamine, N-(2',5'-dichloro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-28-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-29-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-pyridinylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI)  
(CA INDEX NAME)


RN 477769-30-5 CAPLUS

CN 2-Pyrimidinamine, N-(2',3'-dichloro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-31-6 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-33-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 477769-34-9 CAPLUS


CN 2-Pyrimidinamine, N-(6-chloro-2-pyridinyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 477769-35-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1H-pyrrol-1-yl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)







RN 477769-36-1 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 477769-37-2 CAPLUS  
 CN 2-Pyrimidinamine, N-(3-iodophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-38-3 CAPLUS  
 CN 2-Pyrimidinamine, N-(4'-ethoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477769-39-4 CAPLUS  
 CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-40-7 CAPLUS  
 CN 2-Pyrimidinamine, N-[3-[(2-nitrophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-41-8 CAPLUS

CN 2-Pyrimidinamine, N-(2'-ethoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 477769-42-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI)  
(CA INDEX NAME)




RN 477769-43-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-aminophenyl)methoxy]phenyl]-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 477769-44-1 CAPLUS

CN 2-Pyrimidinamine, N-(2',5'-dimethyl[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 477769-45-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-nitrophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-46-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-fluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-47-4 CAPLUS

CN 2-Pyrimidinamine, N-(3'-ethoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-48-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-49-6 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-methoxyphenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-50-9 CAPLUS

CN 2-Pyrimidinamine, N-[4'-(methanesulfonyl)[1,1'-biphenyl]-3-yl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-51-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-52-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 477769-53-2 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 3'-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 477769-54-3 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX  
NAME)




RN 477769-55-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-pyridinyloxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA  
INDEX NAME)




RN 477769-56-5 CAPLUS

CN 2-Pyrimidinamine, N-(2',6'-dimethoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 477769-57-6 CAPLUS

CN 2-Pyrimidinamine, N-2-naphthalenyl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-58-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-(2-pyridinyloxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-59-8 CAPLUS

CN 2-Pyrimidinamine, N-(2',5'-dimethoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-60-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477769-61-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-(4-pyridinyloxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-62-3 CAPLUS

CN [1,1'-Biphenyl]-3,3'-diamine, N-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477769-63-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 477769-64-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-nitrophenoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-65-6 CAPLUS

CN 2-Pyrimidinamine, N-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)


RN 477769-66-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,6-dichlorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-67-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-aminophenoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477769-68-9 CAPLUS


CN 2-Pyrimidinamine, N-[3-(3-pyridinyl)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477769-69-0 CAPLUS


CN 2-Pyrimidinamine, N-(2,6-difluorophenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)





RN 477769-70-3 CAPLUS


CN 2-Pyrimidinamine, N-[6-(phenylthio)-2-pyridinyl]-4-(2-thiazolyl)- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 477769-71-4 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 3'-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 477769-72-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-methylphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477769-73-6 CAPLUS


CN 2,6-Pyridinediamine, N-phenyl-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 477769-74-7 CAPLUS

CN [1,1'-Biphenyl]-2-ol, 3'-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 477769-75-8 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-76-9 CAPLUS

CN 2-Pyrimidinamine, 5-methyl-N-(3-phenoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-77-0 CAPLUS


CN [1,1'-Biphenyl]-3-ol, 3'-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 477769-78-1 CAPLUS  
 CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-79-2 CAPLUS  
 CN 2-Pyrimidinamine, N-[1,1'-biphenyl]-3-yl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-80-5 CAPLUS  
 CN [1,1'-Biphenyl]-4-ol, 2-methoxy-3'--[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477769-81-6 CAPLUS  
 CN 2-Pyrimidinamine, N-[3-(cyclohexylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-82-7 CAPLUS  
 CN 2-Pyrimidinamine, N-[3-(1-naphthalenyl)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-83-8 CAPLUS  
 CN 2-Pyrimidinamine, N-[3-(1H-indol-5-yl)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-84-9 CAPLUS  
 CN Benzonitrile, 3-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 477769-85-0 CAPLUS  
 CN 2-Pyrimidinamine, N-(6-phenyl-2-pyridinyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
 RN 477769-86-1 CAPLUS  
 CN [1,1'-Biphenyl]-3,4'-diamine, N4',N4'-dimethyl-N3-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477769-87-2 CAPLUS

CN Benzoic acid, 4-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 477769-88-3 CAPLUS

CN 2-Pyrimidinamine, 5-methyl-N-[3-(phenylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-89-4 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 3'-[[5-methyl-4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477769-90-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3,4-difluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-91-8 CAPLUS

CN [1,1'-Biphenyl]-3-methanol, 3'--[[4-(2-thiazolyl)-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 477769-92-9 CAPLUS

CN 2-Pyrimidinamine, 5-methyl-N-[3-(3-pyridinyl)phenyl]-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 477769-93-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-chlorophenyl)methoxy]phenyl]-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 477769-94-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-(1,3-benzodioxol-5-yl)phenyl]-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 477769-95-2 CAPLUS

CN [1,1'-Biphenyl]-3,3'-diamine, N-[5-methyl-4-(2-thiazolyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 477769-96-3 CAPLUS

CN 1,3-Benzenediamine, N-[(2,6-dichlorophenyl)methyl]-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477769-97-4 CAPLUS

CN 2-Pyrimidinamine, N-[3'-(phenylmethoxy)[1,1'-biphenyl]-3-yl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-98-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy[1,1'-biphenyl]-3-yl)-5-methyl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-99-6 CAPLUS

CN 1,3-Benzenediamine, N-[(2,6-difluorophenyl)methyl]-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477770-00-6 CAPLUS

CN Ethanone, 1-[3'-[[4-(2-thiazolyl)-2-pyrimidinyl]amino][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 477770-01-7 CAPLUS


CN 2-Pyrimidinamine, N-(4-methoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477770-02-8 CAPLUS


CN 1,3-Benzenediamine, N-(3-nitrophenyl)-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 477770-03-9 CAPLUS

CN 2-Pyrimidinamine, N-(3'-fluoro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 477770-04-0 CAPLUS

CN 2-Pyrimidinamine, 5-methyl-4-(2-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 477770-05-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3-fluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-06-2 CAPLUS

CN [1,1'-Biphenyl]-4-methanol, 3'--[[4-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 477770-07-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(3,5-difluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-08-4 CAPLUS

CN 2-Pyrimidinamine, N-(3',4'-dimethyl[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-09-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-fluorophenoxy)-4-methoxyphenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-10-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-11-9 CAPLUS

CN 2-Pyrimidinamine, N-(4'-fluoro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-12-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-(3-chlorophenoxy)-4-methoxyphenyl]-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 477770-13-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(4-fluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 477770-14-2 CAPLUS

CN 2-Pyrimidinamine, N-(4'-chloro[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 477770-15-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-(4-chlorophenoxy)-4-methoxyphenyl]-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 477770-16-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2,3-dichlorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-17-5 CAPLUS

CN 2-Pyrimidinamine, N-(4'-methoxy[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-18-6 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxy-5-phenoxyphenyl)-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-19-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-methylphenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-20-0 CAPLUS

CN 2-Pyrimidinamine, N-(4'-methyl[1,1'-biphenyl]-3-yl)-4-(2-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 477770-21-1 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxy-5-phenoxyphenyl)-5-methyl-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)



RN 477770-22-2 CAPLUS


CN 4-Piperidinemethanol, 1-[3-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 477770-23-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477770-24-4 CAPLUS

CN 1-Piperazineethanol, 4-[3-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 477770-25-5 CAPLUS

CN 3-Piperidinol, 1-[3-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 477770-26-6 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(4-morpholinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-27-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-[3-(4-thiomorpholinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-28-8 CAPLUS

CN 4-Piperidinemethanol, 1-[3-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 477770-29-9 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]propyl]-, (2S)- (9CI) (CA INDEX NAME)




RN 477770-30-2 CAPLUS

CN 4-Piperidinol, 1-[3-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 477770-31-3 CAPLUS

CN 1-Butanone, 4-[4-(hydroxymethyl)-1-piperidinyl]-1-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-32-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(3-amino-1-piperidinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-33-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(4-ethyl-1-piperazinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-34-6 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(1-piperazinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-35-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-[4-(4-pyridinylmethyl)-1-piperazinyl]propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477770-36-8 CAPLUS


CN 2-Pyrimidinamine, N-[3-[3-(1-pyrrolidinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)






RN 477770-37-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(1H-imidazol-1-yl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-38-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(4-methyl-1H-imidazol-1-yl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-39-1 CAPLUS

CN 1,3-Benzenediamine, N-[3-(4-morpholinyl)propyl]-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477770-40-4 CAPLUS

CN Butanamide, 4-(dimethylamino)-N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-41-5 CAPLUS


CN 1-Piperidinebutanamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 477770-42-6 CAPLUS


CN 4-Morpholineacetamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-  
(9CI) (CA INDEX NAME)

RN 477770-43-7 CAPLUS

CN 1-Piperazinebutanamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-  
(9CI) (CA INDEX NAME)


RN 477770-44-8 CAPLUS

CN 1-Piperidinebutanamide, 4-(hydroxymethyl)-N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 477770-45-9 CAPLUS


CN 1H-Pyrrole-1-butanamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 477770-46-0 CAPLUS


CN 1-Piperazinebutanamide, 4-(2-hydroxyethyl)-N-[3-[[4-(2-thiazolyl)-2-

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-47-1 CAPLUS

CN Acetamide, 2-[(2-hydroxyethyl)amino]-N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-48-2 CAPLUS

CN Acetamide, 2-[(3-hydroxypropyl)amino]-N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-49-3 CAPLUS

CN Carbamic acid, [3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 477770-50-6 CAPLUS

CN Carbamic acid, [3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, (tetrahydro-2-furanyl)methyl ester (9CI) (CA INDEX NAME)




RN 477770-51-7 CAPLUS

CN Carbamic acid, [3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, (tetrahydro-2H-pyran-2-yl)methyl ester (9CI) (CA INDEX NAME)




RN 477770-52-8 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-53-9 CAPLUS

CN Ethanol, 2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 477770-54-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-55-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-56-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1-piperidinyl)ethoxy]phenyl]-4-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 477770-57-3 CAPLUS

CN 4-Piperidinol, 1-[2-[3-[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl-  
(9CI) (CA INDEX NAME)



RN 477770-58-4 CAPLUS


CN 4-Piperidinol, 1-[2-[3-[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl-  
(9CI) (CA INDEX NAME)



RN 477770-59-5 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[3-[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl-, (2S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477770-60-8 CAPLUS

CN 1-Piperazineethanol, 4-[2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 477770-61-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1-piperazinyl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-62-0 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(3-piperidynyl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-63-1 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(dimethylamino)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-64-2 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-65-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(diethylamino)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-66-4 CAPLUS

CN Ethanol, 2-[methyl[2-[3-[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 477770-67-5 CAPLUS


CN 2-Pyrimidinamine, N-[3-[3-[(2-methoxyethyl)amino]propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477770-68-6 CAPLUS


CN 1,3-Benzenediamine, N-[2-[(2-methoxyethyl)amino]ethyl]-N'-[4-(2-thiazolyl)-

2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477770-69-7 CAPLUS

CN 1,3-Benzenediamine, N-[2-(diethylamino)ethyl]-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477770-70-0 CAPLUS

CN Ethanol, 2-[methyl[2-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 477770-71-1 CAPLUS


CN 1-Piperazineethanol, 4-[2-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L8 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:641097 CAPLUS  
 DN 138:122613  
 TI Structure-Activity Relationship Studies of Ethyl 2-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: An Inhibitor of AP-1 and NF- $\kappa$ B Mediated Gene Expression  
 AU Palanki, Moorthy S. S.; Gayo-Fung, Leah M.; Shevlin, Graziella I.; Erdman, Paul; Sato, Mark; Goldman, Mark; Ransone, Lynn J.; Spooner, Cheryl  
 CS Celgene Signal Research Division, San Diego, CA, 92121, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(18), 2573-2577  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 138:122613  
 AB Several analogs of Et 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate (I) were synthesized and tested as inhibitors of AP-1 and NF- $\kappa$ B mediated transcriptional activation in Jurkat T cells. From our SAR work, Et 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))-N-methylamino]-4-(trifluoromethyl)-pyrimidine-5-carboxylate was identified as a novel and potent inhibitor.  
 IT 188936-89-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn of pyrrolinylaminopyrimidine analogs from  $\beta$ -keto esters and their activity as inhibitors of AP-1 and NF- $\kappa$ B mediated gene expression)  
 RN 188936-89-2 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 2-[(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl)amino]-4-(2-thiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:730738 CAPLUS  
 DN 135:288789  
 TI 2-Substituted 4-heteroaryl-pyrimidines with activity as inhibitors of cyclin-dependent kinases and their preparation and use in the treatment of proliferative disorders  
 IN Fischer, Peter Martin; Wang, Shudong  
 PA Cyclacel Limited, UK  
 SO PCT Int. Appl., 95 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072745	A1	20011004	WO 2001-GB1423	20010328
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2401748	AA	20011004	CA 2001-2401748	20010328
	GB 2361236	A1	20011017	GB 2001-7758	20010328
	GB 2361236	B2	20020424		
	EP 1274705	A1	20030115	EP 2001-915544	20010328
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003528872	T2	20030930	JP 2001-570655	20010328
	NZ 521068	A	20050429	NZ 2001-521068	20010328
	US 2002019404	A1	20020214	US 2001-823075	20010329
	US 6531479	B2	20030311		
	US 2003149057	A1	20030807	US 2002-327540	20021220
	US 6699854	B2	20040302		
PRAI	GB 2000-7636	A	20000329		
	GB 2000-15117	A	20000620		
	WO 2001-GB1423	W	20010328		
	US 2001-823075	A3	20010329		

OS MARPAT 135:288789

AB The invention relates to 2-substituted 4-heteroaryl-pyrimidines I and their pharmaceutically acceptable salts [wherein: X1 = CH and X2 = S; or 1 of X1 and X2 = S and the other = N; Z = NH, NHCO, NHSO2, NHCH2, CH2, CH2CH2, or CH:CH; R1, R2, R3 = H, alkyl, aryl, aralkyl, heterocyclyl, halo, NO2, cyano, OH, alkoxy, aryloxy, NH2, NHR', N(R')(R''), NHCOR', NH(aryl), N(aryl)2, COOH, COOR', COO(aryl), CONH2, CONHR', CON(R')(R''), CONH(aryl), CON(aryl)2, SO3H, SO2NH2, CF3, COR', or CO(aryl), wherein alkyl, aryl, aralkyl, heterocyclyl, and NH(aryl) groups may be further substituted with 1 or more halo, NO2, cyano, OH, OMe, NH2, COOH, CONH2, and/or CF3; at least 1 of R1 and R2 ≠ H when either X1 or X2 = S; R4, R5, R6, R7, R8 = H, (un)substituted alkyl, halo, NO2, cyano, OH, (un)substituted alkoxy, NH2, NHR', alkyl-aryl, alkyl-heteroaryl, NH(C:NH)NH2, N(R')3+, N(R')(R''), COOH, COOR', CONH2, CONHR', CON(R')(R''), SO3H, SO2NH2, CF3, or (CH2)nO(CH2)mNR'R'', (CH2)nCO2(CH2)mOR''' wherein n = 0, 1, 2, or 3; m = 1, 2 or 3; R', R'', R''' = alkyl]. The invention also relates to preparation of I, pharmaceutical

compsns. containing them, and their use as inhibitors of cyclin-dependant kinases (CDKs), and hence their use in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like. Examples include 22 syntheses and a variety of bioassays. For instance, 4-FC6H4NH<sub>2</sub> was treated with HNO<sub>3</sub> and cyanamide in EtOH to give 47% 4-FC6H4NHC(:NH)NH<sub>2</sub>.HNO<sub>3</sub> (II). Sep., 5-acetyl-2,4-dimethylthiazole was condensed with N,N-dimethylformamide di-Me acetal to give 79% 3-dimethylamino-1-(2,4-dimethylthiazol-5-yl)propenone (III). Cyclocondensation of II with III in refluxing MeOCH<sub>2</sub>CH<sub>2</sub>OH in the presence of NaOH gave title compound IV in 89% yield. In an assay against multiple kinases, IV selectively inhibited CDKs, showing an IC<sub>50</sub> of 0.019  $\mu$ M against CDK2/cyclin E, and 0.47  $\mu$ M against CDK4/cyclin D1, vs. >20  $\mu$ M against PCK $\alpha$  and SAPK2 $\alpha$ . Addnl. bioassays of I showed antiproliferative and cytotoxic activity.


IT 364333-82-4P 364334-16-7P 364334-85-0P  
364334-88-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of heteroarylpyrimidines as CDK-inhibiting antiproliferative and anticancer agents)


RN 364333-82-4 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI)  
(CA INDEX NAME)




RN 364334-16-7 CAPLUS

CN 1,3-Benzenediamine, N-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 364334-85-0 CAPLUS

CN Benzenemethanol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 364334-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT 364333-75-5P 364333-76-6P 364333-77-7P  
 364333-81-3P 364333-83-5P 364333-88-0P  
 364333-89-1P 364333-90-4P 364333-91-5P  
 364333-92-6P 364333-93-7P 364333-94-8P  
 364333-95-9P 364333-96-0P 364333-97-1P  
 364333-98-2P 364333-99-3P 364334-00-9P  
 364334-01-0P 364334-02-1P 364334-03-2P  
 364334-04-3P 364334-05-4P 364334-06-5P  
 364334-07-6P 364334-08-7P 364334-09-8P  
 364334-10-1P 364334-14-5P 364334-17-8P  
 364334-18-9P 364334-19-0P 364334-20-3P  
 364334-21-4P 364334-22-5P 364334-23-6P  
 364334-24-7P 364334-25-8P 364334-26-9P  
 364334-27-0P 364334-28-1P 364334-29-2P  
 364334-30-5P 364334-31-6P 364334-32-7P  
 364334-33-8P 364334-34-9P 364334-35-0P  
 364334-36-1P 364334-37-2P 364334-38-3P  
 364334-39-4P 364334-41-8P 364334-42-9P  
 364334-43-0P 364334-44-1P 364334-45-2P  
 364334-46-3P 364334-47-4P 364334-48-5P  
 364334-49-6P 364334-51-0P 364334-52-1P  
 364334-53-2P 364334-54-3P 364334-55-4P  
 364334-56-5P 364334-57-6P 364334-58-7P  
 364334-59-8P 364334-60-1P 364334-61-2P  
 364334-62-3P 364334-63-4P 364334-64-5P  
 364334-66-7P 364334-67-8P 364334-68-9P  
 364334-69-0P 364334-70-3P 364334-71-4P  
 364334-72-5P 364334-73-6P 364334-74-7P  
 364334-75-8P 364334-76-9P 364334-77-0P  
 364334-78-1P 364334-79-2P 364334-80-5P  
 364334-81-6P 364334-82-7P 364334-83-8P  
 364334-84-9P 364334-86-1P 364334-87-2P


364334-89-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteroarylpyrimidines as CDK-inhibiting antiproliferative and anticancer agents)


RN 364333-75-5 CAPLUS

CN 2-Pyrimidinamine, N-(2-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 364333-76-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 364333-77-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
(CA INDEX NAME)




RN 364333-81-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-nitrophenyl)- (9CI)  
(CA INDEX NAME)




RN 364333-83-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-nitrophenyl)- (9CI)  
(CA INDEX NAME)




RN 364333-88-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-fluorophenyl)- (9CI)  
(CA INDEX NAME)



RN 364333-89-1 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)- (9CI)  
(CA INDEX NAME)




RN 364333-90-4 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-


(9CI) (CA INDEX NAME)



RN 364333-91-5 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)

RN 364333-92-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dichlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)


RN 364333-93-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-dichlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 364333-94-8 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-95-9 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364333-96-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)







RN 364333-97-1 CAPLUS  
 CN 2-Pyrimidinamine, N-(2-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
 (CA INDEX NAME)




RN 364333-98-2 CAPLUS  
 CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
 (CA INDEX NAME)



RN 364333-99-3 CAPLUS  
 CN 2-Pyrimidinamine, N-(4-bromophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI)  
 (CA INDEX NAME)




RN 364334-00-9 CAPLUS  
 CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-iodophenyl)- (9CI)  
 (CA INDEX NAME)




RN 364334-01-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-iodophenyl)- (9CI)  
(CA INDEX NAME)




RN 364334-02-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-iodophenyl)- (9CI)  
(CA INDEX NAME)



RN 364334-03-2 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-2-pyridinyl- (9CI) (CA  
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 364334-04-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-fluorophenyl)- (9CI)  
(CA INDEX NAME)




RN 364334-05-4 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 364334-06-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-methoxyphenyl)- (9CI)  
(CA INDEX NAME)




RN 364334-07-6 CAPLUS


CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-methoxyphenyl)- (9CI)  
(CA INDEX NAME)




RN 364334-08-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-methoxyphenyl)- (9CI)  
(CA INDEX NAME)

RN 364334-09-8 CAPLUS


CN Phenol, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA  
INDEX NAME)

RN 364334-10-1 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA  
INDEX NAME)


RN 364334-14-5 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-nitro-  
(9CI) (CA INDEX NAME)




RN 364334-17-8 CAPLUS

CN Benzonitrile, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 364334-18-9 CAPLUS

CN Benzonitrile, 3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)



RN 364334-19-0 CAPLUS


CN Benzoic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-,  
methyl ester (9CI) (CA INDEX NAME)



RN 364334-20-3 CAPLUS


CN 2-Pyrimidinamine, N-(3-chloro-4-methylphenyl)-4-(2,4-dimethyl-5-thiazolyl)-

(9CI) (CA INDEX NAME)




RN 364334-21-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 364334-22-5 CAPLUS

CN Benzoic acid, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-23-6 CAPLUS


CN 2-Pyrimidinamine, 4-bromo-6-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-24-7 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)-6-phenyl-  
(9CI) (CA INDEX NAME)

RN 364334-25-8 CAPLUS


CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-6-phenyl-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)

RN 364334-26-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(4-methyl-2-phenyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)


RN 364334-27-0 CAPLUS

CN Phenol, 4-[[4-(4-methyl-2-phenyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 364334-28-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-phenyl-  
(9CI) (CA INDEX NAME)




RN 364334-29-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(methylamino)-5-  
thiazolyl]- (9CI) (CA INDEX NAME)



RN 364334-30-5 CAPLUS

CN Phenol, 4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 364334-31-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[4-




(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-32-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-33-8 CAPLUS

CN Phenol, 4-[[4-(2,4-dimethyl-5-thiazolyl)-6-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]-2-nitro- (9CI) (CA INDEX NAME)




RN 364334-34-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-35-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-36-1 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 364334-37-2 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 364334-38-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(3-pyridinyl)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-39-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-iodophenyl)-4-[4-methyl-2-(methyamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-41-8 CAPLUS

CN Phenol, 4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-2-nitro- (9CI) (CA INDEX NAME)




RN 364334-42-9 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-43-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(ethylamino)-4-methyl-5-thiazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 364334-44-1 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methyamino)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 364334-45-2 CAPLUS

CN Phenol, 3-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-46-3 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-[2-(ethylamino)-4-methyl-5-thiazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-47-4 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-48-5 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-49-6 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-51-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[4-methyl-2-(2-propenylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-52-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-[4-methyl-2-(methylenamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-53-2 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(2-propenylamino)-5-thiazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 364334-54-3 CAPLUS


CN Phenol, 3-[[4-[4-methyl-2-(methylenamino)-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 364334-55-4 CAPLUS


CN 2-Pyrimidinamine, N-(4-bromophenyl)-4-[4-methyl-2-(methylenamino)-5-

thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-56-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-57-6 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 364334-58-7 CAPLUS


CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)






RN 364334-59-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-methyl-2-(methylamino)-5-thiazolyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-60-1 CAPLUS

CN Benzoic acid, 2-chloro-5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-61-2 CAPLUS

CN Benzoic acid, 3-chloro-2-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364334-62-3 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(2-fluoro-4-iodophenyl)- (9CI) (CA INDEX NAME)




RN 364334-63-4 CAPLUS

CN Phenol, 2-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-5-methoxy-  
(9CI) (CA INDEX NAME)




RN 364334-64-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-iodophenyl)-4-(2,4-dimethyl-5-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 364334-66-7 CAPLUS

CN Phenol, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 364334-67-8 CAPLUS

CN Benzoic acid, 5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-2-fluoro-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 364334-68-9 CAPLUS

CN Benzoic acid, 2-chloro-5-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-69-0 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-70-3 CAPLUS

CN Benzoic acid, 2-chloro-4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 364334-71-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-iodophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-72-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-73-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-74-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-75-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-difluorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-76-9 CAPLUS

CN 2-Pyrimidinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-77-0 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-78-1 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-79-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluoro-3-nitrophenyl)-4-[4-methyl-2-(methylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-80-5 CAPLUS

CN Phenol, 4-[[4-[2-[(4-nitrophenyl)amino]-5-thiazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-81-6 CAPLUS

CN Acetamide, N-[5-[2-[(4-hydroxyphenyl)amino]-4-pyrimidinyl]-4-methyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-82-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[2-[(4-nitrophenyl)amino]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 364334-83-8 CAPLUS

CN Phenol, 4-[[4-(2-amino-4-methyl-5-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 364334-84-9 CAPLUS

CN Guanidine, [3-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]phenyl]-  
(9CI) (CA INDEX NAME)


RN 364334-86-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 364334-87-2 CAPLUS


CN 2-Pyrimidinamine, N-[3-[[2-(diethylamino)ethoxy]methyl]phenyl]-4-(2,4-dimethyl-5-thiazolyl)- (9CI) (CA INDEX NAME)



RN 364334-89-4 CAPLUS

CN Benzenaminium, 4-[[4-(2,4-dimethyl-5-thiazolyl)-2-pyrimidinyl]amino]-N,N,N-trimethyl- (9CI) (CA INDEX NAME)





RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2000:911230 CAPLUS  
 DN 134:71598  
 TI Preparation of 2-arylamino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFR kinase.  
 IN Batchelor, Mark James; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive  
 PA Celltech Chiroscience Limited, UK  
 SO PCT Int. Appl., 102 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000078731	A1	20001228	WO 2000-GB2382	20000619
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6579983	B1	20030617	US 2000-596952	20000616
	CA 2375182	AA	20001228	CA 2000-2375182	20000619
	BR 2000011770	A	20020305	BR 2000-11770	20000619
	EP 1187816	A1	20020320	EP 2000-940569	20000619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	DE 10084704	T	20020529	DE 2000-10084704	20000619
	GB 2369360	A1	20020529	GB 2001-30563	20000619
	JP 2003502406	T2	20030121	JP 2001-504897	20000619
	ES 2188429	A1	20030616	ES 2001-50085	20000619
	ES 2188429	B2	20050616		
	AU 778533	B2	20041209	AU 2000-55488	20000619
	BG 106116	A	20020731	BG 2001-106116	20011119
	ZA 2001009841	A	20020429	ZA 2001-9841	20011129
	NO 2001006162	A	20020218	NO 2001-6162	20011217
	US 2002147339	A1	20021010	US 2002-151518	20020520
	HK 1048815	A1	20050429	HK 2003-101022	20030212
	US 2004180914	A1	20040916	US 2004-812293	20040329
PRAI	GB 1999-14258	A	19990618		
	US 2000-596952	A1	20000616		
	WO 2000-GB2382	W	20000619		
	US 2002-151518	B1	20020520		
OS	MARPAT 134:71598				
AB	Title compds. [I; Ar = (substituted) aryl, heteroaryl; R1 = H, alkyl; R2 = X1R3; X1 = bond, linker atom or group; R3 = (substituted) aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom. group] and the salts, solvates, hydrates and N-oxides thereof, were prepared Thus, 3,4,5-trimethoxyphenylguanidinium nitrate (preparation given), 1-phenyl-2-cyano-3-dimethylaminopropen-1-one, and NaOH were refluxed in EtOH to give 5-cyano-4-phenyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine. I inhibited KDR kinase and FGFR kinase with IC50 ≤1 μM.				
IT	314268-96-7P 314268-97-8P 314268-98-9P 314268-99-0P 314269-00-6P 314269-01-7P				

314269-02-8P 314269-03-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 2-aryl-amino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFr kinase)

RN 314268-96-7 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(2-thiazolyl)-2-[(3,4,5-trimethoxyphenyl)amino]- (9CI) (CA INDEX NAME)



2 D 465


RN 314268-97-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(2-thiazolyl)-2-[[4-(1H-1,2,4-triazol-1-yl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 314268-98-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3,4-dimethoxyphenyl)amino]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 314268-99-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(2-thiazolyl)-2-[[4-[2-(1H-1,2,4-triazol-1-yl)ethoxy]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 314269-00-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(2-thiazolyl)-2-[[4-[2-(1H-1,2,3-triazol-1-

yl)ethoxy]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 314269-01-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(2-thiazolyl)-2-[[4-[2-(2H-1,2,3-triazol-2-yl)ethoxy]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 314269-02-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 314269-03-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-(4-fluorophenyl)amino]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:505664 CAPLUS

DN 131:144609

TI Preparation of pyrimidinecarboxylates and analogs as transcription factor activation inhibitors

IN Suto, Mark J.; Gayo, Leah M.; Palanki, Moorthy S. S.; Ransone-Fong, Lynn J.

PA Signal Pharmaceuticals, Inc., USA

SO U.S., 32 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5935966	A	19990810	US 1997-807677	19970227
	US 5852028	A	19981222	US 1995-574406	19951218
	WO 9709325	A1	19970313	WO 1996-US14089	19960830
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	WO 9838171	A1	19980903	WO 1998-US3616	19980224
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9866667	A1	19980918	AU 1998-66667	19980224
PRAI	US 1995-3109P	P	19950901		
	US 1995-574406	A2	19951218		
	WO 1996-US14089	W	19960830		
	US 1997-807677	A	19970227		
	WO 1998-US3616	W	19980224		

OS MARPAT 131:144609


AB Title compds. [I; 1 of R2,R4 = NRR9 and the other = H, halo, alkyl, aryl, etc.; R = (un)substituted phthalimido, -maleimido, etc.; R5 = CO2R7, COR8, 4-methyl-2-oxazolyl, etc.; R6 = H, F, Me, CF3, CH2Ph; R7 = H, (ar)alkyl, aryl, etc.; R8 = (ar)alkyl, aryl, etc.; R9 = (ar)alkyl, COZR7, etc.; Z = bond, O, NH] were prepared Thus, EtCOCH2CO2Et was condensed with (H2N)2CO/HC(OEt)3 and the product cyclized to give, in 2 addnl. steps, I (R4 = Et, R5 = CO2Et, R6 = H) (II; R2 = NHH2) which was cyclocondensed with citraconic anhydride to give II [R2 = (methylmaleimido)amino]. Data for biol. activity of I were given.

IT 188936-89-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrimidinecarboxylates and analogs as transcription factor activation inhibitors)

RN 188936-89-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl)amino]-4-(2-thiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)




RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1998:608604 CAPLUS  
 DN 129:216625  
 TI Preparation of pyrimidinecarboxylates for treating inflammatory conditions  
 IN Suto, Mark J.; Gayo, Leah M.; Palanki, Moorthy S. S.; Ransone-Fong, Lynn J.  
 PA Signal Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 95 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9838171	A1	19980903	WO 1998-US3616	19980224
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5935966	A	19990810	US 1997-807677	19970227
	AU 9866667	A1	19980918	AU 1998-66667	19980224
PRAI	US 1997-807677	A	19970227		
	US 1995-3109P	P	19950901		
	US 1995-574406	A2	19951218		
	WO 1996-US14089	W	19960830		
	WO 1998-US3616	W	19980224		
OS	MARPAT 129:216625				
AB	The title compds. [I; R2 = R2a when R4 = R4a, and R2 = R2b when R4 = R4b; R2b, R4a = H, halo, C1-8 alkyl, etc.; R2a, R4b = II-V; R5 = CO2R7, C(O)R8, etc.; R6 = H, Me, PhCH2, F, CF3; R7 = H, C1-8 alkyl, etc.; R8 = (un)substituted C1-8 alkyl, C6-12 aryl, C7-12 aralkyl; R9 = H, C1-8 alkyl, etc.; R10, R11 = H, (un)substituted C1-8 alkyl, C6-12 aryl], useful as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases such as rheumatoid arthritis, osteoarthritis, transplant rejection, sepsis, ARDS, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease, glomerulonephritis, lupus, uveitis, chronic hepatitis, trauma, oxidative stress, cell death, irradiation damage, ischemia, reperfusion, cancer, and viral infection, were prepared Thus, reaction of Et 2-hydrazino-4-trifluoromethylpyrimidine-5-carboxylate with citraconic anhydride in CHCl3 afforded 39% I [R2 = III (R9 = R11 = H; R10 = Me); R4 = CF3; R5 = H; R6 = CO2Et] which showed IC50 of 0.7 $\mu$ M against activation of transcription factors NF $\kappa$ B and AP-1.				
IT	188936-89-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrimidinecarboxylates for treating inflammatory conditions)				
RN	188936-89-2 CAPLUS				
CN	5-Pyrimidinecarboxylic acid, 2-[(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl)amino]-4-(2-thiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)				



RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L8 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1997:457074 CAPLUS  
 DN 127:81461  
 TI Preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors  
 IN Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive  
 PA Celltech Therapeutics Limited, UK; Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive  
 SO PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9719065	A1	19970529	WO 1996-GB2854	19961120
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5958935	A	19990928	US 1996-753041	19961119
	AU 9676314	A1	19970611	AU 1996-76314	19961120
	EP 862560	A1	19980909	EP 1996-939171	19961120
	EP 862560	B1	20030402		
	R: CH, DE, ES, FR, GB, IT, LI				
	ES 2195020	T3	20031201	ES 1996-939171	19961120
	US 6235746	B1	20010522	US 1999-249760	19990216
PRAI	GB 1995-23675	A	19951120		
	US 1996-753041	A3	19961119		
	WO 1996-GB2854	W	19961120		

OS MARPAT 127:81461

AB The title compds. [I; R1 = H, halo, (un)substituted alkyl, etc.; R2, R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = H, alkyl; R5 = H, (un)substituted alkyl, alkenyl, alkynyl; R6 = H, halo, (un)substituted NH2, etc.; X = a direct bond, a linker atom, group; R7 = (un)substituted aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom.


group], selective protein kinase inhibitors, particularly the kinases p56lck, p59fyn, ZAP-70 and protein kinase C, and useful in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role, were prepared Thus, treatment of 4-[3-(3-phthalimidopropoxy)phenyl]-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine with N2H4.H2O in EtOH afforded I.2HCl [R1 = MeO; R2, R3 = Me; R4-R6 = H; R7 = H2N(CH2)3; X = O] which showed IC50 of 22 nM in the protein kinase assay.

IT 191727-12-5P 191727-26-1P 191727-35-2P  
 191727-40-9P 191727-46-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors)


RN 191727-12-5 CAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 191727-26-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2-benzothiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 191727-35-2 CAPLUS

CN 2-Pyrimidinamine, 4-(5-thiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 191727-40-9 CAPLUS

CN 2-Pyrimidinamine, 4-(4,5-dimethyl-2-thiazolyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 191727-46-5 CAPLUS

CN 5-Thiazoleethanol, 4-methyl-2-[2-[(3,4,5-trimethoxyphenyl)amino]-4-

10/809,946

pyrimidinyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1997:302930 CAPLUS  
 DN 126:277492  
 TI Preparation of pyrimidinecarboxylates and related compounds for treating inflammatory conditions  
 IN Suto, Mark J.; Gayo, Leah M.; Palanki, Moorthy S. S.; Ransone-Fong, Lynn J.  
 PA Signal Pharmaceuticals, Inc., USA; Suto, Mark J.; Gayo, Leah M.; Palanki, Moorthy, S. S.; Ransone-Fong, Lynn J.  
 SO PCT Int. Appl., 81 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9709325	A1	19970313	WO 1996-US14089	19960830
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	US 5852028	A	19981222	US 1995-574406	19951218
	CA 2230896	AA	19970313	CA 1996-2230896	19960830
	AU 9670130	A1	19970327	AU 1996-70130	19960830
	AU 726058	B2	20001026		
	JP 11512390	T2	19991026	JP 1996-511324	19960830
	US 5935966	A	19990810	US 1997-807677	19970227
PRAI	US 1995-3109P	P	19950901		
	US 1995-574406	A	19951218		
	WO 1996-US14089	W	19960830		

OS MARPAT 126:277492

AB The title compds. [I; R2 = R2a when R4 = R4a, and R2 = R2b when R4 = R4b; R2b, R4a = H, halo, (un)substituted C1-8 alkyl, etc.; R2a, R4b = II, III, N(R9)NHC(O)R10, N(R9)NHC(O)C(R10):CHR11 (wherein R9 = H, (un)substituted C1-8 alkyl, etc.; R10, R11 = H, (un)substituted C1-8 alkyl, C6-12; n = 0-4; A = halo, OH, COOH, etc.); R5 = C(O)OR7, C(O)R8 (wherein R7 = H, (un)substituted C1-8 alkyl, etc.; R8 = (un)substituted C1-8 alkyl, C6-12 aryl, C7-12 aralkyl), etc.; R6 = H, Me, F, etc.], anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases such as rheumatoid arthritis, osteoarthritis, transplant rejection, sepsis, ARDS, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease, glomerulonephritis, lupus, uveitis, chronic hepatitis, trauma, oxidative stress, ischemia, reperfusion, cancer and viral infection, were prepared. Thus, refluxing of Et 2-hydrazino-4-trifluoromethylpyrimidine with citraconic anhydride in CHCl3 afforded IV which showed IC50 of 0.7  $\mu$ M against transcription factors NF $\kappa$ B and AP-1.

IT 188936-89-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrimidinecarboxylates and related compds. for treating inflammatory conditions)

RN 188936-89-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 2-[(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-

10/809,946

1-yl)amino]-4-(2-thiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1996:495435 CAPLUS  
 DN 125:184908  
 TI Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)  
 AU Zimmermann, Juerg; Caravatti, Giorgio; Mett, Helmut; Meyer, Thomas; Mueller, Marcel; Lydon, Nicholas B.; Fabbro, Dorian  
 CS CIBA Pharmaceuticals Div., Oncology Virology Res. Dep., Ciba-Geigy Limited, Basel, CH-4002, Switz.  
 SO Archiv der Pharmazie (Weinheim, Germany) (1996), 329(7), 371-376  
 CODEN: ARPMAS; ISSN: 0365-6233  
 PB VCH  
 DT Journal  
 LA English  
 AB Phenylamino-pyrimidines represent a novel class of inhibitors of protein kinase C with a high degree of selectivity vs. other serine/threonine and tyrosine kinases. Steady state kinetic anal. of N-(3-[1-imidazolyl]-phenyl)-4-(3-pyridyl)-2-pyrimidinamine, which showed potent inhibitory activity, revealed competitive kinetics relative to ATP. The adjacent H-bond acceptor of the pyrimidine moiety next to an H-bond donor of the phenylamine was found to be crucial for inhibitory activity. N-(3-Nitro-phenyl)-4-(3-pyridyl)-2-pyrimidinamine preferentially inhibited PKC- $\alpha$  (IC<sub>50</sub> = 0.79  $\mu$ M) and not the other subtypes tested. The inhibition consts. of PKC- $\alpha$  and the antiproliferative effect on T24 human bladder carcinoma cells showed a qual. correlation, although with some exceptions.  
 IT 181065-62-3P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of phenylamino-pyrimidine derivs. as a new class of potent and selective inhibitors of protein kinase C)  
 RN 181065-62-3 CAPLUS  
 CN 2-Pyrimidinamine, N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-4-(2-thiazolyl)-(9CI) (CA INDEX NAME)



*Homolog  
Same as #26*

L8 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1974:108415 CAPLUS  
DN 80:108415  
TI Vilsmeier-Haack reaction. VIII. Synthesis of new heterocyclic derivatives from benzothiazole, 6-methoxybenzoxazole, naphth-1,2-oxazole and naphth-2,1-oxazole  
AU Jayanth, M. R.; Naik, H. A.; Tatke, D. R.; Seshadri, S.  
CS Dep. Chem. Technol., Univ. Bombay, Bombay, India  
SO Indian Journal of Chemistry (1973), 11(11), 1112-14  
CODEN: IJOCAP; ISSN: 0019-5103  
DT Journal  
LA English  
AB The Vilsmeier-Haack reaction was utilized to synthesize malonaldehyde derivs. (e.g. I and II) of benzothiazole, 6-hydroxy- and 6-methoxybenzoxazole, naphth-1,2-oxazole, and naphth-2,1-oxazoles. The malonaldehydes were converted into a variety of heterocycles by reaction with suitable reagents. The corresponding cyanoacetaldehyde derivs. were also made and reacted with phenylhydrazine to yield the 5-amino-1-phenylpyrazoles. The pyrimidine derivs. were strongly fluorescent.  
IT 51864-30-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 51864-30-3 CAPLUS  
CN 2-Pyrimidinamine, 5-(2-benzothiazolyl)-N-phenyl- (9CI) (CA INDEX NAME)



No activity !

=&gt; =&gt; d his

(FILE 'HOME' ENTERED AT 12:21:00 ON 03 AUG 2006)

FILE 'REGISTRY' ENTERED AT 12:21:11 ON 03 AUG 2006

L1           STRUCTURE UPLOADED

L2           0 S L1 SSS SAM

L3           STRUCTURE UPLOADED

L4           50 S L3 SSS SAM

L5           STRUCTURE UPLOADED

L6           50 S L5 SSS SAM

L7           1187 S L5 SSS FUL

FILE 'CAPLUS' ENTERED AT 12:27:55 ON 03 AUG 2006

L8           35 S L7

FILE 'CAOLD' ENTERED AT 12:29:32 ON 03 AUG 2006

=&gt; s 17

L9           0 L7

=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.44	352.22

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-26.25

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:29:42 ON 03 AUG 2006